

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 December 2002 (12.12.2002)

PCT

(10) International Publication Number
WO 02/098856 A2

(51) International Patent Classification⁷:

C07D

(21) International Application Number: PCT/US02/17821

(22) International Filing Date: 6 June 2002 (06.06.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/296,498 6 June 2001 (06.06.2001) US
10/163,742 5 June 2002 (05.06.2002) US

(71) Applicant (for all designated States except US): SCHERRING AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 170/178, Postfach 65 03 11, D-13342 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRYANT, Judi, A. [US/US]; 318 Forest Run, Mill Valley, CA 94941 (US). BUCKMAN, Brad, O. [US/US]; 2042 Leimert Boulevard, Oakland, CA 94602 (US). ISLAM, Imadul [US/US]; 165 Caprice Circle, Hercules, CA 94547 (US). MOHAN, Raju [US/US]; 3125 Caminito Ricardo, Encinitas, CA 92024 (US). MORRISSEY, Michael, M. [US/US]; 129 Alta Vista Way, Danville, CA 94806 (US). WEI, Guo, Pin [CN/US]; 1105 Vista Point Circle, San Ramon, CA 94583 (US). XU, Wei [CN/IS]; 327 Glasgow Circle, Danville, CA 94526 (US). YUANG, Shendong [CN/US]; 708 Forest Run, Hercules, CA 94547 (US).

(74) Agents: ZELANO, Antony, J. Millen, White, Zelano & Branigan, P.C. et al.; Arlington Courthouse Plaza 1, 2200 Clarendon Boulevard, Suite 1400, Arlington, VA 22201 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2

WO 02/098856 A2

(54) Title: PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

(57) Abstract: Compounds of the following formula (I): where a, b, R¹, R², R³, R⁴ and R⁶ are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

Field of the Invention

The invention relates to piperazine derivatives, their use as platelet adenosine diphosphate receptor antagonists, pharmaceutical compositions containing them and processes for their preparation.

Background of the Invention

Platelets interact with the coagulation and fibrinolysis systems in the maintenance of hemostasis and in the pathogenesis of thrombosis and thromboembolism. Platelets rapidly adhere to damaged vascular tissue, and release a variety of prothrombotic, chemotactic, and mitogenic factors, aimed at prompting hemostasis and wound healing. Platelets also play an important role in arterial thrombosis, a common cause of death and disability in patients with cardiovascular disease. Platelet inhibitors have been successfully used for secondary prevention of arterial thrombosis in patients with coronary, cerebral, and peripheral vascular disease.

Platelets adhere to exposed subendothelium after vessel wall injury by binding to von Willebrand factor (vWF) and collagen. This induces platelets to change shape from a disc shape to a round form with pseudopodia, which enforces platelet adhesion and aggregation. The final common pathway for platelet aggregation is the activation of the fibrinogen receptor (GPIIb-IIIa). As a result, dimeric fibrinogen molecules present in plasma can bind and link platelets together to form aggregates.

Activated platelets secrete their granule contents, many of which act directly on blood cells, including platelets themselves, and endothelium. Platelets contain several kinds of secretory granules. The dense-granules contain adenosine diphosphate ("ADP"), adenosine triphosphate ("ATP") and serotonin. The α -granules contain several platelet-specific proteins (platelet factor 4 and β -thromboglobulin), growth factors (PDGF, TGF- β , EGF and ECGF) and coagulation factors (fibrinogen, Factor V and vWF). Platelets also secrete biologically active arachidonic acid products. Well known is TxA₂ which is inhibited by aspirin through irreversible inactivation of the cyclooxygenase producing TxA₂.

Many stimuli, such as thrombin, collagen, ADP and thromboxane A2 (TxA2), activate platelets by binding to their cell surface receptors. Most of these receptors are G-protein-coupled receptors. Activation of G-proteins has been shown to be an essential event in platelet activation. For example, platelets from Gq/- mice do not

aggregate in response to thrombin, collagen, ADP or TxA2 (Offermans, S. et al., Nature (1998), Vol. 389, No. 11, pp. 183-185). Many down-stream signaling events have been elucidated, including activation of phospholipase-C (PLC) and protein kinase C, increase in intracellular calcium concentration, decrease in cAMP level and 5 tyrosine phosphorylation.

ADP plays a pivotal role in platelet activation. ADP not only causes primary aggregation of platelets but is also responsible for the secondary aggregation following activation by other agonists such as thrombin and collagen. Contained at very high concentrations in the platelet dense-granules, ADP is released when platelets are 10 activated to reinforce platelet aggregation.

ADP-induced platelet activation plays an important role in maintaining normal hemostasis. Several congenital bleeding disorders have been linked to the decreased number of platelet ADP receptors and deficiency of ADP-induced platelet aggregation. Patients having "storage pool disease", which is due to defects in the storage of 15 nucleotides and/or their secretion from the platelet dense-granules, have impaired platelet aggregation in response to collagen and other stimuli due to the absence of the amplification effects by ADP.

ADP-induced platelet activation also plays a key role in the initiation and propagation of thrombosis. Administration of ADP has been shown to induce 20 thrombus formation in rat and mice mesenteric venules. In contrast, ADP-removing enzymes have been shown to dramatically reduce platelet deposition on collagen and to inhibit laser-induced thrombosis in rat mesenteric arterioles and venules, supporting the theory that ADP plays a role in mediating platelet recruitment in thrombus formation. Several ADP-induced early signaling events in platelets have been 25 described. These include a transient rise in free cytoplasmic calcium, an inhibition of adenylate cyclase through activation of G_{i2}, an increase in cytosolic pH by activating the Na⁺/H⁺-exchange, and exposure of the platelet binding sites for fibrinogen independent of protein kinase C. While these signaling events collectively contribute to platelet aggregation, the specific role of each remains the subject of on-going 30 investigations.

The current model of ADP-induced platelet activation involves two G-protein coupled purinergic receptors, one of which is coupled to the activation of the phospholipase-C pathway (P2Y₁) and the other is coupled to the inhibition of adenylate cyclase (P2Y_{AC}). P2Y_{AC} is the best target for a platelet ADP receptor antagonist for 35 several reasons. First, P2Y_{AC} is predominately platelet specific. Secondly, it is

required for ADP-induced aggregation. Thirdly, it plays an important role in sustaining thrombin or collagen-induced aggregation. Finally, it is the molecular target for anti-aggregatory drugs such as Clopidogrel and Ticlopidine. Both of these drugs have been shown to be efficacious in various thrombosis models. However, Clopidogrel has

5 been shown to be an irreversible inhibitor of platelet aggregation with a slow onset of action. Similarly, the ATP analogues, AR-C67085 and AR-C69931MX, which are potent antagonists for ADP-induced platelet aggregation, have also been shown to be effective in thrombosis models and are currently under clinical investigation. All these findings indicate that ADP is a critical mediator of arterial thrombus formation and

10 hence an excellent target for antithrombotic intervention.


When the properties of current oral platelet inhibitors, such as aspirin, Clopidogrel and Ticlopidine are compared, it becomes clear that, while relatively safe, current oral platelet inhibitors are only modestly effective in preventing thrombotic complications in patients with underlying vascular disease. It is clear that there is a

15 need in this field for a potent, selective, reversible, orally active platelet ADP receptor ($P2Y_{AC}$) inhibitor.

SUMMARY OF THE INVENTION

The compounds of the invention are antagonists of the platelet ADP receptor,

20 $P2Y_{AC}$, and are therefore useful in treating disease-states characterized by thrombotic activity and in so doing are useful as antithrombotic agents in the treatment and prevention of thrombosis. Accordingly, in one aspect, the invention is directed to compounds selected from the group consisting of the following formula (I):



25 wherein:

a and b are independently 1 to 4;

A is $=CH-$ or $=N-$;

R^1 is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, alkoxyalkoxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl,

30 alkoxy carbonylalkylcarbonyl, alkoxy carbonylalkyl, alkoxy carbonyl, arylcarbonyl,

aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, alkoxy carbonylaminocarbonyl, alkylsulfonyl, arylsulfonyl, heterocycl, or heterocyclcarbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl,
5 aminoalkyl, haloalkylsulfonylamoalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxylalkyl, alkoxy carbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxy carbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylamoalkyl,
10 alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxy carbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, tetrahydrofuranonyl, or heterocyclalkyl;

R³ is hydrogen, alkyl, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl,
15 alkoxy carbonylalkoxy, di(alkoxy carbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyloxy, carboxyalkenyloxy, alkoxy carbonylalkenyloxy, (cycloalkyl)(alkoxy carbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy,
20 (dialkylamino carbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxy carbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxy carbonyl)alkyl)aminocarbonyl, mono((alkoxy carbonyl)(carboxy)alkyl)aminocarbonyl,
25 mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylamino carbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, mono(alkoxy carbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy, alkoxy carbonylcycloalkoxy, aminocarbonylcycloalkoxy, heterocycl,
30 tetrahydrofuranonyloxy, or heterocyclalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino,

hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxy carbonyl, aralkoxy carbonyl, carboxyalkyl, and alkoxy carbonylalkyl;

5 R⁶ is -N(R⁷)-C(O)- or -C(O)-N(R⁷)-;

R⁷ is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

10 In another aspect, this invention is directed to pharmaceutical compositions useful in treating a mammal having a disease-state characterized by thrombotic activity, which composition comprises a pharmaceutically acceptable excipient and a compound of formula (I) as defined above.

In another aspect, this invention is directed to methods of treating disease-15 states characterized by thrombotic activity, which methods comprise administering to a mammal having a disease-state characterized by thrombotic activity a therapeutically effective amount of a compound of formula (I) as defined above.

Detailed Description of the Invention

20 Definitions

As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated:

"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to 25 eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), and the like. Unless stated otherwise specifically in the specification, it is understood that for radicals, as defined below, that contain a substituted alkyl or alkenyl group that the substitution can occur on any carbon of the 30 alkyl group.

"Alkylcarbonyl" refers to a radical of the formula -C(O)-R_a where R_a is an alkyl radical as defined above, e.g., acetyl, ethylcarbonyl, n-propylcarbonyl, and the like.

"Alkylcarbonylamino" refers to a radical of the formula -N(H)-C(O)-R_a where R_a is an alkyl radical as defined above, e.g., acetyl amino, ethylcarbonylamino, n-propylcarbonylamino, and the like.

"Alkylthio" refers to a radical of the formula $-S-R_a$ where R_a is an alkyl radical as defined above, e.g., methylthio, ethylthio, *n*-propylthio, and the like.

"Alkylsulfonyl" refers to a radical of the formula $-S(O)_2R_a$ where R_a is an alkyl radical as defined above, e.g., methylsulfonyl, ethylsulfonyl, *n*-propylsulfonyl, and the like.

"Alkylsulfonylalkyl" refers to a radical of the formula $-R_a-S(O)_2-R_a$ where each R_a is independently an alkyl radical as defined above, e.g., methylsulfonylmethyl, 2-methylsulfonylethyl, 2-ethylsulfonylpropyl, and the like.

"Alkenyl" refers to a straight or branched chain monovalent or divalent radical consisting solely of carbon and hydrogen, containing at least one double bond and having from two to eight carbon atoms, e.g., ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.

"Alkoxy" refers to a radical of the formula $-OR_a$ where R_a is an alkyl radical as defined above, e.g., methoxy, ethoxy, *n*-propoxy, 1-methylethoxy (*iso*-propoxy), *n*-butoxy, *n*-pentoxy, 1,1-dimethylethoxy (*t*-butoxy), and the like.

"Alkoxycarbonyl" refers to a radical of the formula $-C(O)OR_a$ where R_a is an alkyl radical as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, *n*-propoxycarbonyl, and the like.

"Alkoxycarbonylalkyl" refers to a radical of the formula $-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethyl, (1,1-dimethylethoxy)carbonylmethyl, 2-(methoxycarbonyl)ethyl, and the like.

"Alkoxycarbonylaminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-C(O)OR_a$ where R_a is an alkyl radical as defined above, e.g., methoxycarbonylaminocarbonyl, ethoxycarbonylaminocarbonyl, *n*-propoxycarbonylaminocarbonyl, and the like.

"Alkoxycarbonylcycloalkoxy" refers to a radical of the formula $-O-R_c-C(O)OR_a$ where R_a is an alkyl radical as defined above and R_c is a cycloalkyl radical as defined below, e.g., 1-methoxycarbonylcyclobut-1-oxy, 1-ethoxycarbonylcyclobut-1-oxy, 1-*n*-propoxycarbonylcyclobutoxy, and the like.

"Alkoxyalkoxyalkylcarbonyl" refers to a radical of the formula $-C(O)-R_a-O-R_a-O-R_a$ where each R_a is independently an alkyl radical as defined above, e.g., 2-(ethoxy)ethoxymethylcarbonyl, 3-(2-(*n*-butoxy)ethoxy)propylcarbonyl, and the like.

"Alkoxy carbonyl alkyl" refers to a radical of the formula $-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethyl, 2-(ethoxycarbonyl)ethyl, 2-(methoxycarbonyl)propyl, and the like.

5 "Alkoxy carbonyl alkoxy" refers to a radical of the formula $-O-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethoxy, 2-(ethoxycarbonyl)ethoxy, 2-(methoxycarbonyl)propoxy, and the like.

10 "Alkoxy carbonyl alkenyloxy" refers to a radical of the formula $-O-R_d-C(O)OR_a$ where R_a is an alkyl radical as defined above and R_d is an alkenyl radical as defined above, e.g., 2-(methoxycarbonyl)ethenyloxy, 3-(ethoxycarbonyl)prop-1-enyloxy, and the like.

15 "Alkoxy carbonyl alkyl carbonyl" refers to a radical of the formula $-C(O)-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethylcarbonyl, 2-(ethoxycarbonyl)ethylcarbonyl, 2-(methoxycarbonyl)propylcarbonyl, and the like.

20 "Alkoxy carbonyl alkyl aminocarbonyl alkyl" refers to a radical of the formula $-R_a-C(O)-N(H)-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethyl, 2-(ethoxycarbonyl)ethylaminocarbonylmethyl, 2-(2-(methoxycarbonyl)propylaminocarbonyl)propyl, and the like.

25 "Alkoxy carbonyl alkyl thioalkyl" refers to a radical of the formula $-R_a-S-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethylthiomethyl, 2-(ethoxycarbonyl)ethylthiomethyl, 2-(2-(methoxycarbonyl)propylthio)propyl, and the like.

30 "Alkoxy carbonyl alkoxycarbonyl alkyl" refers to a radical of the formula $-R_a-C(O)-O-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethoxy, 2-(ethoxycarbonyl)ethoxycarbonylmethyl, 3-(2-(methoxycarbonyl)propoxycarbonyl)propyl, and the like.

35 "Alkoxy carbonyl alkyl (alkyl) aminocarbonyl alkyl" refers to a radical of the formula $-R_a-C(O)-N(R_a)-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., (methoxycarbonylmethyl)(methyl)aminocarbonylmethyl, 2-((ethoxycarbonylmethyl)(methyl)aminocarbonyl)ethyl, and the like.

"Amino" refers to the $-NH_2$ radical.

"Aminoalkyl" refers to a radical of the formula $-R_a-NH_2$, e.g., aminomethyl, 2-aminomethyl, 2-aminopropyl, and the like.

"Aminocarbonyl" refers to the $-C(O)NH_2$ radical.

"Aminocarbonylalkoxy" refers to a radical of the formula $-O-R_a-C(O)NH_2$, e.g., aminocarbonylmethoxy, 2-(aminocarbonyl)ethoxy, 2-(aminocarbonyl)propoxy, and the like.

5 "Aminocarbonylalkyl" refers to a radical of the formula $-R_a-C(O)NH_2$, e.g., aminocarbonylmethyl, 2-(aminocarbonyl)ethyl, 2-(aminocarbonyl)propyl, and the like.

"Aminocarbonylcycloalkoxy" refers to a radical of the formula $-O-R_c-C(O)NH_2$ where R_c is a cycloalkyl radical as defined below, e.g., 1-(aminocarbonyl)cyclobutoxy, 2-(aminocarbonyl)cyclohexyl, and the like.

10 "Aryl" refers to a phenyl or naphthyl radical. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents selected from the group consisting of hydroxy, hydroxalkyl, halo, haloalkyl, haloalkoxy, alkyl, alkoxy, carboxy, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, 15 carboxyalkoxy, alkoxycarbonylalkoxy, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, alkylcarbonylamino, nitro, cyano, amino, monoalkylamino, dialkylamino, and aminoalkyl, as defined herein. For R^1 , preferred aryl radicals are those radicals which are optionally substituted by one or more substituents selected from the group consisting of halo and alkyl. For R^2 , preferred 20 aryl radicals are those radicals which are optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, carboxyalkoxy and alkoxycarbonylalkoxy.

"Aralkyl" refers to a radical of the formula $-R_aR_b$ where R_a is an alkyl radical as defined above, substituted by R_b , an aryl radical, as defined above, e.g., benzyl. For R^1 , preferred aralkyl radicals are those radicals wherein the R_b group is optionally substituted by one or more substituents independently selected from the group consisting of halo and alkyl. For R^2 , preferred aralkyl radicals are those radicals wherein the R_b group is optionally substituted by one or more substituents independently selected from the group consisting of alkoxycarbonyl, carboxy, 30 alkoxycarbonylalkoxy, carboxyalkoxy, and hydroxy. For R^5 , preferred aralkyl radicals are those radicals wherein the R_b group is optionally substituted by one or more hydroxy radicals.

"Aryloxy" refers to a radical of the formula $-OR_b$ where R_b is an aryl radical as defined above, e.g., phenoxy.

35 "Arylcarbonyl" refers to a radical of the formula $-C(O)-R_b$ where R_b is an aryl

radical as defined above, e.g., phenylcarbonyl, (4-acetylaminophenyl)carbonyl, (2-methoxyphenyl)carbonyl, and the like. For R¹, preferred arylcarbonyl radicals are those radicals wherein the R_b group is optionally substituted by one or more substituents independently selected from the group consisting of acetylamino,

5 carboxy, aminocarbonyl, alkoxy carbonyl, haloalkoxy, alkoxy, and alkyl.

"Arylsulfonyl" refers to a radical of the formula -S(O)₂-R_b where R_b is an aryl radical as defined above, e.g., phenylsulfonyl, 4-chlorophenylsulfonyl, 4-methylphenylsulfonyl, and the like. For R¹, preferred arylsulfonyl radicals are those radicals wherein the R_b group is optionally substituted by one or more substituents

10 independently selected from the group consisting of halo and alkyl.

"Aryloxycarbonyl" refers to a radical of the formula -C(O)OR_b where R_b is an aryl radical as defined above, e.g., phenoxy carbonyl.

"Aryloxyalkylcarbonyl" refers to a radical of the formula -C(O)OR_bR_a where R_a is an alkyl radical, as defined above, substituted by R_b, an aryl radical, as defined above, e.g., phenoxy methyl carbonyl, (2-phenoxyethyl)carbonyl, and the like.

"Aralkoxy" refers to a radical of the formula -OR_e where R_e is an aralkyl radical as defined above, e.g., benzyloxy, 3-phenylpropoxy, and the like.

15 "Aralkoxyalkyl" refers to a radical of the formula -R_a-OR_e where R_a is an alkyl radical as defined above and R_e is an aralkyl radical as defined above, e.g.,
20 benzyloxymethyl, 2-(benzyloxy)ethyl, 2-(benzyloxy)propyl, and the like.

"Aralkoxycarbonyl" refers to a radical of the formula -C(O)OR_e where R_e is an aralkyl radical as defined above, e.g., benzyloxycarbonyl, and the like.

25 "Aralkoxycarbonylalkyl" refers to a radical of the formula -R_a-C(O)OR_e where R_a is an alkyl radical as defined above and R_e is an aralkyl radical as defined above, e.g.,
benzyloxycarbonylmethyl, 2-(benzyloxycarbonyl)ethyl, 3-((naphthalen-2-yl)oxy)carbonylpropyl, and the like.

30 "Aralkoxycarbonylaminoalkyl" refers to a radical of the formula -R_a-N(H)-C(O)OR_e where R_a is an alkyl radical as defined above and R_e is an aralkyl radical as defined above, e.g., benzyloxycarbonylaminomethyl, 2-(benzyloxycarbonylamino)ethyl, 2-(benzyloxycarbonylamino)propyl, and the like.

"Carboxy" refers to the -C(O)OH radical.

"Carboxyalkyl" refers to a radical of the formula -R_a-C(O)OH, where R_a is an alkyl radical as defined above, e.g., carboxymethyl, 2-carboxyethyl, 2-carboxypropyl and the like.

"Carboxyalkoxy" refers to a radical of the formula $-O-R_a-C(O)OH$, where R_a is an alkyl radical as defined above, e.g., carboxymethoxy, 2-carboxyethoxy, 2-carboxypropoxy, and the like.

"Carboxyalkylcarbonyl" refers to a radical of the formula $-C(O)-R_a-C(O)OH$,
5 where R_a is an alkyl radical as defined above, e.g., 2-carboxyethylcarbonyl, carboxymethylcarbonyl, 3-carboxypropylcarbonyl, and the like.

"Carboxyalkylamino" refers to a radical of the formula $-N(H)-R_a-C(O)OH$ where R_a is an alkyl radical as defined above, e.g., carboxymethylamino, 2-carboxyethylamino, 3-carboxypropylamino, and the like.

10 "Carboxyalkylaminocarbonylalkyl" refers to a radical of the formula $-R_a-C(O)-N(H)-R_a-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., carboxymethylaminocarbonylmethyl, 2-(carboxymethylaminocarbonyl)ethyl, 2-(2-carboxyethyl)aminocarbonyl)ethyl, 3-(2-carboxyethyl)aminocarbonyl)butyl, and the like.

15 "Carboxyalkylthioalkyl" refers to a radical of the formula $-R_a-S-R_a-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., carboxymethylthiomethyl, (1-carboxyethyl)thiomethyl, 2-((1-carboxypropyl)thio)ethyl, and the like.

"Carboxyalkoxyalkyl" refers to a radical of the formula $-R_a-O-R_a-C(O)OH$ where
20 each R_a is independently an alkyl radical as defined above, e.g., 2-(carboxymethoxy)ethyl, (2-carboxyethoxy)methyl, 3-(2-carboxypropoxy)propyl, and the like.

"Carboxyalkoxycarbonylalkyl" refers to a radical of the formula $-R_a-O-R_a-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., carboxymethoxycarbonylmethyl, 2-(carboxymethoxycarbonyl)ethyl, 2-((2-carboxyethoxy)carbonyl)propyl, and the like.

"Carboxyalkenyl" refers to a radical of the formula $-R_d-C(O)OH$ where R_d is an alkenyl radical as defined above, e.g., 2-carboxyethenyl, 3-carboxyprop-1-enyl, 3-carboxybut-1-enyl and the like.

30 "Carboxyalkenyloxy" refers to a radical of the formula $-O-R_d-C(O)OH$ where R_d is an alkenyl radical as defined above, e.g., 2-carboxyethenyloxy, 3-carboxyprop-1-enyloxy, 3-carboxybut-1-enyloxy, and the like.

"Cycloalkyl" refers to a stable 3- to 10-membered monocyclic or bicyclic radical which is saturated, and which consist solely of carbon and hydrogen atoms, e.g.,
35 cyclopropyl, cyclobutyl, cyclobutyl, cyclohexyl, decalinyl and the like. Unless otherwise

stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halo, hydroxy, amino, nitro, alkoxy, carboxy, phenyl and alkoxy carbonyl.

5 "Cycloalkyl carbonyl" refers to a radical of the formula $-C(O)-R_c$ where R_c is a cycloalkyl radical as defined above, e.g., cyclobutyl carbonyl, cyclopropyl carbonyl, and the like. For R^1 , a preferred cycloalkyl carbonyl radical is that radical wherein the R_c group is optionally substituted by a phenyl group.

10 "(Cycloalkyl)(alkoxy carbonyl)alkoxy" refers to a radical of the formula $-OR_a(R_c)-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above and R_c is a cycloalkyl radical as defined above, e.g., (cyclohexyl)(methoxycarbonyl)methoxy, (cyclobutyl)(ethoxycarbonyl)methoxy, and the like.

15 "(Cycloalkyl)(carboxy)alkoxy" refers to a radical of the formula $-OR_a(R_c)-C(O)OH$ where R_a is an alkyl radical as defined above and R_c is a cycloalkyl radical as defined above, e.g., (cyclohexyl)(carboxy)methoxy, (cyclobutyl)(carboxy)methoxy, and the like.

20 "Carboxycycloalkoxy" refers to a radical of the formula $-O-R_c-C(O)OH$ where R_c is a cycloalkyl radical as defined above, e.g., 1-carboxycyclobut-1-oxy, 1-carboxycyclohex-1-oxy, and the like.

25 "(Carboxy)(hydroxy)alkoxy" refers to a radical of the formula $-O-R_a(OH)-C(O)OH$ wherein R_a is an alkyl radical defined above substituted by an hydroxy radical and a carboxy radical, as defined herein, e.g., 1-carboxy-3-hydroxypropoxy, 2-carboxy-4-hydroxybutoxy, 1-carboxy-5-hydroxypent-2-oxy, and the like.

30 "(Carboxy)(hydroxy)alkyl" refers to a radical of the formula $-R_a(OH)-C(O)OH$ wherein R_a is an alkyl radical defined above substituted by an hydroxy radical and a carboxy radical, as defined herein, e.g., 1-carboxy-3-hydroxypropyl, 2-carboxy-4-hydroxybutyl, 1-carboxy-5-hydroxypent-2-yl, and the like.

35 "(Carboxyalkyl)(alkyl)amino" refers to a radical of the formula $-N(R_a)-R_a-C(O)OH$ wherein each R_a is independently an alkyl radical as defined above, and wherein the nitrogen atom is substituted by the R_a group and the $-R_a-C(O)OH$ group, e.g., (carboxyethyl)(ethyl)amino, (2-carboxyethyl)(methyl)amino, and the like.

"(Carboxyalkyl)(alkyl)aminocarbonylalkyl" refers to a radical of the formula $-R_a-C(O)-N(R_a)-R_a-C(O)OH$ wherein each R_a is independently an alkyl radical as

defined above, and wherein the nitrogen atom is substituted by the R_a group and the $-R_a-C(O)OH$ group, e.g., (carboxyethyl)(ethyl)aminocarbonylmethyl, 2-((2-carboxyethyl)(methyl)aminocarbonyl)ethyl, and the like.

"Cyano" refers to the $-C\equiv N$ radical.

5 "Cyanoalkoxy" refers to a radical of the formula $-O-R_a-C\equiv N$ where R_a is an alkyl radical as defined above, e.g., 2-cyanoethoxy, 2-cyanopropoxy, 4-cyanobut-2-oxy, and the like.

10 "Dialkylamino" refers to a radical of the formula $-N(R_a)-R_a$ where each R_a is independently an alkyl radical, e.g., dimethylamino, diethylamino, methylethylamino, and the like.

"Dialkylaminocarbonyl" refers to a radical of the formula $-C(O)-N(R_a)-R_a$ where each R_a is independently an alkyl radical, e.g., dimethylaminocarbonyl, diethylaminocarbonyl, methyl(ethyl)aminocarbonyl, and the like.

15 "Dialkylaminoalkyl" refers to a radical of the formula $-R_a-N(R_a)-R_a$ where each R_a is independently an alkyl radical as defined above, e.g., dimethylaminomethyl, 2-(diethylamino)ethyl, 3-(methyl(ethyl)amino)propyl, and the like.

20 "Dialkylaminoalkoxy" refers to a radical of the formula $-O-R_a-N(R_a)-R_a$ where each R_a is independently an alkyl radical as defined above, e.g., dimethylaminomethoxy, 2-(diethylamino)ethoxy, 3-(methyl(ethyl)amino)propoxy, and the like.

"Dialkylaminocarbonylalkoxy" refers to a radical of the formula $-O-R_a-C(O)-N(R_a)-R_a$ where each R_a is independently an alkyl radical, e.g., dimethylaminocarbonylmethoxy, diethylaminocarbonylmethoxy, 2-(methyl(ethyl)aminocarbonyl)ethoxy, and the like.

25 "Di(alkoxycarbonyl)alkoxy" refers to a radical of the formula $-O-R_a(C(O)O-R_a)-C(O)O-R_a$ where each R_a is independently an alkyl radical as defined above, e.g., di(methoxycarbonyl)methoxy, di(ethoxycarbonyl)methoxy, 2,2-di(ethoxycarbonyl)ethoxy, and the like.

30 "Di(carboxy)alkoxy" refers to a radical of the formula $-O-R_a(C(O)OH)-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., di(carboxy)methoxy, di(carboxy)methoxy, 2,2-di(carboxy)ethoxy, and the like.

"Di(alkylcarbonyl)amino" refers to a radical of the formula $-N(C(O)-R_a)-C(O)-R_a$ where each R_a is independently an alkyl radical as defined above, e.g., di(acetyl)amino, di(ethylcarbonyl)amino, and the like.

"(Dialkylaminoalkyl)(alkyl)amino" refers to a radical of the formula $-N(R_a)-R_a-N(R_a)R_a$, where each R_a is independently an alkyl radical as defined above and where each nitrogen atom is disubstituted, e.g., (dimethylaminomethyl)(methyl)amino, (diethylaminomethyl)(methyl)amino,

5 (2-(dimethylamino)ethyl)(ethyl)amino, and the like.

"(Dialkylamino)(carboxy)alkoxy" refers to a radical of the formula $-O-R_a(C(O)OH)-N(R_a)R_a$, where each R_a is independently an alkyl radical as defined above and where the first R_a group is substituted by a $-C(O)OH$ group and a $-N(R_a)R_a$ group, e.g., 3-dimethylamino-1-carboxymethoxy, 4-diethylamino-1-carboxymethoxy,

10 and the like.

"(Dialkylaminocarbonylalkyl)(alkyl)amino" refers to a radical of the formula $-N(R_a)-R_a-C(O)-N(R_a)R_a$ where each R_a is independently an alkyl radical as defined above and where each nitrogen atom is disubstituted, e.g., (dimethylaminocarbonylmethyl)(methyl)amino,

15 (diethylaminocarbonylmethyl)(methyl)amino, (2-(diethylaminocarbonyl)ethyl)(ethyl)amino, and the like.

"Formyl" refers to the radical $-C(O)H$.

"Halo" refers to bromo, chloro, iodo or fluoro.

"Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by

20 one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like.

"Haloalkylsulfonylaminoalkyl" refers to a radical of the formula $-R_a-N(H)-S(O)_2R_f$ where R_a is an alkyl radical as defined above and R_f is a haloalkyl radical as defined

25 above, e.g., 2-(trifluoromethoxysulfonylamino)ethyl, 3-(trifluoromethoxysulfonylamino)propyl, and the like.

"Haloalkenyl" refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1,2-difluoroethyl, 3-bromo-2-fluoroprop-1-enyl, 1,2-dibromoethyl, and the like.

30 "Haloalkoxy" refers to a radical of the formula $-OR_f$ where R_f is an haloalkyl radical as defined above, e.g., trifluoromethoxy, difluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, 1-fluoromethyl-2-fluoroethoxy, 3-bromo-2-fluoropropoxy, 1-bromomethyl-2-bromoethoxy, and the like.

"Haloalkenyloxy" refers to a radical of the formula $-OR_g$ where R_g is an haloalkenyl radical as defined above, as defined above, e.g., 1,2-difluoroethenyloxy, 3-bromo-2-fluoroprop-1-enyloxy, 1,2-dibromoethenyloxy, and the like.

"Haloalkoxycarbonyl" refers to a radical of the formula $-C(O)OR_f$ where R_f is an 5 haloalkyl radical as defined above, e.g., trifluoromethoxycarbonyl, difluoromethoxycarbonyl, trichloromethoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 1-fluoromethyl-2-fluoroethoxycarbonyl, 3-bromo-2-fluoropropoxycarbonyl, 1-bromomethyl-2-bromoethoxycarbonyl, and the like.

"Hydroxy" refers to the $-OH$ radical. 10 "Hydroxyalkyl" refers to a alkyl radical as defined above that is substituted by a hydroxy radical, e.g., hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, and the like.

"Hydroxyalkoxy" refers to a radical of the formula $-OR_a-OH$ where R_a is an alkyl radical as defined above, e.g., 2-hydroxyethoxy, 2-hydroxypropoxy, 4-hydroxybutoxy, 15 3-hydroxybutoxy, and the like.

"(Hydroxyalkyl)(alkyl)amino" refers to a radical of the formula $-N(R_a)-R_a-OH$ where each R_a is independently an alkyl radical as defined above, e.g., (2-hydroxyethyl)(methyl)amino, (2-hydroxyethyl)(ethyl)amino, (3-hydroxypropyl)(ethyl)amino, and the like.

20 "Heterocycl" refers to a stable 3- to 15-membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For purposes of this invention, the heterocycl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocycl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; 25 and the heterocycl radical may be aromatic or partially or fully saturated. The heterocycl radical may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Examples of such heterocycl radicals include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl, carbazolyl, cinnolinyl, decahydroisoquinolyl, dioxolanyl, furanyl, furanonyl, isothiazolyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, indolyl, isoindolyl, indoliny, isoindolinyl, indanyl, indolizinyl, isoxazolyl, isoxazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, octahydroindolyl, octahydroisoindolyl, 30 35 2-oxopiperazinyl, 2-oxopiperidiny, 2-oxopyrrolidinyl, 2-oxoazepinyl, oxazolyl,

oxazolidinyl, oxiranyl, piperidinyl, piperazinyl, 4-piperidonyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxaliny, quinoliny, quinuclidinyl, isoquinoliny, thiazolyl, thiazolidinyl, thiadiazolyl, triazolyl, 5 tetrazolyl, tetrahydrofuryl, triazinyl, tetrahydropyranyl, thienyl, thiamorpholiny, thiamorpholiny sulfoxide, and thiamorpholiny sulfone. Unless stated otherwise specifically in the specification, the term "heterocyclyl" is meant to include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of hydroxy, halo, alkyl, alkoxy, phenoxy, haloalkyl, 10 haloalkoxy, formyl, nitro, cyano, amino, monoalkylamino, dialkylamino, carboxy, alkoxy carbonyl, benzyl carbonyl, alkyl carbonyl, carboxy alkyl, alkoxy carbonyl alkyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyl alkyl, monoalkylaminocarbonyl alkyl, dialkylaminocarbonyl alkyl, as defined herein.

For R¹, preferred heterocyclyl radicals are those radicals selected from the 15 group consisting of benzoxazolyl, benzthiazolyl, pyridinyl, and pyrimidinyl. For R³, preferred heterocyclyl radicals are those radicals selected from the group consisting of morpholinyl, piperidinyl (optionally substituted by one or more substituents selected from the group consisting of aminocarbonyl, alkoxy carbonyl, carboxy and hydroxy), pyrrolidinyl (optionally substituted by hydroxy), and piperazinyl (optionally substituted 20 by one or more substituents selected from the group consisting of alkyl and carboxy alkyl).

"Heterocyclylalkyl" refers to a radical of the formula -R_a-R_h where R_a is an alkyl radical as defined above and R_h is an heterocyclyl radical as defined above, e.g., imidazol-3-ylmethyl, triazol-3-ylmethyl, 2-tetrazolylethyl, and the like. For R², preferred 25 heterocyclylalkyl radicals are those radicals where R_h is selected from the group consisting of imidazolyl (optionally substituted by carboxy alkyl), indolyl, triazolyl and tetrazolyl.

"Heterocyclylalkoxy" refers to a radical of the formula -O-R_a-R_h where R_a is an alkyl radical as defined above and R_h is an heterocyclyl radical as defined above, e.g., 30 1-tetrazolylethoxy, oxiranylmethoxy, and the like. For R³, preferred heterocyclylalkoxy radicals are those radicals where R_h is selected from the group consisting of oxiranyl or tetrazolyl. For R⁴, preferred heterocyclylalkoxy radicals are those radicals where R_h is pyrrolidinyl (optionally substituted by one or more substituents independently selected from the group consisting of hydroxy and carboxy).

"Heterocyclcarbonyl" refers to a radical of the formula $-C(O)-R_h$ where R_h is a heterocycl radical as defined above, e.g., furan-2-ylcarbonyl, piperidin-4-ylcarbonyl, thien-2-ylcarbonyl, morpholin-4-ylcarbonyl, and the like. For R^1 , preferred heterocyclcarbonyl radicals are those radicals wherein R_h is selected from the group 5 consisting of furanyl, thietyl, piperidinyl, morpholinyl and pyridinyl (optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, halo and alkyl).

"Monoalkylamino" refers to a radical of the formula $-N(H)-R_a$ where R_a is an alkyl radical as defined above, e.g., methylamino, ethylamino, *n*-propylamino, and the like.

10 "Monoalkylaminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-R_a$ where R_a is an alkyl radical as defined above, e.g., methylaminocarbonyl, ethylaminocarbonyl, *n*-propylaminocarbonyl, and the like.

15 "Monoaralkylaminocarbonylalkoxy" refers to a radical of the formula $-O-R_a-C(O)-N(H)-R_e$ where R_a is an alkyl radical as defined above and R_e is an aralkyl radical as defined above, e.g., benzylaminocarbonylmethoxy, 2-(benzylaminocarbonyl)ethoxy, 2-(4-hydroxybenzylaminocarbonyl)propoxy, and the like.

20 "Mono(carboxyalkyl)aminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-R_a-C(O)OH$ where R_a is an alkyl radical as defined above, e.g., (2-carboxyethyl)aminocarbonyl, carboxymethylaminocarbonyl, and the like.

25 "Mono(carboxyalkyl)aminocarbonylalkoxy" refers to a radical of the formula $-O-R_a-C(O)-N(H)-R_a-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., (2-carboxyethyl)aminocarbonylmethoxy, 2-(carboxymethylaminocarbonyl)propoxy, and the like.

30 "Mono(alkoxycarbonylalkyl)aminocarbonylalkoxy" refers to a radical of the formula $-O-R_a-C(O)-N(H)-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., (2-ethoxycarbonylethyl)aminocarbonylmethoxy, 2-(ethoxycarbonylmethylaminocarbonyl)propoxy, and the like.

35 "Mono(alkoxycarbonylalkyl)aminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., (2-methoxycarbonylethyl)aminocarbonyl, ethoxycarbonylmethylaminocarbonyl, and the like.

40 "Mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-R_a-(C(O)OH)-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., (1-carboxy-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl, and the like.

"Mono(di(alkoxycarbonyl)alkyl)aminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-R_a(C(O)OR_a)-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., (1-methoxycarbonyl-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl, and the like.

5 "Mono(dicarboxyalkyl)aminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-R_a(C(O)OH)-C(O)OH$ where R_a is an alkyl radical as defined above, e.g., (1,3-dicarboxypropyl)aminocarbonyl, and the like.

"Mammal" includes humans and domesticated animals, such as cats, dogs, swine, cattle, sheep, goats, horses, rabbits, and the like.

10 "Nitro" refers to the $-NO_2$ radical.

"Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.

"Pharmaceutically acceptable salt" includes both acid and base addition salts.

20 "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 25 p -toluenesulfonic acid, salicylic acid, and the like.

25 "Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases 30 include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring 35 substituted amines, cyclic amines and basic ion exchange resins, such as

isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, 5 piperidine, *N*-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

As used herein, compounds which are "commercially available" may be obtained from standard commercial sources including Acros Organics (Pittsburgh PA), 10 Aldrich Chemical (Milwaukee WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park UK), Avocado Research (Lancashire U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemserv Inc. (West Chester PA), Crescent Chemical Co. (Hauppauge NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester NY), Fisher Scientific Co. (Pittsburgh PA), Fisons 15 Chemicals (Leicestershire UK), Frontier Scientific (Logan UT), ICN Biomedicals, Inc. (Costa Mesa CA), Key Organics (Cornwall U.K.), Lancaster Synthesis (Windham NH), Maybridge Chemical Co. Ltd. (Cornwall U.K.), Parish Chemical Co. (Orem UT), Pfaltz & Bauer, Inc. (Waterbury CN), Polyorganix (Houston TX), Pierce Chemical Co. (Rockford IL), Riedel de Haen AG (Hannover, Germany), Spectrum Quality Product, 20 Inc. (New Brunswick, NJ), TCI America (Portland OR), Trans World Chemicals, Inc. (Rockville MD), and Wako Chemicals USA, Inc. (Richmond VA).

As used herein, "suitable conditions" for carrying out a synthetic step are explicitly provided herein or may be discerned by reference to publications directed to methods used in synthetic organic chemistry. The reference books and treatise set 25 forth above that detail the synthesis of reactants useful in the preparation of compounds of the present invention, will also provide suitable conditions for carrying out a synthetic step according to the present invention.

As used herein, "methods known to one of ordinary skill in the art" may be identified through various reference books and databases. Suitable reference books 30 and treatise that detail the synthesis of reactants useful in the preparation of compounds of the present invention, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; H. O. House, "Modern Synthetic Reactions", 35 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, "Heterocyclic

Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992. Specific and analogous reactants may also be identified through the indices of known chemicals prepared by the Chemical Abstract

5 Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., www.acs.org may be contacted for more details).

10 Chemicals that are known but not commercially available in catalogs may be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services.

"Prodrugs" is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term "prodrug" refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when

15 administered to a subject in need thereof, but is converted *in vivo* to an active compound of the invention. Prodrugs are typically rapidly transformed *in vivo* to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., *Design of Prodrugs* (1985), pp.

20 7-9, 21-24 (Elsevier, Amsterdam).

A discussion of prodrugs is provided in Higuchi, T., *et al.*, "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in *Bioreversible Carriers in Drug Design*, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.

25 The term "prodrug" is also meant to include any covalently bonded carriers which release the active compound of the invention *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or *in*

30 *vivo*, to the parent compound of the invention. Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate

35 and benzoate derivatives of alcohol and amine functional groups in the compounds of

the invention and the like.


"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

5 "Therapeutically effective amount" refers to that amount of a compound of the invention which, when administered to a human in need thereof, is sufficient to effect treatment, as defined below, for a disease-state characterized by thrombotic activity. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, and the 10 age of the human to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.

"Treating" or "treatment" as used herein covers the treatment of a disease-state in a mammal, preferably a human, which disease-state is characterized by thrombotic activity, and includes:

15 (i) preventing the condition from occurring in a human, in particular, when such human is predisposed to the condition but has not yet been diagnosed as having it;
 (ii) inhibiting the condition, *i.e.*, arresting its development; or
 (iii) relieving the condition, *i.e.*, causing regression of the condition.


In the above definitions, the use of parentheses in a formula is used to conserve 20 space. Accordingly, the use of parenthesis in a formula indicates that the group enclosed within the parentheses is attached directly to the atom preceding the parenthesis. For example, the term "di(carboxy)alkoxy" is defined as a radical of the formula -O-R_a(C(O)OH)-C(O)OH. This formula can be drawn as follows:



25 It will also be appreciated that certain compounds of the invention or pharmaceutically acceptable salts thereof, may exist in, and be isolated in, isomeric forms, including tautomeric forms, *cis*- or *trans*-isomers. In addition, certain compounds of the invention or pharmaceutically acceptable salts thereof may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other 30 stereoisomeric forms that may be defined, in terms of absolute stereochemistry, such as (R)- or (S)-. The present invention is meant to include all such possible isomers, as

well as their racemic and optically pure forms. Optically active (*R*)- and (*S*)- isomers may be prepared using chiral synthons or chiral reagents by methods known to those of ordinary skill in the art, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of 5 geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

The nomenclature used herein is a modified form of the I.U.P.A.C. nomenclature system wherein the compounds of the invention are named herein as derivatives of the quinoline or naphthalene moiety.



10

is named herein as 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-amino-4-(1-carboxycyclobut-1-oxy)quinoline. Unless otherwise indicated, compound names are intended to include any single stereoisomer, enantiomer, racemate or mixtures thereof.

15

Utility of the Compounds of the Invention

The compounds of the invention act as selective antagonists of the platelet ADP receptor, P2Y_{AC}. Accordingly, the compounds are useful in treating disease-states which are characterized as having thrombotic activity. In particular, the 20 compounds are useful as inhibitors of platelet activation, aggregation and degranulation, anti-thrombotic agents or in the treatment or prophylaxis of unstable angina, coronary angioplasty (PTCA), myocardial infarction, perithrombolysis, primary arterial thrombotic complications of atherosclerosis such as thrombotic or embolic stroke, peripheral vascular disease, myocardial infarction with or without thrombolysis, 25 arterial complications due to interventions in atherosclerotic disease such as angioplasty, endarterectomy, stent placement, coronary and other vascular graft surgery, thrombotic complications of surgical or mechanical damage such as tissue

salvage following accidental or surgical trauma, reconstructive surgery including skin and muscle flaps, conditions with a diffuse thrombotic/platelet consumption component such as disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, thrombotic complications of septicemia, adult respiratory distress syndrome, anti-phospholipid syndrome, heparin-induced thrombocytopaenia and pre-eclampsia/eclampsia, or venous thrombosis such as deep vein thrombosis, venoocclusive disease, hematological conditions such as myeloproliferative disease, including thrombocythemia; or in the prevention of mechanically-induced platelet activation *in vivo*, such as cardiopulmonary bypass (prevention of microthromboembolism), mechanically- induced platelet activation *in vitro*, such as use in the preservation of blood products, e.g. platelet concentrates, or shunt occlusion such as in renal dialysis and plasmapheresis, thrombosis secondary to vascular damage/inflammation such as vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease and organ graft rejection, conditions such as migraine, Raynaud's phenomenon, atheromatous plaque formation/progression, vascular stenosis/restenosis and asthma, in which platelet-derived factors are implicated in the disease process.

The compounds of formula (I) are also useful as standard or reference compounds, for example, as a quality standard or control, in tests or assays involving the inhibition of the platelet ADP receptor, P2Y_{Ac}. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving the platelet ADP receptor, P2Y_{Ac}. For example, a compound of formula (I) could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure that the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds of formula (I) could be used to test their effectiveness.

30 Testing of the Compounds of the Invention

The ability of the compounds to inhibit the platelet adenosine diphosphate receptor known as the P2Y_{Ac} receptor, and its biological effects may be tested in a variety of *in vitro*, *ex vivo* and *in vivo* assays. For example, the ability of the compounds to bind to the P2Y_{Ac} receptor may be measured by methods similar to those described in Gachet, C. et al., *Br. J. Haematol.* (1995), Vol. 91, pp. 434-444 and

Mills, D.C.B., *Thromb. Haemost.* (1996), Vol. 76, No. 6, pp. 835-856, and by the method described below in Example 17. The ability of the compounds to inhibit ADP-induced aggregation of platelets may be measured by methods similar to those described in R.G. Humphries, *Br. J. Pharm.* (1995), Vol. 115, pp. 1110-1116 and

5 5 *Methods in Enzymology*, Vol. 169, p. 3 and by the method described below in Example 18. The ability of the compounds to inhibit thrombus formation *in vivo* or *ex vivo* may be measured by methods similar to those described in J.M. Herbert, *Cardiovasc. Drug Reviews* (1993), Vol. 11, No. 2, pp. 180-198 or J.D. Folts, *Circulation* (1976), Vol. 54, No. 3, p. 365, or by the methods described below in Example 19. The results of these

10 10 assays clearly demonstrate that the compounds of the invention are functional antagonists of the platelet adenosine diphosphate receptor and are therewith useful in inhibiting platelet aggregation and thrombus formation.

Administration of the Compounds of the Invention

15 15 Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out *via* any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally, topically, transdermally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid

20 20 dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The compositions will include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other

25 25 medicinal agents, pharmaceutical agents, carriers, adjuvants, *etc.*

Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. Preferably, the composition

30 30 will be about 5% to 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.

The preferred route of administration is oral, using a convenient daily dosage regimen which can be adjusted according to the degree of severity of the disease-state

35 35 to be treated. For such oral administration, a pharmaceutically acceptable composition

containing a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, 5 gelatin, sucrose, citrate, propyl gallate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.

Preferably such compositions will take the form of capsule, caplet or tablet and therefore will also contain a diluent such as lactose, sucrose, dicalcium phosphate, and 10 the like; a disintegrant such as croscarmellose sodium or derivatives thereof; a lubricant such as magnesium stearate and the like; and a binder such as a starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose ether derivatives, and the like.

The compounds of the invention, or their pharmaceutically acceptable salts, may also be formulated into a suppository using, for example, about 0.5% to about 50% 15 active ingredient disposed in a carrier that slowly dissolves within the body, e.g., polyoxyethylene glycols and polyethylene glycols (PEG), e.g., PEG 1000 (96%) and PEG 4000 (4%).

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., a compound(s) of the invention (about 0.5% to 20 about 20%), or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension.

If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering 25 agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.

Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, 18th Ed., (Mack Publishing Company, Easton, Pennsylvania, 1990). The composition to be 30 administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state characterized by thrombotic activity in accordance with the teachings of this invention.

The compounds of the invention, or their pharmaceutically acceptable salts, are 35 administered in a therapeutically effective amount which will vary depending upon a

variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disease-states; and the host undergoing therapy. Generally, a therapeutically effective daily dose is from about 0.14 mg to about 14.3 mg/kg of body weight per day of a compound of the invention, or a pharmaceutically acceptable salt thereof; preferably, from about 0.7 mg to about 10 mg/kg of body weight per day; and most preferably, from about 1.4 mg to about 7.2 mg/kg of body weight per day. For example, for administration to a 70 kg person, the dosage range would be from about 10 mg to about 10,000 mg per day of a compound of the invention, or a pharmaceutically acceptable salt thereof, preferably from about 50 mg to about 700 mg per day, and most preferably from about 100 mg to about 500 mg per day.

Preferred Embodiments

15 Of the compounds of formula (I) as set forth above in the Summary of the Invention, several groups of compounds are particularly preferred.

One preferred group is that group of compounds wherein:

a is 1 or 2;

b is 1;

20 A is =N-;

R¹ is alkoxy carbonyl;

R² is carboxy alkyl, alkoxy carbonyl alkyl, carboxy alkoxy carbonyl alkyl or heterocyclyl alkyl;

R³ is alkoxy, alkoxy carbonyl alkoxy, alkoxy carbonyl cyclo alkoxy, carboxy alkoxy,

25 carboxy cyclo alkoxy, aminocarbonyl cyclo alkoxy, heterocyclyl, tetrahydro furanonyl oxy or heterocyclyl alkoxyl;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, halo alkyl, halo alkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkyl carbonyl, nitro, amino, mono alkylamino, 30 dialkylamino, carboxy alkylamino, alkyl carbonyl amino, di(alkyl carbonyl) amino, hydroxy alkyl, dialkylamino alkyl, carboxy alkoxy, alkoxy carbonyl alkoxy, dialkylamino alkoxy, and heterocyclyl alkoxy;

R⁵ is hydrogen, alkyl or hydroxalkyl;

R⁶ is -N(R⁷)-C(O)-; and

35 R⁷ is hydrogen or alkyl.

A preferred subgroup of this group of compounds is that subgroup of compounds wherein:

- a is 1 or 2;
- b is 1;
- 5 A is =N-;
- R¹ is alkoxycarbonyl;
- R² is carboxyalkyl, alkoxycarbonylalkyl or heterocyclalkyl;
- R³ is alkoxy, alkoxycarbonylcycloalkoxy, carboxycycloalkoxy, tetrahydrofuranonyloxy, aminocarbonylcycloalkoxy, heterocyclyl, or heterocyclalkoxy;
- 10 each R⁴ is independently selected from the group consisting of hydrogen, alkyl and heterocyclalkoxy;
- R⁵ is hydrogen, alkyl or hydroxyalkyl;
- R⁶ is -N(R⁷)-C(O)-; and
- R⁷ is hydrogen.
- 15 A preferred class of this subgroup of compounds is that class of compounds wherein R² is carboxyalkyl.

Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(20 oxiranyl)methoxyquinoline;
- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(morpholin-4-yl)quinoline;
- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-tetrazol-5-ylethoxy)quinoline;
- 25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(tetrazol-5-yl)methoxyquinoline;
- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-aminocarbonylpiperidin-1-yl)quinoline;
- 30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxypiperidin-1-yl)quinoline;
- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-ethoxycarbonylpiperidin-1-yl)quinoline;
- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-methylpiperazin-1-yl)quinoline;
- 35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-

hydroxypyrrolidin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-hydroxypiperidin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-

5 (carboxymethyl)piperazin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(carboxymethyl)piperazin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(2-carboxy-4-hydroxypyrrolidin-1-yl)ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(tetrazol-5-yl)methoxyquinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-tetrazol-5-ylethoxy)quinoline.

Particularly preferred of these preferred compounds is 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-tetrazol-5-ylethoxy)quinoline.

Another preferred class of this subgroup of compounds is that class of compounds wherein R² is alkoxy carbonylalkyl.

Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(tetrahydro-2-oxofuran-3-yl)oxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(oxiranyl)methoxyquinoline;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(3-ethoxycarbonylpiperidin-1-yl)quinoline; and;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-4-(1-tetrazol-5-ylethoxy)quinoline.

Another preferred class of this subgroup of compounds is that class of compounds wherein R² is heterocyclalkyl.

Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(imidazol-4-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(indol-3-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(1-(carboxymethyl)imidazol-4-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(1,2,4-triazol-3-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-4-(1-ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; and

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(tetrazol-5-yl)ethyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline.

Particularly preferred of these preferred compounds are the following compounds:

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(tetrazol-5-yl)ethyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline.

Another preferred subgroup of this group of compounds is that subgroup of compounds wherein:

25 a is 1 or 2;

b is 1;

A is =N-;

R¹ is alkoxy carbonyl;

R² is carboxyalkyl, carboxyalkoxycarbonylalkyl or alkoxy carbonylalkyl;

30 R³ is alkoxy, alkoxy carbonylalkoxy, alkoxy carbonylcycloalkoxy, aminocarbonylcycloalkoxy, carboxyalkoxy or carboxycycloalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkyl carbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkyl carbonylamino, di(alkyl carbonyl)amino,

hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, and dialkylaminoalkoxy;

R⁵ is hydrogen, alkyl or hydroxyalkyl;

R⁶ is -N(R⁷)-C(O)-; and

5 R⁷ is hydrogen or alkyl.

A preferred class of this subgroup of compounds is that class of compounds wherein:

R³ is alkoxy carbonylalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl or halo;

10 and

R⁵ is hydrogen.

Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

15 (methoxycarbonyl)propyl]aminocarbonyl-4-(methoxycarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

(methoxycarbonyl)propyl]aminocarbonyl-4-(1-methyl-1-

(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-

20 dimethylethoxycarbonylpropyl]aminocarbonyl-4-(1-

(ethoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-

(ethoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

25 (methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)-2-

methoxypropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-

30 dimethylethoxycarbonylpropyl]aminocarbonyl-4-(1-methyl-1-

(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-

methyl-1-(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-5 methyl-4-(1-(ethoxycarbonyl)propoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)-2-methylpropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline; and

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline.

Particularly preferred of these preferred compounds are the following compounds:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-15 methyl-4-(1-(ethoxycarbonyl)propoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)-2-methylpropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline; and

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline.

Another preferred class of this subgroup of compounds is that class of compounds wherein:

R³ is alkoxy carbonylcycloalkoxy or aminocarbonylcycloalkoxy; and

25 R⁵ is hydrogen.

Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-30 dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

35

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(dimethylethoxycarbonyl)propyl]aminocarbonyl-7-(benzyloxy)-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-hydroxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-(aminocarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-fluoro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-hydroxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-fluoro-6-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(1-methylethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

15 15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

20 20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

25 25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

30 30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methylthio-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(methoxycarbonyl)cyclobut-1-oxy)quinoline.

Particularly preferred of these preferred compounds are the following

35 35 compounds:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline.

15 Another preferred class of this subgroup of compounds is that class of compounds wherein:

R^3 is carboxyalkoxycarbonylalkyl or carboxyalkoxy; and

R^5 is hydrogen.

Preferred compounds of this class of compounds are those compounds

20 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((carboxy)methoxycarbonyl)propyl]aminocarbonyl-4-(carboxy)methoxyquinoline

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxy)methoxyquinoline;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-methyl-1-carboxyethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxy-2,2-dimethylpropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxyethoxy)quinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(carboxy)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxyethoxy)quinoline;

35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(carboxy)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxypropoxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxy-2-methylpropoxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline.

Particularly preferred of these preferred compounds are the following compounds:

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(carboxy)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxypropoxy)quinoline;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxy-2-methylpropoxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline.

25 Another preferred class of this subgroup of compounds is that class of compounds wherein:

R^3 is carboxycycloalkoxy; and

R^5 is hydrogen.

A preferred subclass of this class of compounds is that subclass of compounds 30 wherein each R^4 is independently selected from the group consisting of alkyl, hydroxyalkyl, alkoxy, halo, haloalkyl, and dialkylaminoalkyl.

Preferred compounds of this subclass of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-8-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(diethylamino)methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(diethylamino)methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(trifluoromethyl)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(hydroxymethyl)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-ethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-ethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-bromo-4-(1-carboxycyclobut-1-oxy)quinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-difluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-fluoro-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-5 methylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1- methylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-15 1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1- methylethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1- methylethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-30 methylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-5 chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-15 dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline.

Particularly preferred of these preferred compounds are the following compounds:

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-35 dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline.

Another preferred subclass of this class of compounds is that subclass of compounds wherein each R⁴ is independently selected from the group consisting of cyano, nitro, amino, monoalkylamino, and dialkylamino.

Preferred compounds of this subclass of compounds are those compounds

5 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-nitro-
4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-
amino-4-(1-carboxycyclobut-1-oxy)quinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
cyano-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-
cyano-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-nitro-
15 4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
amino-4-(1-carboxycyclobut-1-oxy)quinoline.

Another preferred subclass of this class of compounds is that subclass of compounds wherein each R⁴ is independently selected from the group consisting of
20 alkoxy, aralkoxy, haloalkoxy, hydroxy, alkylthio, carboxyalkoxy, alkoxy carbonylalkoxy and dialkylaminoalkoxy.

Preferred compounds of this subclass of compounds are those compounds selected from the group consisting of the following:

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
(benzyloxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-n-
propoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
(carboxy)methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
(diethylamino)ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
35 methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(benzyloxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(carboxy)methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-10 methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(1-methylethoxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(trifluoromethoxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-trifluoromethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-20 hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methylthio-4-(1-carboxycyclobut-1-oxy)quinoline.

Another preferred subclass of this class of compounds is that subclass of compounds wherein each R⁴ is independently selected from the group consisting of 25 hydrogen, carboxy, alkoxy carbonyl, aminocarbonyl and alkylcarbonyl.

Preferred compounds of this subclass of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxybutyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-35 carboxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-acetyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-ethoxycarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-acetyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-carboxy-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-10 aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline.

Another preferred class of this subgroup of compounds is that class of compounds wherein:

R^3 is alkoxy; and

R^6 is hydrogen.

15 Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-20 methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-4-(1,1-dimethylethoxy)carbonylbutyl]-aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-4-carboxybutyl]aminocarbonyl-4-methoxyquinoline;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-ethoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-30 methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-((1,1-dimethylethoxy)carbonyl)ethyl]-aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl][methyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-((1,1-dimethylethoxy)carbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-(methoxycarbonyl)pentyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-(carboxy)pentyl]aminocarbonyl-4-methoxyquinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-methoxyquinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-methoxyquinoline.

15 Another preferred class of this subgroup of compounds is that class of compounds wherein:

R³ is alkoxy; and

R⁵ is alkyl or hydroxyalkyl.

Preferred compounds of this class of compounds are those compounds

20 selected from the group consisting of the following:

2-[1-(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

25 2-[1-(3-(1-methylethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

30 2-[1-(2-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(2-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(1-methylethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(1-hydroxyethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; and
2-[1-(3-(1-hydroxyethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline.

5 Another preferred group of compounds of formula (I) as set forth above in the Summary of the Invention is that group of compounds wherein:
a is 1 or 2;
b is 1;
A is =N-;

10 R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, alkoxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxy carbonylalkylcarbonyl, alkoxy carbonylalkyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, alkoxy carbonylaminocarbonyl, alkylsulfonyl, arylsulfonyl, heterocyclyl, or heterocyclylcarbonyl;

15 R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonyl aminoalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxy carbonylalkyl, aralkoxy carbonylalkyl,

20 carboxyalkoxycarbonylalkyl, alkoxy carbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonyl aminoalkyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxy carbonylalkyl)(alkyl)aminocarbonylalkyl, and (carboxyalkyl)(alkyl)aminocarbonylalkyl;

25 R³ is hydrogen, alkyl, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxy carbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyl oxy, carboxyalkenyl oxy, alkoxy carbonylalkenyl oxy, (cycloalkyl)(alkoxy carbonyl)alkoxy,

30 (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxy carbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxy carbonyl)alkyl)aminocarbonyl,

35 mono((alkoxy carbonyl)(carboxy)alkyl)aminocarbonyl,

mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy,
dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy,
mono(carboxyalkyl)aminocarbonylalkoxy,
mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy,
5 alkoxy carbonylcycloalkoxy, and aminocarbonylcycloalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy,
aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy,
alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino,
10 dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino,
hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy,
dialkylaminoalkoxy, or heterocyclylalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl,
hydroxyalkyl, aralkyl, carboxy, alkoxy carbonyl, aralkoxycarbonyl, carboxyalkyl,
or alkoxy carbonylalkyl;

15 R⁶ is -N(R⁷)-C(O)-; and
R⁷ is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl.
A preferred subgroup of this group of compounds is that subgroup of
compounds wherein:
R³ is hydrogen or alkoxy;

20 each R⁴ is independently hydrogen, halo or carboxyalkylamino;
R⁵ is hydrogen or alkyl; and
R⁷ is hydrogen or alkyl.
A preferred class of this subgroup of compounds is that class of compounds
wherein R¹ is hydrogen, alkyl, aralkyl, carboxyalkyl or alkoxy carbonylalkyl.

25 Preferred compounds of this class of compounds are those compounds
selected from the group consisting of the following:
2-[(piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(2-methyl-4-(4-fluorobenzyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;

30 2-[(2-methyl-4-benzylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;
2-[(4-benzylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-ethylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(1,1-dimethylethoxy)carbonylmethyl)piperazin-1-yl]carbonylmethyl]aminocarbonyl-
35 4-methoxyquinoline;

2-[(4-(carboxymethyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-methylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-
5 methoxyquinoline; and
2-[1-(2-methyl-4-(benzyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline.

Another preferred class of this subgroup of compounds is that class of compounds wherein R¹ is aryl.

10 Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[(4-(2-methyl-5-chlorophenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
15 2-[1-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-chlorophenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
20 2-[1-(4-(3-methylphenyl)-3-methylpiperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-chlorophenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
25 2-[1-(3-methyl-4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(3-chlorophenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(3-methyl-4-(3-methylphenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; and
30 2-[(4-(3-methylphenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

Another preferred class of this subgroup of compounds is that class of compounds wherein R¹ is heterocyclyl or heterocyclycarbonyl.

Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl-3-
(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(benzoxazol-2-yl)piperazin-1-yl)carbonyl-3-
(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

5 2-[1-(4-(benzthiazol-2-yl)piperazin-1-yl)carbonyl-3-
(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
10 methoxyquinoline;

2-[1-(4-(benzoxazol-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(benzthiazol-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
15 methoxyquinoline;

2-[(4-(2-hydroxy-3-chloropyridin-5-yl)carbonyl)piperazin-1-
y]carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

15 2-[1-(3-(2-methylpropyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(1-methylethyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
20 carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-benzyl-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(4-hydroxybenzyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
25 carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl-3-(1,1-
30 dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(piperidin-4-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-
4-methoxyquinoline;

2-[(4-(furan-2-yl)carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;

2-[(4-(thien-2-yl)carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;

2-[(4-(morpholin-4-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; and
2-[(4-(pyridin-2-yl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

Another preferred class of this subgroup of compounds is that class of
5 compounds wherein R¹ is aminocarbonyl, monoalkylaminocarbonyl or
alkoxycarbonylaminocarbonyl.

Preferred compounds of this class of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonyl-3-
10 (methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonyl-3-
carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(aminocarbonyl)piperazin-1-yl)carbonyl-3-
15 (methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(aminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
methoxyquinoline;
2-[(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-
4-methoxyquinoline;
2-[(4-((1-methylethyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
20 methoxyquinoline;
2-[(4-((n-propyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;
2-[(4-((n-butyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;
25 2-[(4-((n-hexyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;
2-[(4-((n-pentyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; and
2-[(4-((ethoxycarbonyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
30 methoxyquinoline.

Another preferred class of this subgroup of compounds is that class of compounds wherein R¹ is alkylcarbonyl, alkoxyalkoxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, or haloalkoxycarbonyl.

35 Preferred compounds of this class of compounds are those compounds

selected from the group consisting of the following:

2-[(4-(trichloromethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(benzyloxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

5 2-[(4-(1-chloroethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(phenoxy carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

10 2-[(4-(2-carboxyethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(5-(ethoxycarbonyl)pentyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

15 2-[(4-(5-carboxypentyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-acetamidophenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

20 2-[(4-((2-methoxyethoxy)methyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-methoxycarbonylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

25 2-[(4-(n-propylsulfonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2,5-dibromophenyl)sulfonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2,6-difluorophenyl)sulfonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

30 2-[(4-(3-bromophenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-ethylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-n-propylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

35 2-[(4-(4-n-butylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(phenoxyethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2,2-dimethylpropyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

5 2-[(4-(2-ethoxycarbonyethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(*n*-propyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(*n*-pentyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

10 2-[(4-(2-phenylcyclopropyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-bromo-5-methoxyphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; and

15 2-[(4-(*n*-butyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(3-trifluoromethoxyphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

Another preferred group of compounds of formula (I) as set forth above in the

20 Summary of the Invention is that group of compounds wherein:

a is 1 or 2;

b is 1;

A is =N-;

R¹ is alkoxy carbonyl;

25 R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonyl aminoalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, aralkoxy carbonylalkyl, carboxyalkoxy carbonylalkyl, alkoxy carbonylalkoxy carbonylalkyl, aminocarbonylalkyl,

30 aralkoxy carbonyl aminoalkyl, alkoxy carbonylalkyl amino carbonylalkyl, carboxyalkyl amino carbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, or (carboxyalkyl)(alkyl)aminocarbonylalkyl;

R³ is hydrogen, alkyl, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxycarbonyl)alkoxy, carboxyalkoxy,

35 di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy,

hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyloxy, carboxyalkenyloxy, alkoxy carbonyl alkenyloxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, 5 mono(alkoxycarbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxycarbonyl)alkyl)aminocarbonyl, mono(alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, 10 dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy, alkoxy carbonylcycloalkoxy, aminocarbonylcycloalkoxy or tetrahydrofuranonlyloxy;

15 each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, 20 dialkylaminoalkoxy, and heterocyclalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxy carbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxy carbonylalkyl;

R⁶ is -N(R⁷)-C(O)-; and

25 R⁷ is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl.

A preferred subgroup of this group of compounds is that subgroup of compounds wherein:

R² is hydrogen, alkyl, aryl, aralkyl, hydroxyalkyl, haloalkylsulfonylaminoalkyl, or alkoxy carbonylalkoxycarbonylalkyl; and

30 R³ is alkyl, halo, carboxyalkenyl, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxycarbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyloxy, carboxyalkenyloxy, alkoxy carbonyl alkenyloxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, 35 (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy,

(dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxycarbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxycarbonyl)alkyl)aminocarbonyl,
5 mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy,
10 alkoxycarbonylcycloalkoxy, aminocarbonylcycloalkoxy, or tetrahydrofuranonyloxy.

Preferred compounds of this subgroup of compounds are those compounds selected from the group consisting of the following:

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
15 (ethoxycarbonyl)methoxyquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
(carboxy)methoxyquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
(aminocarbonyl)methoxyquinoline;
20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(((1,1-
dimethylethoxy)carbonyl)methoxy)-carbonylpropyl]aminocarbonyl-4-((1,1-
dimethylethoxy)carbonyl)methoxyquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
25 (ethoxycarbonyl)propoxy)quinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
carboxypropoxy)quinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
30 (ethoxycarbonyl)prop-2-en-1-oxy)quinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(tetrahydro-2-
oxofuran-3-yl)oxyquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-carboxy-3-
hydroxypropoxy)quinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1,1-
di(ethoxycarbonyl)methoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1,1-di(carboxy)methoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(ethoxycarbonyl)ethoxy)quinoline;

5 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-carboxyethoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-(carboxy)prop-1-en-1-oxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-10 (methoxycarbonyl)propoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(carboxy)propoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline;

15 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-methyl-1-(carboxy)ethoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-20 (carboxy)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((trifluoromethyl)sulfonylamino)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((trifluoromethyl)sulfonylamino)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline.

25 Another preferred subgroup of this group of compounds is that subgroup of compounds wherein:

R² is alkylsulfonylalkyl, aralkoxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl,

30 carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxy carbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl,

35 (carboxyalkyl)(alkyl)aminocarbonylalkyl; and

R³ is hydrogen, hydroxy or alkoxy.

Preferred compounds of this subgroup of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-((2-chlorobenzyl)oxy)carbonyl]amino-
5 pentyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
(benzyloxycarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(benzyloxy)ethyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-aminopentyl]aminocarbonyl-4-
methoxyquinoline;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(aminocarbonyl)ethyl]aminocarbonyl-
4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
(aminocarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
(benzyloxycarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
(((carboxy)methyl)aminocarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
(benzyloxycarbonyl)propyl]aminocarbonyl-4-ethoxyquinoline;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-(1,1-
dimethylethoxy)carbonylphenyl)-ethyl]aminocarbonyl-4-methoxyquinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
((methoxycarbonyl)methyl)thioethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
(carboxymethyl)thioethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
35 ((carboxymethyl)aminocarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(((1,1-
5 dimethylethoxycarbonyl)methyl)aminocarbonyl)propyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(((1,1-
10 dimethylethoxycarbonyl)methyl)(methyl)aminocarbonyl)ethyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
15 (((carboxy)methyl)(methyl)aminocarbonyl)ethyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
20 (carboxy)methoxyethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
25 (benzyloxycarbonyl)propyl]aminocarbonyl-5-nitroquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
30 ((ethoxycarbonyl)methoxycarbonyl)propyl]aminocarbonyl-5-aminoquinoline;
and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
35 (methylsulfonyl)propyl]aminocarbonyl-4-methoxyquinoline.

Another preferred subgroup of this group of compounds is that subgroup of
40 compounds wherein:

R² is hydrogen, alkyl, aryl, aralkyl or hydroxyalkyl; and

R³ is hydrogen, hydroxy, or alkoxy.

Preferred compounds of this subgroup of compounds are those compounds
selected from the group consisting of the following:

2-[[(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
45 methoxyquinoline;

2-[[(3-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
50 methoxyquinoline;

2-[[(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
55 methoxyquinoline;

2-[[(4-(2-methylpropoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
60 methoxyquinoline;

2-[[(4-(methoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
65 methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonylethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-phenylethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-methylpropyl]aminocarbonyl-4-methoxyquinoline;

10 2-[(4-(methoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-hydroxyethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-ethoxyquinoline;

2-[(3-benzyloxy)carbonyl-4-(ethoxycarbonyl)piperazin-1-

15 yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(3-carboxy-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl](carboxymethyl)aminocarbonyl-4-methoxyquinoline;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2,4-di(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-carboxy-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-

25 methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-n-propoxyquinoline;

2-[(3-(methoxycarbonyl)methyl-4-(ethoxycarbonyl)piperazin-1-

yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

30 2-[(3-(carboxy)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-

hydroxyphenyl)methyl]aminocarbonyl-4-methoxyquinoline;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-

35 carboxyphenyl)methyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-(methoxycarbonyl)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-(carboxy)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-(carboxymethoxy)phenyl)methyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(ethoxycarbonyl)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(carboxy)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(ethoxycarbonyl)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-

20 (carboxy)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-4-hydroxyquinoline;

25 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonylquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-hydroxyquinoline; and

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

30 Another preferred group of compounds of formula (I) as set forth above in the Summary of the Invention is that group of compounds wherein:

a is 1 or 2;

b is 1;

A is =N-;

35 R¹ is hydrogen or alkoxy carbonyl;

R² is carboxyalkyl or alkoxycarbonylalkyl;

R³ is hydrogen, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxycarbonyl, di(alkoxycarbonyl)alkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, 5 haloalkenyloxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxycarbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, 10 mono(di(alkoxycarbonyl)alkyl)aminocarbonyl, mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, mono(dicarboxyalkyl)aminocarbonyl, dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, or mono(alkoxycarbonylalkyl)aminocarbonylalkoxy;

15 each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, 20 dialkylaminoalkoxy, and heterocyclalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R⁶ is -N(R⁷)-C(O)-; and

25 R⁷ is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl.

A preferred subgroup of this group of compounds is that subgroup of compounds wherein R³ is hydrogen, hydroxy, halo, alkoxy, hydroxyalkoxy, haloalkoxy, haloalkenyloxy or alkylthio.

Preferred compounds of this subgroup of compounds are those compounds 30 selected from the group consisting of the following:

2-[1-(piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;.

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-hydroxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-8-

35 methoxy-4-hydroxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-5-nitroquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(2,2,2-trifluoroethoxy)quinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(3,3,3-trifluoropropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3,3,3-trifluoropropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

10 (methoxycarbonyl)propyl]aminocarbonyl-4-(3,4,4-trifluorobut-3-en-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3,4,4-trifluorobut-3-en-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-

15 hydroxyethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(methylthio)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-(methylthio)quinoline.

20 Another preferred subgroup of this group of compounds is that subgroup of compounds wherein R³ is carboxyalkenyl, alkoxy carbonyl, di(alkoxycarbonyl)alkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, cyanoalkoxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, carboxy, dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy,

25 mono(carboxyalkyl)aminocarbonylalkoxy, or mono(alkoxycarbonylalkyl)aminocarbonylalkoxy.

Preferred compounds of this subgroup of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-

30 hydroxy-1-carboxypropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(cyanomethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-

35 (dimethylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(dimethylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-

5 (ethoxycarbonylmethylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-cyanoethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-

10 (benzylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(benzylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-

15 ((carboxy)methylamino)carbonylmethoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxy-3-(diethylamino)propoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-

20 (methoxycarbonyl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-

25 (methoxycarbonyl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-carboxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

30 (methoxycarbonyl)propyl]aminocarbonyl-4-(1,1-di(ethoxycarbonyl)methoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1,1-di(carboxy)methoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-carboxyethenyl)quinoline (34 mg);

35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-cyclohexyl-1-carboxymethoxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-cyclohexyl-1-(methoxycarbonyl)methoxy)quinoline.

Another preferred subgroup of this group of compounds is that subgroup of

35 compounds wherein R^3 is mono(alkoxycarbonylalkyl)aminocarbonyl,

mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxycarbonyl)alkyl)aminocarbonyl, mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, or mono(dicarboxyalkyl)aminocarbonyl.

Preferred compounds of this subgroup of compounds are those compounds

5 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]-aminocarbonyl-4-(methoxycarbonylmethyl)aminocarbonylquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]-aminocarbonyl-4-(carboxymethyl)aminocarbonylquinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)aminocarbonylquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-carboxy-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-carboxypropyl)aminocarbonyl]quinoline; and

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-[(1,3-dicarboxypropyl)aminocarbonyl]quinoline.

Another preferred subgroup of this group of compounds is that subgroup of compounds wherein R³ is (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, or carboxyalkylamino.

Preferred compounds of this subgroup of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-(carboxymethyl)aminoquinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-((dimethylamino)carbonylmethyl)(methyl)aminoquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)(methyl)aminoquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-di(acetyl)aminoquinoline;

35

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-acetamidoquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methyl)(2-hydroxyethyl)aminoquinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methyl)(2-(dimethylamino)ethyl)aminoquinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)aminoquinoline.

Another preferred group of compounds of formula (I) as set forth above in the

10 Summary of the Invention is that group of compounds wherein:

a is 1 or 2;

b is 1;

A is =CH-;

R¹ is alkoxy carbonyl;

15 R² is hydrogen, carboxyalkyl, or aralkoxycarbonylalkyl;

R³ is hydrogen;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and hydroxy;

R⁵ is hydrogen;

20 R⁶ is -N(R⁷)-C(O)-; and

R⁷ is hydrogen or alkyl.

Preferred compounds of this group of compounds are those compounds selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

25 (benzyloxycarbonyl)propyl]aminocarbonylnaphthalene;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

carboxypropyl]aminocarbonylnaphthalene; and

2-[4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonylnaphthalene.

Another preferred group of compounds of formula (I) as set forth above in the

30 Summary of the Invention is that group of compounds wherein:

a is 1;

b is 1;

A is =CH- or =N-;

R¹ is alkoxy carbonyl;

R^2 is hydrogen, aralkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, alkoxy carbonylalkyl, or tetrahydrofuranonyl;

R^3 is hydrogen, alkoxy, or carboxyalkoxy;

R^4 is hydrogen, hydroxy, carboxyalkoxy, or alkoxy carbonylalkoxy;

5 R^5 is hydrogen;

R^6 is $-C(O)-N(R^7)-$; and

R^7 is hydrogen, alkyl or carboxyalkyl.

Preferred compounds of this group of compounds are those compounds selected from the group consisting of the following:

- 10 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]aminonaphthalene;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(ethoxycarbonyl)ethyl)carbonyl]aminonaphthalene;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl)carbonyl]aminonaphthalene;
- 15 2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(methoxycarbonyl)phenyl)ethyl)carbonyl]aminonaphthalene;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-carboxyphenyl)ethyl)carbonyl]aminonaphthalene;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-
- 20 (methoxycarbonyl)phenyl)ethyl)carbonyl]aminonaphthalene;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(tetrahydro-2-oxofuran-3-yl)methyl)carbonyl]aminonaphthalene;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxy-4-hydroxybutyl)carbonyl]aminonaphthalene;
- 25 2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-carboxyphenyl)ethyl)carbonyl]aminonaphthalene;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-5-hydroxynaphthalene;
- 30 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-4-methoxynaphthalene;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-5-(carboxymethoxy)naphthalene;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-5-(3-(ethoxycarbonyl)propoxy)naphthalene;

2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-5-(3-carboxypropoxy)naphthalene;

2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-4-(carboxymethoxy)naphthalene;

5 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][carboxymethyl]-aminonaphthalene; and

2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][carboxymethyl]amino-4-methoxynaphthalene.

Of the pharmaceutical compositions of the invention as set forth above in the

10 Summary of the Invention, preferred pharmaceutical compositions comprise a pharmaceutically acceptable excipient and a preferred compound of formula (I) as set forth above.

Of the methods of using the compounds of formula (I) as set forth above in the Summary of the Invention, preferred methods are those methods of using the

15 preferred compounds of formula (I) as set forth above.

Preparation of the Compounds of the Invention

The compounds of the invention are prepared according to the methods described below in the following Reaction Schemes. It is understood that those

20 compounds of the invention which are not specifically prepared in the following Reaction Schemes may be prepared by similar synthetic processes with the appropriately substituted starting materials and reagents. It is also understood that during the preparation of the compounds of the invention, as described below, additional reactive groups (for example, hydroxy, amino or carboxy groups) on the

25 intermediate compounds utilized in the preparation may be protected as needed by the appropriate protecting group by treating the intermediate compound prior to the desired reaction with the appropriate protecting group precursor by methods known to those of ordinary skill in the art. The protecting groups may then be removed as desired by methods known to those of ordinary skill in the art, for example, by acidic or

30 basic hydrolysis. Such protecting groups and methods are described in detail in Greene, T.W. and Wuts, P.G.M., *Protective Groups in Organic Synthesis*, 2nd Edition, 1991, John Wiley & Sons. Preferred nitrogen-protecting groups are "Boc" (*t*-butoxycarbonyl) and "CBZ" (benzyloxycarbonyl).

It will also be appreciated by those skilled in the art, although such protected

35 derivatives of compounds of formula (I) as described above in the Summary of the

Invention, may not possess pharmacological activity as such, they may be administered to a mammal having a disease-state characterized by thrombotic activity and thereafter metabolized in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs".

5 All prodrugs of compounds of formula (I) are included within the scope of the invention.

It is understood that in the following description, combinations of substituents and/or variables of the depicted formulae are permissible only if such combinations result in stable compounds which can be isolated by methods known to those of ordinary skill in the art. Transient compounds are indicated by brackets.


10

A. Preparation of Compounds of formula (D)

Compounds of formula (D) are intermediates used in the preparation of the compounds of the invention. They may be prepared as described below in Reaction Scheme 1 wherein b, R¹, R⁵, and R⁷ are as described above in the Summary of the 15 Invention; PG is a nitrogen-protecting group; R^{1a} is hydrogen or a nitrogen protecting group and R^{2a} is hydrogen, alkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, alkoxy carbonylalkyl, aralkoxy carbonylalkyl, aminocarbonylalkyl, aralkoxy carbonyl aminoalkyl, heterocyclylalkyl or cyanoalkyl:

20

REACTION SCHEME 1



Compounds of formulae (A) and (B) are commercially available, for example, from Aldrich, or may be prepared according to methods known to those of ordinary skill in the art, or by methods as described herein.

In general, compounds of formula (D) are prepared by first treating a compound of formula (B) in an aprotic solvent mixture, such as tetrahydrofuran (THF) and methylene chloride, with a slightly excess equimolar amount of a peptide coupling reaction additive, such as 1-hydroxybenzotriazole (HOBT) and a slightly excess equimolar amount of coupling agent for amide formation, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) at ambient temperature. To this mixture is added a slightly excess equimolar amount of a compound of formula (A) where R^{1a} is hydrogen and the resulting reaction mixture is allowed to stir overnight at ambient temperature. The compound of formula (C) is isolated from the reaction mixture by standard isolation techniques, such as evaporation and extraction.

Depending on what PG is, the compound of formula (C) is then reduced under standard hydrogenation conditions, such as treatment with platinum over carbon under hydrogen or treated under standard hydrolysis conditions to form a compound of formula (D), which is isolated from the reaction mixture by filtration.


Alternatively, compounds of formula (A) where R1 is hydrogen and R1a is a nitrogen protecting group can be treated with the appropriately substituted acid halide, sulfonyl halide, carbamoyl halide or isocyanate to yield the corresponding appropriately substituted compounds of formula (A), which can then be deprotected under standard deprotecting conditions prior to being reacted with the compound of formula (B) to form compounds of formula (C) and (D) wherein R1 is as described above in the Summary of the Invention.

B. Preparation of compounds of formula (Ia) and (Ib)

Compounds of formula (Ia) and (Ib) are compounds of formula (I) and are prepared as described below in Reaction Scheme 2 wherein A is =N- and R⁶ is -N(R⁷)-C(O)-; a and b are as described as above in the Summary of the Invention; R¹ is a nitrogen protecting group or is described as above in the Summary of the Invention; R^{2a} is hydrogen, alkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, alkoxy carbonylalkyl, aralkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminolalkyl, heterocyclylalkyl or cyanoalkyl; R^{3a} is alkyl, alkoxy carbonylalkyl, di(alkoxycarbonyl)alkyl, carboxyalkyl, di(carboxy)alkyl, (carboxy)(hydroxy)alkyl, (dialkylamino)(carboxy)alkyl, hydroxyalkyl, cyanoalkyl, haloalkyl, haloalkenyl, carboxyalkenyl, alkoxy carbonylalkenyl, (cycloalkyl)(alkoxycarbonyl)alkyl, (cycloalkyl)(carboxy)alkyl, aminocarbonylalkyl, dialkylaminocarbonylalkyl, monoaralkylaminocarbonylalkyl,

mono(carboxyalkyl)aminocarbonylalkyl, mono(alkoxycarbonylalkyl)aminocarbonylalkyl,
carboxycycloalkyl, alkoxy carbonylcycloalkyl, aminocarbonylcycloalkyl,
tetrahydrofuranonyl, or heterocyclalkyl; R^{3b} is alkoxy, alkoxy carbonylalkoxy,
di(alkoxycarbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy,
5 (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy,
haloalkenyloxy, carboxyalkenyloxy, alkoxy carbonylalkenyloxy,
(cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, aminocarbonylalkoxy,
dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy,
mono(carboxyalkyl)aminocarbonylalkoxy,
10 mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy,
alkoxycarbonylcycloalkoxy, aminocarbonylcycloalkoxy, tetrahydrofuranonyloxy, or
heterocyclalkoxy; R⁴, R⁵ and R⁷ are as described above in the Summary of the
Invention; R⁸ is alkyl or aralkyl, and X is halo:

REACTION SCHEME 2



Compounds of formulae (E), (F), and (J) are commercially available, for example, from Aldrich, or may be prepared according to methods known to those of ordinary skill in the art. Compounds of formula (G) and formula (H) may alternatively be prepared by methods disclosed in Great Britain Patent No. 1,334,705.

In general, compounds of formulae (Ia) and (Ib) are prepared by first treating a compound of formula (F) in a protic solvent, such as methanol, with an equimolar amount of a compound of formula (E) with stirring at ambient temperature for about 30 minutes to about an hour, preferably for about 30 minutes. The solvent is removed by evaporation to form a residue.

To an aprotic polar solvent, such as diphenyl ether, heated to between about 200°C and about 250°C, preferably to about 250°C is then added the residue and the temperature of the reaction mixture is maintained at the high temperature for about 30 minutes to an hour, preferably for about 30 minutes, at which point the reaction

mixture is allowed to cool to ambient temperature. The resulting precipitate is collected and washed with a aprotic polar solvent, such as ether, which is previously heated to below boiling temperature, to give compounds of formula (G). Further purification, for example, by dissolving the mixture in a protic solvent at boiling temperature, such as methanol, and then allowing the mixture to cool to ambient temperature for a period of about 1 to about 2 days, preferably for about 2 days, yields a compound of formula (H), which is isolated from the reaction mixture by standard techniques.

Compound of formula (H) in an aprotic solvent mixture, for example, methylene chloride and N,N-dimethylformamide (DMF), is then treated with a slightly excess equimolar amount of a peptide coupling reaction additive, such as 1-hydroxybenzotriazole (HOBT) and a slightly excess equimolar amount of coupling agent for amide formation, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) at ambient temperature. An equimolar amount of a compound of formula (D) in an aprotic solvent, such as methylene chloride, is then added to the reaction mixture. The reaction mixture is stirred at ambient temperature for about 4 to 6 hours, preferably for about 6 hours. The compound of formula (Ia) is then isolated from the reaction mixture by standard isolation techniques, such as evaporation of the solvents, extraction, and concentration.

The compound of formula (Ia) is then treated under standard Williamson synthesis conditions, such as in the presence of a base in an aprotic solvent, for example, cesium carbonate in DMF, with an equimolar amount of a compound of formula (J) at temperatures between about ambient temperature and 100°C. The reaction mixture is stirred from about 2 hours to about 10 hours, preferably for about 10 hours. The compound of formula (Ib) is then isolated from the reaction mixture by standard isolation techniques, such as preparative HPLC.

In addition, compounds of formula (Ib) where R^{2a} is alkoxy carbonylalkyl or aralkoxy carbonylalkyl may be treated under appropriate standard hydrolysis conditions known to those of ordinary skill in the art to form compounds of formula (Ib) where R^{2a} is carboxyalkyl.

In addition, compounds of formula (Ib) where R^{3b} is alkoxy carbonylalkoxy, di(alkoxy carbonyl)alkoxy, alkoxy carbonylalkenyloxy, (cycloalkyl)(alkoxy carbonyl)alkoxy, mono(alkoxy carbonylalkyl)aminocarbonylalkoxy, or alkoxy carbonylcycloalkoxy may be treated under appropriate standard hydrolysis conditions known to those of ordinary skill in the art to form compounds of formula (Ib)

- 68 -

where R^{3a} is carboxyalkyl, di(carboxy)alkoxy, carboxyalkenyloxy, (cycloalkyl)(carboxy)alkoxy, mono(carboxyalkyl)aminocarbonylalkoxy or carboxycycloalkoxy.

In addition, compounds of formula (Ib) where R^4 is nitro can be reduced under standard reducing conditions to form compounds of formula (Ib) where R^4 is amino. Such compounds can be further treated with an alkylating agent or an acylating agent to form compounds of formula (Ib) where R^4 is monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, or di(alkylcarbonyl)amino.

In addition, compounds of formula (Ib) where R^4 is a halo may be treated with a compound of formula HR^{3c} wherein R^{3c} is amino, monoalkylamino, dialkylamino, carboxyalkylamino or optionally substituted N-heterocycl (where the hydrogen in HR^{3c} is attached to the nitrogen in the N-heterocycl) in a similar manner as described below for compounds of formula (Iw) to form compounds of formula (Ib) wherein R^4 is amino, monoalkylamino, dialkylamino, carboxyalkylamino or optionally substituted N-heterocycl (where the N-heterocycl is attached to the quinoline ring via the nitrogen atom in the N-heterocycl). These compounds may be further treated with an appropriate acylating agent under standard acylation conditions to form compounds of formula (Ib) wherein R^4 is alkylcarbonylamino or di(alkylcarbonyl)amino.

In addition, compounds of formula (Ib) where R^{2a} is cyanoalkyl and/or R^{3b} is cyanoalkoxy can be treated under standard conditions, such as sodium azide, tributyl tin chloride in refluxing toluene, to form compounds of formula (Ib) where R^{2a} is tetrazolylalkyl and/or R^{3b} is tetrazolylalkoxy.

In addition, compounds of formula (Ib) where R^{2a} is aminoalkyl can be treated under standard acylation conditions, such as treatment with a haloalkylsulfonyl halide in the presence of a base, such as triethylamine, in an aprotic solvent, to form compounds of formula (Ib) where R^{2a} is haloalkylsulfonylaminoalkyl.

In addition, compounds of formula (Ib) where R^4 is alkyl can be treated under standard bromination conditions, such as treatment with N-bromosuccinimide carbon tetrachloride and azobisisobutyronitrile (AIBN) to form compounds of formula (Ib) where R^4 is bromoalkyl. These compounds may be further treated with a nucleophile, such as a dialkylamine group, to form compounds of formula (Ib) where R^4 is dialkylaminoalkyl.


In addition, compounds of formula (Ib) where R^4 is hydroxy may be treated with the appropriate group under standard ether synthesis conditions, such as Williamson ether synthesis conditions, to form compounds of formula (Ib) where R^4 is

- 69 -

alkoxy, aralkoxy, haloalkoxy, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy or heterocyclalkoxy.

In addition, compounds of formula (Ib) where R^{2a} and/or R^{3b} contain a carboxy group may be esterified under standard esterification conditions, such as Fischer esterification conditions, to form compounds of formula (Ib) where R^{2a} and/or R^{3b} contain a corresponding alkoxy carbonyl group.


Alternatively, compounds of formula (D) as prepared above in Reaction Scheme 1 can be reacted with compounds of the following structure:



which are commercially available or prepared by methods known to one of ordinary skill in the art, under standard acylation conditions to form additional compounds of the invention.

A preferred method of making intermediates used in the preparation of the compounds of the invention which avoids the formation of undesired regiosomers with respect to the substitution on the quinoline ring is illustrated below in Reaction Scheme 2a wherein R^{4b} is alkyl, alkoxy, aralkoxy, carboxy, alkoxy carbonyl, aminocarbonyl, alkyl carbonyl amino, di(alkyl carbonyl) amino, carboxyalkoxy, alkoxy carbonylalkoxy or heterocyclalkoxy; X is iodo, chloro or bromo; and R⁸ is alkyl or aralkyl:

REACTION SCHEME 2a



Compounds of formula (Fa) and formula (E) are commercially available, or can be prepared according to methods known to those of ordinary skill in the art.

5 In general, compounds of formula (Gb) are prepared by first treating a compound of formula (Fa) with a reducing agent, such as tin (II) chloride dihydrate, under standard chemical reduction conditions, such as in a protic solvent, to form the compound of formula (Fb), which is isolated from the reaction mixture by standard isolation techniques.

10 The compound of formula (Fb) in a protic solvent, such as methanol, is then treated with a slightly excess equimolar amount of a compound of formula (E) at reflux temperatures for about 2 to about 4 hours, preferably for about 4 hours. The reaction mixture is then concentrated. An organic solvent is heated to a non-boiling point temperature of between about 240°C and about 260°C, and the concentrate is then added to the solvent. The temperature of the mixture is maintained at the non-boiling point temperature for about 10 to 20 minutes, preferably for about 20 minutes. The reaction mixture is then cooled slowly to ambient temperature and diluted with an organic solvent. The compound of formula (Ga) is isolated from the reaction mixture by standard isolation techniques, such as filtration.

15


The compound of formula (Ga) is treated with a hydrolyzing agent under standard hydrolysis conditions and then treated under standard reducing conditions, such as hydrogen gas and palladium over carbon, to form a compound of formula (Gb).

5 Compounds of formula (Gb) may then be used in place of compounds of formula (G) in Reaction Scheme 1 to prepare compounds of formula (Ia) and formula (Ib).

C. Preparation of compounds of formulae (Ic) and (Id)

10 Compounds of formula (Ic) and (Id) are compounds of formula (I) wherein R⁸ are -C(O)-N(R⁷)- where R⁷ is hydrogen and are prepared as described below in Reaction Scheme 3 wherein A, a, b, R¹, R³, R⁴ and R⁵ are as described above in the Summary of the Invention; R^{1a} is hydrogen; R^{2a} is alkyl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl,
15 alkoxy carbonylalkylthioalkyl, alkoxy carbonylalkyl, aralkoxy carbonylalkyl, alkoxy carbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxy carbonylaminoalkyl, alkoxy carbonylalkylaminocarbonylalkyl, (alkoxy carbonylalkyl)(alkyl)aminocarbonylalkyl, tetrahydrofuranonyl, or heterocyclalkyl; R⁸ is alkyl or aralkyl; and each X is independently halo:

REACTION SCHEME 3



Compounds of formulae (A), (K), (L) and (O) are commercially available, for example, from Aldrich, or may be prepared according to methods known to those of ordinary skill in the art.

In general, compounds of formulae (Ic) and (Id) are prepared by first treating a compound of formula (L) in an aprotic solvent, such as methylene chloride, with a slightly excess equimolar amount of a compound of formula (K) in an aprotic solvent, such as methylene chloride, in the presence of a base, such as triethylamine, at a temperature of between about 5°C to about 10°C, preferably at about 5°C. The reaction mixture is stirred from about 30 minutes to about an hour, preferably for about an hour, at a temperature of between about 5°C to about 15°C, preferably at about 10°C. The compound of formula (M) is then isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction, and evaporation.

The compound of formula (M) is then hydrolyzed under standard hydrolysis conditions, such as treatment with lithium hydroxide in a protic solvent, such as

methanol, to form a compound of formula (N), which is isolated from the reaction mixture by standard isolation techniques, such as acidifying the reaction mixture, organic solvent extraction and evaporation. Compounds of formula (N) wherein the R³ substituent contains a carboxy group are protected accordingly prior to the next step.

5 The compound of formula (N) in an aprotic solvent, such as methylene chloride, in the presence of a base, such as triethylamine, and a slightly excess equimolar amount of a peptide coupling agent, such as HOBT and/or EDCI, at ambient temperature, is treated with a compound of formula (A). The resulting reaction mixture is stirred from about 6 hours to about 12 hours, preferably for about 10 12 hours, at ambient temperature. The compound of formula (Ic) is isolated from the reaction mixture by standard isolation techniques.

A compound of formula (Ic) in an aprotic solvent, such as DMF, was slowly added to a suspension of a strong base in an aprotic solvent, such as sodium hydride in DMF. The resulting reaction mixture was stirred at ambient temperature for a few 15 minutes, preferably for about 5 minutes. An equimolar amount of a compound of formula (O) in an aprotic solvent, such as DMF, was then added to the reaction mixture. After quenching the reaction with the addition of water after about 10 to about 20 minutes, preferably after about 10 minutes, the compound of formula (Id) was isolated from the reaction mixture by standard isolation techniques, such as organic 20 solvent extraction, evaporation and purification by flash chromatography.

Compounds of formula (Id) wherein R^{2a} is aryl (substituted by alkoxy carbonyl), aralkyl (substituted by alkoxy carbonyl), alkoxy carbonyl alkylthio alkyl, alkoxy carbonyl alkyl, aralkoxy carbonyl alkyl, alkoxy carbonyl alkylthio carbonyl alkyl, aralkoxy carbonyl amino alkyl, alkoxy carbonyl alkylaminocarbonyl alkyl, 25 (alkoxy carbonyl alkyl)(alkyl)aminocarbonyl alkyl, heterocyclyl alkyl (wherein the heterocyclyl radical is substituted by alkoxy carbonyl); may be further treated under standard hydrolysis or de-protecting conditions to form compounds of formula (Id) wherein R^{2a} is aryl (substituted by carboxy), aralkyl (substituted by carboxy), carboxy alkylthio alkyl, carboxy alkyl, carboxy alkylthio carbonyl alkyl, amino alkyl, 30 aminocarbonyl alkyl, (carboxy alkyl)(alkyl)aminocarbonyl alkyl, heterocyclyl alkyl (wherein the heterocyclyl radical is substituted by carboxy).


In a similar manner, compounds of formula (Ic) or (Id) wherein the R³ substituent contains a protected carboxy group may be treated to form the corresponding compounds of formula (Ic) and (Id) wherein the R³ substituent contains 35 a free carboxy group.

Compounds of formula (Ic) and (Id) may further be treated with an appropriate alkylating agent under standard conditions to form compounds of formula (Ic) and (Id) wherein R⁷ is alkyl, carboxyalkyl or alkoxycarboxyalkyl (R⁷).

5 D. **Preparation of compounds of formulae (If) and (Ig)**

Compounds of formulae (If) and (Ig) are compounds of formula (I) and are prepared as described below in Reaction Scheme 4 from compounds of formula (Ie), which are compounds of formula (I) synthesized as described above in Reaction Scheme 2 and Reaction Scheme 3 where R^{2a} is hydroxybenzyl. In the following 10 Reaction Scheme 4, R⁶ and A are as described above in the Summary of the Invention; R¹, R³, R⁴, R⁵, a, and b are as described above in Reaction Scheme 2 and Reaction Scheme 3; and R⁸ is alkyl or aralkyl:

REACTION SCHEME 4



Compounds of formula (Ie) are prepared as disclosed herein. (CF₃SO₂)₂O is commercially available or may be prepared according to methods known to those skilled in the art.

In general, compounds of formulae (If) and (Ig) are prepared by first treating a compound of formula (Ie) in an aprotic solvent, such as methylene chloride, at a temperature of between -40°C and -30°C, preferably at -30°C, in the presence of a base, such as triethylamine and/or dimethylaminopyridine, with a excess equimolar amount of (CF₃SO₂)₂O. The resulting reaction mixture is allowed to warm to ambient temperature. The compound of formula (Q) is then isolated from the reaction mixture by standard isolation techniques, such as evaporation and purification by flash chromatography.

The compound of formula (Q) in an aprotic solvent and base is treated with carbon monoxide in the presence of a compound of formula R⁸OH and a palladium (II) catalyst at ambient temperature. The reaction mixture is heated to between about 50°C and about 100°C for about 30 minutes to about one hour. The reaction mixture


is cooled to ambient temperature and a compound of formula (If) is isolated from the reaction mixture by standard isolation techniques, such as filtration, concentration and flash column chromatography.

The compound of formula (If) is hydrolyzed under standard hydrolysis
5 conditions to form the compound of formula (Ig).

E. Preparation of compounds of formula (Ih)

Compounds of formula (Ih) are compounds of formula (I) and are prepared as described below from compounds of formula (Ie), which are compounds of formula (I)
10 prepared as described herein. In particular, in the following Reaction Scheme 5, R¹, R³, R⁴, R⁵, R⁶, A, a and b are as described above in the Summary of the Invention; each R_a is independently an alkyl radical; and X is halo:

REACTION SCHEME 5



15

Compounds of formula (Ie) are prepared by methods disclosed herein. Compounds of the formula X-R_a-C(O)R_a where each R_a is independently an alkyl radical are commercially available or may be prepared according to methods known to those of ordinary skill in the art.


In general, compounds of formula (Ih) are prepared by treating a compound of formula (Ie) in an aprotic solvent, such as DMF, in the presence of a base, preferably cesium carbonate, with a compound having the formula $X-R_a-C(O)OR_a$ where X is halo, preferably bromo or chloro, and each R_a is independently an alkyl radical. The 5 resulting reaction mixture is stirred at ambient temperature for about 4 hours to about 8 hours, preferably for about 6 hours. The compound of formula (Ih) is isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction, evaporation and purification by HPLC.

Compounds of formula (Ih) may be further hydrolyzed under standard 10 hydrolysis conditions to form compounds having the corresponding acid substituents.

F. Preparation of compounds of formula (Ij)

Compounds of formula (Ij) are compounds of invention and are prepared as described below in Reaction Scheme 6 from compounds of formula (II), which are 15 compounds of formula (I) prepared as described herein. In the following Reaction Scheme 6, R^1 , R^3 , R^4 , R^5 , R^6 , A, a and b are as described above in the Summary of the Invention; each R_a is independently an alkyl radical; and X is halo:

REACTION SCHEME 6



Compounds of formula (li) are prepared by methods disclosed herein. Compounds of formula $X-R_a-C(O)OR_a$ are commercially available or may be prepared according to methods known to those skilled in the art.


In general, compounds of formula (lj) are prepared by treating a compound of formula (li) in an aprotic solvent, such as tetrahydrofuran, at a temperature of between about -5°C and about 5°C, preferably at 0°C, in the presence of a base, such as potassium hexamethyldisilazide, with a compound having the formula $X-R_a-C(O)ORA$ where X is halo, preferably bromo, and each Ra is independently an alkyl radical. The resulting reaction mixture is stirred from about 30 minutes to 2 hours, preferably for an hour, at a temperature of between about -5°C and about 5°C, preferably at 0°C. The reaction is quenched with the addition of water. The compound of formula (lj) is isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction, concentration and purification by elution through silica gel.

Compounds of formula (lj) may be further hydrolyzed under standard hydrolysis conditions to form compounds having the corresponding acid substituents.

G. Preparation of compounds of formulae (ll), (lm) and (ln)

Compounds of formulae (ll), (lm) and (ln) are compounds of formula (l) and are prepared as described below in Reaction Scheme 7 from compounds of formula (lk), which are compounds of formula (l) prepared as described herein. In the following Reaction Scheme 7, A, a, b, R¹, R³, R⁴, R⁵ and R⁸ are as described above in the Summary of the Invention; each R_a is independently an alkyl radical; R⁹ is hydrogen or alkyl; and X is halo:

REACTION SCHEME 7



Compounds of formula (Ik) are prepared according to methods disclosed

5 herein. Compounds of the formula $HN(R^9)-R_a-C(O)OR_a$ and formula $X-R_a-C(O)OR_a$ are commercially available or may be prepared according to methods known to those of ordinary skill in the art. If desired, compounds of formula (Ik) wherein R^3 is hydroxy or contains a hydroxy group may be protected by an appropriate oxygen-protecting group to avoid undesired side reactions.

10 In general, compounds of formula (II) and (Im) are prepared by treating a compound of formula (Ik) in an aprotic solvent, such as DMF, with an excess equimolar amount of a compound having the formula $X-R_a-C(O)OR_a$ where X is halo, preferably bromo, and each R_a is 2-[(4-(*n*-butyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline reaction mixture is heated to a temperature of between about 45°C and about 55°C, preferably at about 50°C, for about 30 minutes to about an hour, preferably for about an hour. The compound of formula (II) is then isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction and evaporation.

15 The compound of formula (II) in an aprotic solvent, such as methylene chloride, is treated under standard hydrolysis conditions to form a compound of formula (Im).

20 In general, compounds of formula (In) are prepared by treating a compound of formula (Ik) in an aprotic solvent, such as tetrahydrofuran, with a slightly excess equimolar amount of a compound having the formula $HN(R^9)-R_a-C(O)OR_a$ where R^9 is

hydrogen or alkyl and each R_a is independently an alkyl radical, in the presence of equimolar amounts of a peptide coupling agent, such as EDCI and/or HOBT and a proton scavenger, such as diisopropylethylamine (DIEA). The reaction mixture is stirred from about 6 hours to about 16 hours, preferably for about 12 hours. The 5 compound of formula (In) is isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction, concentration and purification by elution through silica gel.


Compounds of formula (In) may be further hydrolyzed under standard hydrolysis conditions to form compounds having the corresponding acid substituents.

10

H. Preparation of compounds of formula (Ip)

Compounds of formula (Ip) are compounds of formula (I) and are prepared as described below in Reaction Scheme 8 from compounds of formula (Io), which are compounds of formula (I) prepared as described above in Reaction Scheme 2. In the 15 following Reaction Scheme 8, A, a, b, R¹, R³, R⁴, R⁵ and R⁶ are as described above in the Summary of the Invention; each R_a is independently an alkyl radical and R₉ is hydrogen or alkyl:

REACTION SCHEME 8



20

Compounds of formula (lo) are prepared as described herein. Compounds of formula $\text{HN}(\text{R}^9)-\text{R}_a-\text{C}(\text{O})\text{OR}_a$ are commercially available or may be prepared according to methods known to those of ordinary skill in the art.

In general, compounds of formula (lp) are prepared by treating a compound of formula (lo) in an aprotic solvent, such as tetrahydrofuran, with an slight excess equimolar amount of a compound having the formula $\text{HN}(\text{R}^9)-\text{R}_a-\text{C}(\text{O})\text{OR}_a$ where R^9 is hydrogen or alkyl and each R_a is independently an alkyl radical, in the presence of an equimolar amounts of a peptide coupling agent, such as HOBT and EDCI and a proton scavenger, such as DIEA. The resulting reaction mixture is stirred at ambient temperature for between about 6 hours and about 16 hours, preferably for about 12 hours. The compound of formula (lp) is isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction and concentration.


If desired, compounds of formula (lp) may be further hydrolyzed under standard conditions to form compounds having the corresponding acid substituents.

15

I. Preparation of compounds of formula (lr) and (ls)

Compounds of formula (lr) and (ls) are compounds of formula (l) and are prepared as described below in Reaction Scheme 9 from compounds of formula (lq), which are compounds of formula (l) prepared as described above in Reaction Scheme 20 2. In the following Reaction Scheme 9, A, a, b, R^1 , R^3 , R^4 , R^5 and R^6 are as described above in the Summary of the Invention; each R_a is independently an alkyl radical; and X is halo:

REACTION SCHEME 9



Compounds of formula (Iq) are prepared by methods described herein or
 5 according to methods known to those of ordinary skill in the art. Compounds of
 formula $\text{X}-\text{R}_a-\text{C}(\text{O})\text{OR}_a$ are commercially available or may be prepared by methods
 known to those of ordinary skill in the art.

In general, compounds of formula (Ir) and (Is) are prepared by first treating a compound of formula (Iq) in an aprotic solvent, such as DMF, with a slightly excess
 10 equimolar amount of a compound of formula $\text{X}-\text{R}_a-\text{C}(\text{O})\text{OR}_a$ where X is halo, preferably bromo, and each R_a is independently an alkyl radical, in the presence of a base, such as potassium carbonate, and a metal halide, such as sodium iodide. The reaction mixture is heated at between about 40°C and about 60°C, preferably at about




50°C, for about 30 minutes to about an hour, preferably for about an hour. The compound of formula (I_r) is isolated from the reaction mixture by standard techniques, such as evaporation and flash column chromatography.

The compound of formula (Ir) is the hydrolyzed under standard hydrolysis conditions to form the compound of formula (Is).

J. Preparation of Compounds of Formula (Ii)

Compounds of formula (It) are compounds of formula (I) wherein A is =N- and R⁶ is -N(R⁷)-C(O)- and are prepared as described below in Reaction Scheme 10
 10 wherein a, b, R¹, R², R³, R⁴, and R⁵ are as described above in the Summary of the Invention; R^{7a} is carboxyalkyl or alkoxy carbonylalkyl; and each X is independently halo;

REACTION SCHEME 10



15

Compounds of formula (A), formula (R), and formula (T) are commercially available or may be prepared according to methods known to those of ordinary skill in the art. Compounds of formula (V) may be prepared according to methods disclosed herein.

20 In general, compounds of formula (I α) are prepared by first treating a compound of formula (A) in an aprotic solvent, such as methylene chloride, with an one-half

equimolar amount of a compound of formula (R) in the presence of a base, such as triethylamine, at a temperature of about -10°C to about 10°C, preferably at about 0°C. The resulting reaction is stirred at ambient temperature for about 2 hours to about 6 hours, preferably for about 2 hours. The compound of formula (S) is isolated from the 5 reaction mixture by standard isolation techniques.

The compound of formula (S) is then treated with an equimolar amount of a compound of formula (T) in the presence of a base, such as cesium carbonate. The resulting reaction mixture is stirred at a temperature of about 40°C to about 60°C, preferably at about 50°C, for about 30 minutes to about 2 hours, preferably for about 10 an hour. The compound of formula (U) is isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction and evaporation.


To a compound of formula (V) in an aprotic solvent, such as methylene chloride, in the presence of a base, such as triethylamine, and a slightly excess equimolar amount of a peptide coupling agent, such as HOBT and/or EDCI, is then 15 added the compound of formula (U). The reaction mixture is stirred at ambient temperature for about 6 hours to about 16 hours, preferably for about 12 hours. The compound of formula (It) is isolated from the reaction mixture by standard isolation techniques, such as evaporation of the solvents and purification by flash column chromatography.

20 The compound of formula (It) may then be hydrolyzed under standard hydrolysis conditions to form compounds having the corresponding acid substituents.

K. Preparation of Compounds of Formula (Iu)

Compounds of formula (Iu) are compounds of formula (I) wherein A is =CH- 25 and R⁶ is -C(O)-N(R⁷)- and are prepared as described in Reaction Scheme 11 below wherein a, b, R¹, R³, R⁴ and R⁵ are as described above in the Summary of the Invention; R^{2b} is hydrogen; R^{7b} is alkoxy carbonyl alkyl; R⁸ is alkyl or aralkyl; and each X is independently halo:

REACTION SCHEME 11



Compounds of formula (L), formula (W), formula (Y) and formula (A) are
 5 commercially available, or may be prepared according to methods known to those of
 ordinary skill in the art.

In general, compounds of formula (Iu) are prepared by first treating a
 compound of formula (L) in an aprotic solvent, such as DMF, with an excess equimolar
 amount of a compound of formula (W) in the presence of a base, such as potassium
 10 carbonate. The resulting reaction mixture was stirred at ambient temperature for
 about 6 hours to about 24 hours, preferably for about 24 hours. The compound of

formula (X) is isolated from the reaction mixture by standard isolation techniques, such as organic solvent extraction and evaporation.

The compound of formula (X) in an aprotic solvent, such as methylene chloride, was treated with an excess equimolar amount of a compound of formula (Y)

- 5 in the presence of a base, such as triethylamine. The resulting reaction mixture was stirred at ambient temperature for about 6 hours to about 2 days, preferably for about 12 hours. The compound of formula (Z) is isolated from the reaction mixture by standard isolation techniques, such as evaporation of the solvents and purification by flash chromatography. The compound of formula (Z) is then hydrolyzed under
- 10 standard hydrolysis conditions to form a compound of formula (AA).

The compound of formula (AA) in an aprotic solvent, such as methylene chloride, in the presence of a base, such as triethylamine, and in the presence of an equimolar amount of peptide coupling reagent, such as HOBT and/or EDCI, is treated with an equimolar amount of a compound of formula (A). The reaction mixture is

- 15 stirred from about 6 hours to about 16 hours, preferably for about 16 hours. The compound of formula (Iu) is isolated from the reaction mixture by standard isolation techniques, such as concentration, organic solvent extraction, evaporation of the solvents and purification by flash column chromatography.


- 20 The compound of formula (Iu) may then be hydrolyzed under standard hydrolysis conditions to form compounds having the corresponding acid substituents.

L. Preparation of Compounds of Formula (Iv) and Formula (Iw)

Compounds of formula (Iv) and compounds of formula (Iw) are compounds of formula (I) wherein A is =N- and R⁸ is -N(R⁷)-C(O)- and are prepared as described

- 25 below in Reaction Scheme 12 wherein a, b, R¹, R², R⁴ and R⁵ are as described above in the Summary of the Invention; R^{2a} is alkoxy carbonylalkyl or carboxyalkyl; R^{3b} is halo; R^{3c} is optionally substituted N-heterocyclyl, (carboxyalkyl)(alkyl)amino, or carboxyalkenyl; and R^{7a} is hydrogen or alkyl:

REACTION SCHEME 12



Compounds of formula (U) are prepared by methods disclosed herein.

Compounds of formula (BB) are commercially available, or may be prepared according

5 to methods disclosed in *Monatsh. Chem.* (1921), Vol. 42, p. 89, or in *J. Org. Chem.* (1947), Vol. 12, p. 456. Compounds of the formula HR^{3c} are commercially available or may be prepared according to methods known to those of ordinary skill in the art.

In general, compounds of formula (Iv) and formula (Iw) are prepared by treating a compound of formula (BB) in an aprotic solvent, such as tetrahydrofuran, 10 with an equimolar amount of a compound of formula (U) in the presence of a base, such as triethylamine and in the presence of a slightly excess equimolar amount of a peptide coupling agent, such as HOBT and/or EDCI. The resulting reaction mixture is stirred at ambient temperature for about 6 hours to about 16 hours, preferably for about 16 hours. The compound of formula (Iv) is isolated from the reaction mixture by 15 standard isolation techniques, such as organic solvent extraction and purification by

flash column chromatography. The compound of formula (Iv) may be further treated under standard hydrolysis conditions to form additional compounds of formula (Iv).

The compound of formula (Iv) in an aprotic solvent, such as dimethyl sulfoxide, is then treated with an excess equimolar amount of a compound of formula HR^{3c} in the 5 presence of a base, such as DIEA. The resulting reaction mixture is heated to about 100°C to about 110°C, preferably to about 110°C for about 6 hours to about 24 hours, preferably for about 18 hours. The resulting reaction mixture is then treated with a strong base, such as lithium hydroxide, for about 2 hours to about 4 hours, preferably for about 4 hours, to form the compound of formula (Iw), which is isolated from the 10 reaction mixture by preparative HPLC.


Alternatively, the compound of formula (Iv) is treated with a compound of formula HR^{3c} where R^{3c} is carboxyalkenyl under standard palladium catalyzed conditions to form compounds of formula (Iw) where R^{3c} is carboxyalkenyl.

Alternatively, compounds of formula (Iv) and formula (Iw) wherein the R^2 group 15 contains an ester radical, such as alkoxy carbonyl, may be hydrolyzed under standard hydrolysis conditions to form compounds of formula (Iv) and formula (Iw) wherein the R^2 group contains the corresponding carboxy radical.

M. Preparation of Compounds of Formula (Ix) and Formula (Iy)

20 Compounds of formula (Ix) and Formula (Iy) are compounds of formula (I) wherein A is =N- and R^6 is $-N(R^7)-C(O)-$ and are prepared as described below in Reaction Scheme 13 wherein a, b, R^1 , R^2 , R^4 , and R^5 are as described above in the Summary of the Invention; R^{7a} is hydrogen or alkyl; and R^8 is alkyl or aralkyl:

REACTION SCHEME 13



Compounds of formula (CC) are commercially available, for example, from Aldrich Co. Compounds of formula (DD) are commercially available or may be

5 prepared according to methods known to those of ordinary skill in the art. Compounds of formula (U) are prepared by methods disclosed herein or by methods known to those of ordinary skill in the art.

In general, compounds of formula (Ix) and formula (Iy) are prepared by first treating a compound of formula (CC) with a halogenating agent, such as

10 chlorotrimethylsilane (TMSCl) to form the corresponding acid halide, preferably the corresponding acid chloride, which is then treated with an excess molar amount of a compound of formula (DD) to form the compound of formula (EE).

The compound of formula (EE) in an aprotic solvent, such as tetrahydrofuran, is then treated with a slightly excess equimolar amount of a compound of formula (U)

15 in the presence of a slightly excess equimolar amount of a peptide coupling agent, such as HOBT and/or EDCI. The resulting solution is stirred from about 6 hours to about 18 hours, preferably for about 16 hours. The compound of formula (Ix) is isolated from the reaction mixture by standard isolation techniques, such as concentration of the product, organic solvent extraction, evaporation and purification

by flash column chromatography. Compounds of formula (Ix) may be treated under standard hydrolysis conditions to form compounds of formula (Iy).

Compounds of formula (Iy) can be further treated with compounds such as a substituted amine; a mono(alkoxycarbonylalkyl)amine, or a


5 mono(dialkoxycarbonylalkyl)amine under standard peptide coupling reaction conditions, such as in the presence of standard peptide coupling agents such as HOBT and EDCI to form compounds of formula (Iy) wherein R⁴ is aminocarbonyl, mono(alkoxycarbonylalkyl)aminocarbonyl, or mono(di(alkoxycarbonyl)alkyl)aminocarbonyl. These compounds compounds can be

10 further treated under standard hydrolysis conditions to form compounds of formula (Iy) wherein R⁴ is mono(carboxyalkyl)aminocarbonyl, mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl or mono(dicarboxyalkyl)aminocarbonyl.

15 **N. Preparation of Compounds of Formula (Iz)**

Compounds of formula (Iz) are compounds of formula (I) wherein A is =N- and R⁶ is -N(R⁷)-C(O)- and are prepared as described below in Reaction Scheme 14 wherein a, b, R¹, R², R⁴, and R⁵ are as described above in the Summary of the Invention; R^{7a} is hydrogen or alkyl; R⁸ is alkyl or aralkyl; and X is halo:

REACTION SCHEME 14



Compounds of formula (FF) and formula (DD) are commercially available or

5 may be prepared according to methods known to those skilled in the art. Compounds of formula (U) are prepared by methods disclosed herein or by methods known to those of ordinary skill in the art.

In general, compounds of formula (Iz) are prepared by first treating a compound of formula (FF) in an aprotic solvent, such as DMF, with an excess 10 equimolar amount of an alkyl halide, preferably methyl iodide, in the presence of a base, preferably cesium carbonate. The reaction mixture is stirred at a temperature between about 60°C and about 100°C, preferably at about 70°C, from about 6 hours to about 18 hours, preferably for about 12 hours. The compound of formula (GG) is isolated from the reaction mixture by standard isolation techniques, such as organic 15 solvent extraction, evaporation and purification by flash column chromatography.

The compound of formula (GG) is hydrolyzed under standard hydrolysis conditions to form a compound of formula (HH). The compound of formula (HH) in an aprotic solvent, such as THF and/or DMF, is then treated with a slightly excess

equimolar amount of a compound of formula (U) in the presence of a slightly excess equimolar amount of a peptide coupling agent, such as HOBT and/or EDCI. The resulting mixture is stirred at ambient temperature from about 6 hours to about 18 hours, preferably for about 12 hours. The compound of formula (Iz) is isolated from

5 the reaction mixture by standard isolation techniques, such as concentration, organic solvent extraction, evaporation of solvents and purification by flash column chromatography. The compound of formula (Iz) may be further treated under standard hydrolysis conditions to form compounds of the invention having the corresponding acid substituents.

10 All compounds of the invention as prepared above which exist in free base or acid form may be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid. Salts of the compounds prepared above may be converted to their free base or acid form by standard techniques.

* * * *

15 The following specific preparations and examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention. Where one or more NMR's are given for a particular compound, each NMR represents a single stereoisomer, non-racemic mixture or racemic mixture of the compound.

20

PREPARATION 1

Compounds of formula (D)

A. To a solution of *N*-carbobenzyloxy-L-glutamic acid gamma *t*-butyl ester (24.4 g, 72.3 mmol) in tetrahydrofuran ("THF") (400 mL) and CH₂Cl₂ (100 mL) was

25 added 1-hydroxybenzotriazole ("HOBT") (10.7 g, 79.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide ("EDCI") (15.3 g, 79.5 mmol). After 5 minutes, 1-ethoxycarbonylpiperazine (11.7 mL, 79.5 mmol) was added and the reaction was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford an oil, which was dissolved in ethyl acetate, and washed with saturated NaHCO₃, 1M

30 H₂SO₄ and brine. The organic layer was evaporated *in vacuo* to 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (40.7 g), as an oil that was used without further purification. To 4-ethoxycarbonyl-1-(1-

(benzyloxycarbonyl)amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine in MeOH (100 mL) was added 10% Pd/C (1 g) and the mixture was shaken under 50 psi

35 H₂ overnight. The reaction was filtered and stripped to 4-ethoxycarbonyl-1-(1-amino-3-

(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (25 g, 99%) and used without further purification; NMR (CDCl₃) 1.25 (t, 3), 1.43 (s, 9), 2.55 (m, 1), 1.90 (m, 1), 2.37 (m, 1), 2.55 (m, 1), 3.40-3.70 (m, 8), 3.80 (m, 1), 4.18 (q, 2) ppm.

B. In a similar manner, other compounds of formula (D) were prepared.

- 5 4-ethoxycarbonyl-1-(aminomethyl)carbonylpiperazine;
- 4-ethoxycarbonyl-1-(1-amino-3-carboxypropyl)carbonylpiperazine;
- 4-ethoxycarbonyl-2-methyl-1-(aminomethyl)carbonylpiperazine;
- 4-ethoxycarbonyl-3-methyl-1-(aminomethyl)carbonylpiperazine;
- 4-ethoxycarbonyl-1-(1-amino-5-((2-
- 10 chlorobenzyl)oxy)carbonylamino)pentyl)carbonylpiperazine;
- 4-ethoxycarbonyl-1-(1-amino-2-(benzyloxycarbonyl)ethyl)carbonylpiperazine;
- 4-ethoxycarbonyl-1-(1-amino-2-phenylethyl)carbonylpiperazine;
- 4-ethoxycarbonyl-1-(1-amino-2-methylpropyl)carbonylpiperazine;
- 4-ethoxycarbonyl-1-(1-amino-2-carboxyethyl)carbonylpiperazine; and
- 15 4-ethoxycarbonyl-1-(1,5-diaminopentyl)carbonylpiperazine.

PREPARATION 2

Compounds of formula (G)

A. To a solution of *m*-toluidine (20.0 g, 0.186 mol) in methanol (300 mL),

- 20 dimethyl acetylenedicarboxylate (26.42 g, 0.186 mol) was added drop-wise and the reaction mixture was stirred at ambient temperature for 30 minutes. The solvent was removed by evaporation and the residue was added to stirred diphenyl ether (150 ml), which has been preheated to 250°C. After 30 minutes, the mixture was cooled to ambient temperature and the resulting precipitate was collected and washed with hot
- 25 petroleum ether (1.5 L) to give a mixture (27.0 g) of 5-methyl-4-hydroxy-2-methoxycarbonylquinoline and 7-methyl-4-hydroxy-2-methoxycarbonylquinoline. The mixture was dissolved in boiling methanol (1.3 L) and kept at ambient temperature for two days to afford (6.45 g, 16%) of 7-methyl-4-hydroxy-2-methoxycarbonylquinoline, NMR (DMSO-d₆) 2.40 (s, 3), 3.92 (s, 3), 6.56 (s, 1), 7.16 (d, 1), 7.68 (s, 1), 7.94 (d, 1)
- 30 ppm.

B. In a similar manner, other compounds of formula (G) were prepared as follows:

- 8-methoxy-4-hydroxy-2-methoxycarbonylquinoline;
- 5-amino-4-hydroxy-2-methoxycarbonylquinoline;
- 35 5-nitro-4-hydroxy-2-methoxycarbonylquinoline;

5-carboxymethylamino-4-hydroxy-2-methoxycarbonylquinoline;
7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
5-di(acetyl)amino-4-hydroxy-2-methoxycarbonylquinoline;
5-acetylamino-4-hydroxy-2-methoxycarbonylquinoline;
5 5,7-dichloro-4-hydroxy-2-methoxycarbonylquinoline;
6-chloro-4-hydroxy-2-methoxycarbonylquinoline;
6-nitro-4-hydroxy-2-methoxycarbonylquinoline;
6-amino-4-hydroxy-2-methoxycarbonylquinoline;
7-benzyloxy-4-hydroxy-2-methoxycarbonylquinoline;
10 4,7-dihydroxy-2-methoxycarbonylquinoline;
7-prop-1-oxy-4-hydroxy-2-methoxycarbonylquinoline;
7-carboxymethoxy-4-hydroxy-2-methoxycarbonylquinoline;
7-diethylaminoethoxy-4-hydroxy-2-methoxycarbonylquinoline;
7-methoxy-4-hydroxy-2-methoxycarbonylquinoline;
15 7-(2-(4-hydroxy-2-carboxypyrrolidinyl)ethoxy)-4-hydroxy-2-methoxycarbonylquinoline;
8-methyl-4-hydroxy-2-methoxycarbonylquinoline;
6-diethylaminomethyl-4-hydroxy-2-methoxycarbonylquinoline;
6-benzyloxy-4-hydroxy-2-methoxycarbonylquinoline;
4,6-dihydroxy-2-methoxycarbonylquinoline;
20 6-carboxymethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-ethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-methoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-prop-2-oxy-4-hydroxy-2-methoxycarbonylquinoline;
7-fluoro-4-hydroxy-2-methoxycarbonylquinoline;
25 7-trifluoromethyl-4-hydroxy-2-methoxycarbonylquinoline;
7-hydroxymethyl-4-hydroxy-2-methoxycarbonylquinoline;
7-cyano-4-hydroxy-2-methoxycarbonylquinoline;
7-nitro-4-hydroxy-2-methoxycarbonylquinoline;
6-carboxy-4-hydroxy-2-methoxycarbonylquinoline;
30 7-trifluoromethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-trifluoromethoxy-4-hydroxy-2-methoxycarbonylquinoline;
7-acetyl-4-hydroxy-2-methoxycarbonylquinoline;
5-ethoxycarbonyl-4-hydroxy-2-methoxycarbonylquinoline;
6-ethyl-4-hydroxy-2-methoxycarbonylquinoline;
35 7-carboxy-4-hydroxy-2-methoxycarbonylquinoline;

6-aminocarbonyl-4-hydroxy-2-methoxycarbonylquinoline;
6,7-dimethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-chloro-7-methyl-4-hydroxy-2-methoxycarbonylquinoline;
6-fluoro-7-methyl-4-hydroxy-2-methoxycarbonylquinoline;
5 6-fluoro-4-hydroxy-2-methoxycarbonylquinoline;
6-fluoro-7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
7-bromo-4-hydroxy-2-methoxycarbonylquinoline;
6,7-dimethyl-4-hydroxy-2-methoxycarbonylquinoline;
6-methoxy-7-methyl-4-hydroxy-2-methoxycarbonylquinoline;
10 6-methoxy-7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
6-chloro-8-fluoro-4-hydroxy-2-methoxycarbonylquinoline;
6,7-dichloro-4-hydroxy-2-methoxycarbonylquinoline;
6,8-difluoro-4-hydroxy-2-methoxycarbonylquinoline;
6,7-difluoro-4-hydroxy-2-methoxycarbonylquinoline;
15 6-dimethylamino-4-hydroxy-2-methoxycarbonylquinoline;
5-fluoro-6-methyl-4-hydroxy-2-methoxycarbonylquinoline;
6-methyl-7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
6-acetyl-4-hydroxy-2-methoxycarbonylquinoline;
6-methylthio-4-hydroxy-2-methoxycarbonylquinoline;
20 4,5-dihydroxy-2-methoxycarbonylquinoline;
7-ethyl-4-hydroxy-2-methoxycarbonylquinoline;
5-methyl-4-hydroxy-2-methoxycarbonylquinoline;
5-hydroxymethoxy-4-hydroxy-2-methoxycarbonylquinoline;
5-(3-ethoxycarbonylpropoxy)-4-hydroxy-2-methoxycarbonylquinoline; and
25 5-(3-carboxypropoxy)-4-hydroxy-2-methoxycarbonylquinoline.

PREPARATION 3

Compounds of Formula (H)

A. 7-methyl-4-hydroxy-2-methoxycarbonylquinoline (6.45 g, 30.14 mmol)
30 was suspended in MeOH (150 mL) and water (100 mL), and LiOH (3.08 g, 75.5 mmol) was added and stirred at ambient temperature for 2 hours. The methanol was evaporated *in vacuo* and residue was crystallized by addition of 2N hydrochloric acid. The resulting solid was filtered, washed with water and dried to afford 7-methyl-4-hydroxy-2-carboxyquinoline (6.0 g, 98%), NMR (DMSO-d₆) 2.40 (s, 3), 6.68 (s, 1),
35 7.22 (d, 1), 7.68 (s, 1), 7.96 (d, 1).

B. In a similar manner, the following compounds of formula (H) were prepared:

8-methoxy-4-hydroxy-2-carboxyquinoline;

5-amino-4-hydroxy-2-carboxyquinoline;

5-nitro-4-hydroxy-2-carboxyquinoline;

5-carboxymethylamino-4-hydroxy-2-carboxyquinoline;

7-chloro-4-hydroxy-2-carboxyquinoline;

5-di(acetyl)amino-4-hydroxy-2-carboxyquinoline;

5-acetylamino-4-hydroxy-2-carboxyquinoline;

10 5,7-dichloro-4-hydroxy-2-carboxyquinoline;

6-chloro-4-hydroxy-2-carboxyquinoline;

6-nitro-4-hydroxy-2-carboxyquinoline;

6-amino-4-hydroxy-2-carboxyquinoline;

7-benzyloxy-4-hydroxy-2-carboxyquinoline;

15 4,7-dihydroxy-2-carboxyquinoline;

7-prop-1-oxy-4-hydroxy-2-carboxyquinoline;

7-carboxymethoxy-4-hydroxy-2-carboxyquinoline;

7-diethylaminoethoxy-4-hydroxy-2-carboxyquinoline;

7-methoxy-4-hydroxy-2-carboxyquinoline;

20 7-(2-(4-hydroxy-2-carboxypyrrolidinyl)ethoxy)-4-hydroxy-2-carboxyquinoline;

8-methyl-4-hydroxy-2-carboxyquinoline;

6-diethylaminomethyl-4-hydroxy-2-carboxyquinoline;

3-methyl-4-hydroxy-2-carboxyquinoline;

6-benzyloxy-4-hydroxy-2-carboxyquinoline;

25 4,6-dihydroxy-2-carboxyquinoline;

6-carboxymethoxy-4-hydroxy-2-carboxyquinoline;

6-ethoxy-4-hydroxy-2-carboxyquinoline;

6-methoxy-4-hydroxy-2-carboxyquinoline;

6-prop-2-oxy-4-hydroxy-2-carboxyquinoline;

30 7-fluoro-4-hydroxy-2-carboxyquinoline;

7-trifluoromethyl-4-hydroxy-2-carboxyquinoline;

7-hydroxymethyl-4-hydroxy-2-carboxyquinoline;

7-cyano-4-hydroxy-2-carboxyquinoline;

7-nitro-4-hydroxy-2-carboxyquinoline;

35 2,6-dicarboxy-4-hydroxyquinoline;

7-trifluoromethoxy-4-hydroxy-2-carboxyquinoline;
6-trifluoromethoxy-4-hydroxy-2-carboxyquinoline;
7-acetyl-4-hydroxy-2-carboxyquinoline;
5-ethoxycarbonyl-4-hydroxy-2-carboxyquinoline;
5 6-ethyl-4-hydroxy-2-carboxyquinoline;
2,7-dicarboxy-4-hydroxyquinoline;
6-aminocarbonyl-4-hydroxy-2-carboxyquinoline;
6,7-dimethoxy-4-hydroxy-2-carboxyquinoline;
6-methyl-7-chloro-4-hydroxy-2-carboxyquinoline;
10 6-chloro-7-methyl-4-hydroxy-2-carboxyquinoline;
6-fluoro-7-methyl-4-hydroxy-2-carboxyquinoline;
6-fluoro-4-hydroxy-2-carboxyquinoline;
6-fluoro-7-chloro-4-hydroxy-2-carboxyquinoline;
7-bromo-4-hydroxy-2-carboxyquinoline;
15 6,7-dimethyl-4-hydroxy-2-carboxyquinoline;
6-methoxy-7-methyl-4-hydroxy-2-carboxyquinoline;
6-methoxy-7-chloro-4-hydroxy-2-carboxyquinoline;
6-chloro-8-fluoro-4-hydroxy-2-carboxyquinoline;
6,7-dichloro-4-hydroxy-2-carboxyquinoline;
20 6,8-difluoro-4-hydroxy-2-carboxyquinoline;
6,7-difluoro-4-hydroxy-2-carboxyquinoline;
6-dimethylamino-4-hydroxy-2-carboxyquinoline;
5-fluoro-6-methyl-4-hydroxy-2-carboxyquinoline;
6-acetyl-4-hydroxy-2-carboxyquinoline;
25 6-methylthio-4-hydroxy-2-carboxyquinoline;
4,5-dihydroxy-2-carboxyquinoline;
5-hydroxymethoxy-4-hydroxy-2-carboxyquinoline;
7-methyl-4-hydroxy-2-carboxyquinoline;
5-methyl-4-hydroxy-2-carboxyquinoline;
30 5-(3-ethoxycarbonylpropoxy)-4-hydroxy-2-carboxyquinoline; and
5-(3-carboxypropoxy)-4-hydroxy-2-carboxyquinoline.

PREPARATION 4

Compounds of formulae (Fb), (Ga) and (Gb)

A. To a solution of $\text{SnCl}_2\text{H}_2\text{O}$ (140 g, 0.62 mol) in ethanol (350 mL) was added a solution of 2,6-dichloro-3-nitrotoluene (25 g, 0.12 mol) in ethanol (50 mL). The 5 reaction mixture was refluxed for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in water (100 mL), pH was adjusted to approximately pH 12 with 1N NaOH solution and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over sodium sulfate, and concentrated to afford 2,6-dichloro-3-aminotoluene (21 g, 98%); NMR (CDCl_3) 2.42 (s, 3), 6.62 (d, 1), 7.14 (d, 1) ppm.

B. To a solution of 2,6-dichloro-3-aminotoluene (20.5 g, 0.11 mol) in methanol (300 mL) was added dimethyl acetylenedicarboxylate (15 mL, 0.12 mol) and the reaction mixture was refluxed for 2 hours. The reaction mixture was concentrated under reduced pressure to a yellow solid. Diphenyl ether (350 mL) was heated to 230-15 240°C, and the yellow solid was added to it. The temperature was maintained at 230-240°C for 20 minutes and the reaction mixture was cooled slowly to ambient temperature and diluted with petroleum ether (1L). The solid was filtered and washed with hot ethyl acetate to afford a brown solid, 2-(methoxycarbonyl)-4-oxo-6,8-dichloro-7-methylquinoline (28.5 g, 85%); NMR (CDCl_3) 2.62 (s, 3), 4.04 (s, 3), 7.02 (s, 1), 8.24 (s, 1) ppm.

C. 2-(Methoxycarbonyl)-4-oxo-6,8-dichloro-7-methylquinoline (28.5 g, 99.6 mmol) was suspended in methanol (1 L) and a solution of $\text{LiOH}\text{H}_2\text{O}$ (20.5 g, 0.5 mol) in water (200 mL) was added to the solution. The resulting reaction mixture was stirred at ambient temperature for 0.5 hours. Pd/C (5.8 g) was added to the reaction 25 mixture and the resulting reaction mixture was shaken under 50 Psi hydrogen overnight. The reaction mixture was filtered, concentrated under reduced pressure to remove methanol, diluted with water (300 mL) and the pH was adjusted to between pH 3 and pH 4 by 2N HCl. The precipitate was collected by filtration, washed with water and dried to afford a white solid, 2-carboxy-4-oxo-7-methylquinoline (20 g, 90%); NMR (DMSO- d_6) 2.40 (s, 3), 6.60 (s, 1), 7.20 (d, 1), 7.68 (s, 1), 7.96 (d, 1) ppm.

PREPARATION 5

Compounds of formulae (M) and (N)

A. To a solution of 2-aminonaphthalene (1.43 g, 10 mmol) in CH_2Cl_2 (15 mL) and triethylamine (1 mL) was added a solution of ethyl malonyl chloride (1.4 mL,

11mmol) in CH_2Cl_2 (10 mL) dropwise at 5°C. The reaction mixture was stirred at 10°C. After 1 hour the reaction was diluted with 100 mL CH_2Cl_2 , washed with 2N NaHSO_4 and water, brine. The organic layer was evaporated *in vacuo* to afford 2-((ethoxycarbonyl)methylcarbonylamino)naphthalene (2.3 g, 8.9 mmol) as a solid that

5 was used without further purification.

B. To a solution of 2-((ethoxycarbonyl)methylcarbonylamino)naphthalene (2.3 g, 8.9 mmol) in MeOH (40 mL) was added a solution of LiOH (1.18 g, 27 mmol) in water (40 mL). The reaction mixture was stirred at ambient temperature. After 3 hours, the reaction mixture was acidified to pH 2-3 by 2N NaHSO_4 , then extracted with 10 ethyl acetate (3 x 50 mL). The organic layer was dried over Na_2SO_4 and evaporated *in vacuo* to afford 2-((carboxy)methylcarbonylamino)naphthalene (2.0 g, 8.7 mmol) as a solid that was used in further preparations without further purification.

PREPARATION 6

15 **Compounds of formula (S) and formula (U)**

A. To a solution of 1-ethoxycarbonylpiperazine (1.5 mL, 10 mmol) in 40 mL CH_2Cl_2 , was added triethylamine (2 mL, 14 mmol) and chloroacetyl chloride (0.8 mL, 5.0 mmol) at 0°C. The resulting reaction mixture was stirred at ambient temperature for 2 hours. The reaction mixture was washed with water, 2N NaHSO_4 and brine, and 20 dried over sodium sulfate. The solvent was evaporated *in vacuo* to afford 1-ethoxycarbonyl-4-chloromethylcarbonylpiperazine (4.5 g) as an yellow oil, which was used without further purification.

B. To a solution of 1-ethoxycarbonyl-4-chloromethylcarbonylpiperazine (520 mg, 2.21 mmol) in DMF (40 mL) was added cesium carbonate (2.0 g, 6.20 mmol) 25 and glycine ethyl ester hydrochloride (310 mg, 2.21 mmol). The resulting reaction mixture was stirred at 50°C. After 1 hour, the reaction mixture was diluted with ethyl acetate (200 mL), washed with water (3x150 mL) and brine, and concentrated *in vacuo* to afford 1-ethoxycarbonyl-4-(ethoxycarbonylmethyl)aminomethylcarbonylpiperazine as an oil (520 mg), which was used without purification.

30 C. In a similar manner, other compounds of formula (S) and formula (U) are prepared.

PREPARATION 7

Compounds of formula (X), formula (Z) and formula (AA)

A. To a solution of 2-aminonaphthalene (985 mg, 6.8 mmol) in *N,N*-dimethylformamide (DMF) (50 mL) was added potassium carbonate (1.806 g, 13.6 mmol) and *tert*-butyl bromoacetate (1.4 mL, 9.9 mmol). The resulting reaction mixture was stirred at ambient temperature. After 24 hours, the reaction mixture was diluted with water (200 mL), then extracted by ethyl acetate (150 mL). The organic layer was separated and washed with water (3x100 mL), then dried over sodium sulfate. The solvent was evaporated *in vacuo* to afford a product as an yellow oil. Purification of product by flash column on silica gel afforded 2-((1,1-dimethylethoxycarbonyl)methyl)aminonaphthalene (1.2 g).

B. To a solution of 2-((1,1-dimethylethoxycarbonyl)methyl)aminonaphthalene (926 mg, 3.6 mmol) in CH₂Cl₂ (40 mL) was added triethylamine (3 mL, 21.5 mmol) and ethyl 3-chloro-3-oxapropionate (1.3 mL, 10.1 mmol). The resulting reaction mixture was stirred at ambient temperature for 2 days. The reaction mixture was washed with water and brine, and dried over sodium sulfate. The solvent was evaporated *in vacuo* to afford a product as an yellow oil. Purification of the product by flash column on silica gel afforded 2-[ethoxycarbonylmethylcarbonyl][(1,1-dimethylethoxycarbonyl)methyl]aminonaphthalene (730 mg) as a clear oil.

C. To a solution of 2-[ethoxycarbonylmethylcarbonyl][(1,1-dimethylethoxycarbonyl)methyl]aminonaphthalene (730 mg, 1.95 mmol) in methanol (5.0 mL) was added a solution of LiOH (123 mg, 2.91 mmol) in water (3.0 mL). The resulting reaction mixture was stirred at ambient temperature for 1 hour. The reaction mixture was acidified by 2N NaHSO₄ to pH 3, then extracted by ethyl acetate (3 x 10 mL). The organic layer was evaporated *in vacuo* to afford 2-[carboxymethylcarbonyl][(1,1-dimethylethoxycarbonyl)methyl]aminonaphthalene (270 mg) as a white solid.

D. In a similar manner, other compounds of formula (X), formula (Z) and formula (AA) are prepared.

EXAMPLE 1

Compounds of Formula (Ia)

A. To a suspension of 7-methyl-4-hydroxy-2-carboxyquinoline (0.81 g, 4 mmol) in methylene chloride:DMF (4:1, 25 mL) was added 1-hydroxybenzotriazole

(HOBT) (0.64 g, 4.8 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (1.09 g, 4.8 mmol) and the reaction mixture was stirred for 10 minutes. A solution of 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (1.37 g, 4 mmol) in methylene chloride (10 mL) was added to the reaction mixture and 5 the resulting mixture was stirred at ambient temperature for 6 hours. The solvent was evaporated *in vacuo* and the resulting residue was partitioned in ethyl acetate and water. The organic layers were combined and washed with water, brine and concentrated to afford an off-white foam, 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-hydroxyquinoline; (1.44 g, 68%).

10 B. In a similar manner, other compounds of formula (Ia) are prepared.

EXAMPLE 2

Compounds of Formula (Ib)

A. 1-Ethoxycarbonyl-1-bromocyclobutane (0.62 g, 3.03 mmol) was added to 15 a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-hydroxyquinoline (0.8 g, 1.52 mmol) and cesium carbonate (1.00 g, 3.03 mmol) in *N,N*-dimethylformamide (DMF) (15 mL) and stirred at 90-100°C. At every 2 hours, excess equimolar amounts of 1-ethoxycarbonyl-1-bromocyclobutane and cesium carbonate were added to the solution to 20 a total of 8 equivalents of each reagent. After 10 hours, the reaction mixture was filtered, the solvent was evaporated and the residue was purified by preparative HPLC to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]amino-carbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline (0.45 g, 38%) as a white solid (TFA salt); NMR (DMSO-d₆) 1.04 (t, 3), 1.14 (t, 3), 1.32 (s, 9), 1.82 (m, 1), 2.00 (m, 3), 2.26 (m, 2), 2.52 (s, 3), 2.58 (m, 2), 2.78 (m, 2), 3.5 (m, 8), 4.04 (q, 2), 4.15 (q, 2), 5.00 (m, 1), 6.94 (s, 1), 7.52 (d, 1), 7.88 (s, 1), 8.14 (d, 1), 8.84 (d, 1) ppm.

B. A solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline (75 mg, 0.09 mmol) in 50% trifluoroacetic acid-methylene chloride (2 ml) 30 was stirred at ambient temperature for 1 hour. The solvent was evaporated *in vacuo* and the resulting residue was purified by preparative HPLC to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline as a white solid (60 mg, 93%, trifluoroacetic acid salt); NMR (DMSO-d₆) 1.03 (t, 3), 1.16 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.26 (m, 2), 35

2.55 (s, 3), 2.59 (m, 2), 2.77 (m, 2), 3.38 (m, 6), 3.60 (m, 2), 4.02 (q, 2), 4.12 (q, 2), 4.98 (m, 1), 6.92 (s, 1), 7.52 (d, 1), 7.88 (s, 1), 8.14 (d, 1), 8.85 (d, 1) ppm.

C. A solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline 5 (220 mg, 0.29 mmol) in 50% trifluoroacetic acid-methylene chloride (6 mL) was stirred at ambient temperature for 1 hour. The solvent was evaporated *in vacuo* and the residue was dissolved in methanol (5 ml). LiOH (5 mL, 0.025 M) was added and the reaction stirred for 3 hours. The solvent was evaporated and the residue was purified by preparative HPLC to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-10 carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline, as a white solid (190 mg, 95%, trifluoroacetic acid salt); NMR (DMSO-d₆) 1.15 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.51 (s, 3), 2.56 (m, 2), 2.68 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.00 (q, 2), 4.98 (m, 1), 6.98 (s, 1), 7.52 (dd, 1), 7.88 (s, 1), 8.14 (d, 1), 8.85 (d, 1) ppm.

D. In a similar manner as described above in Paragraphs A-C, the following 15 compounds were made:

2-[(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.40 (s, 9), 3.30-3.50 (m, 8), 4.10 (S, 3), 4.24 (d, 2), 7.60 (S, 3), 7.64 (t, 1), 7.82 (t, 1), 8.03 (d, 1), 8.20 (d, 1), 8.94 (t, 1) ppm; 2-[(piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 20 2.60-2.70 (m, 4), 3.35-3.41 (m, 4), 7.58 (s, 3), 7.63 (t, 1), 7.82 (t, 1), 8.03 (d, 1), 8.18 (d, 1), 8.93 (t, 1) ppm; 2-[(2-methyl-4-(4-fluorobenzyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.16-1.34 (m, 3), 1.80-2.20 (m, 2), 2.60-2.90 (m, 3), 3.40-3.70 (m, 3), 4.12 (m, 5), 4.20-4.50 (m, 1), 7.16 (m, 2), 7.34 (m, 2), 25 7.60 (s, 1), 7.63 (t, 1), 7.83 (t, 1), 8.03 (d, 1), 8.20 (d, 1), 8.93 (m, 1) ppm; 2-[(3-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.02-1.21 (m, 6), 2.60-3.20 (m, 3), 3.70-3.90 (m, 2), 4.05 (m, 2), 4.13 (s, 3), 4.17-4.40 (m, 4), 7.60 (s, 2), 7.63 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.97 (m, 1) ppm, and NMR (CDCl₃) 1.30 (m, 6), 2.80-3.20 (m, 3), 3.40 (m, 1), 3.60 (m, 1), 4.00-4.40 (m, 9), 7.55 (m, 1), 7.65 (s, 1), 7.70 (t, 1), 30 8.10 (d, 1), 8.20 (d, 1), 9.10 (m, 1) ppm; 2-[(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.03-1.15 (d, 3), 1.18 (t, 3), 2.8-3.2 (m, 3), 3.7-4.0 (m, 2), 4.06 (q, 2), 4.10 (s, 3), 4.15-4.60 (m, 4), 7.6 (s, 1), 7.63 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.19 (d, 1), 8.96 (m, 1) ppm; 35

2-[(4-(2-methylpropoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.88 (d, 6), 1.86 (m, 1), 3.30-3.50 (m, 8), 3.78 (d, 2), 4.12 (s, 3), 4.25 (d, 2), 7.58 (s, 1), 7.65 (t, 1), 7.84 (t, 1), 8.06 (d, 1), 8.18 (d, 1), 8.95 (t, 1) ppm;

5 2-[(4-(trichloromethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 3.50-3.75 (m, 8), 4.10 (s, 3), 4.26 (d, 2), 7.58 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.05 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

10 2-[(4-(benzyloxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 3.35-3.54 (m, 8), 4.10 (s, 3), 4.26 (d, 2), 5.07 (s, 2), 7.10-7.20 (m, 5), 7.58 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.05 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

15 2-[(4-(1-chloroethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.78 (d, 3), 3.40-3.60 (m, 8), 4.10 (s, 3), 4.26 (d, 2), 6.58 (q, 1), 7.60 (s, 1), 7.64 (t, 1), 7.84 (t, 1), 8.06 (d, 1), 8.19 (d, 1), 8.95 (t, 1) ppm;

20 2-[(4-(methoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 3.30-3.52 (m, 8), 3.60 (s, 3), 4.10 (s, 3), 4.26 (d, 2), 7.60 (s, 1), 7.65 (t, 1), 7.83 (t, 1), 8.06 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

25 2-[(4-(phenoxy carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 3.40-3.70 (m, 8), 4.10 (s, 3), 4.30 (d, 2), 7.13 (d, 1), 7.22 (t, 1), 7.38 (t, 1), 7.60 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.06 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

30 2-[(2-methyl-4-benzylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.16-1.34 (m, 3), 1.80-2.20 (m, 2), 2.60-2.90 (m, 3), 3.40-3.70 (m, 3), 4.12 (m, 5), 4.20-4.50 (m, 1), 7.16 (m, 2), 7.34 (m, 2), 7.60 (s, 1), 7.63 (t, 1), 7.83 (t, 1), 8.03 (d, 1), 8.20 (d, 1), 8.93 (m, 1) ppm, and NMR (CDCl₃) 1.40 (m, 3), 2.10 (m, 1), 2.20 (m, 1), 2.70 (m, 1), 2.90 (m, 1), 3.40-3.60 (m, 3), 4.0 (m, 1), 4.10 (s, 3), 4.20-4.40 (m, 3), 7.20-7.40 (m, 5), 7.60 (m, 1), 7.65 (s, 1), 7.70 (m, 1), 8.10 (d, 1), 8.20 (d, 1), 9.15 (m, 1) ppm;

35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonylethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.26 (t, 3), 1.52 (d, 3), 3.60 (m, 8H), 3.36 (m, 4), 4.12 (s, 3), 4.18 (q, 2), 5.16 (m, 1), 7.56 (t, 1), 7.66 (s, 1), 7.72 (t, 1), 8.08 (d, 1), 8.20 (d, 1H), 9.06 (d, 1) ppm, and NMR (CDCl₃) 1.28 (t, 3), 1.52 (d, 3), 3.40-3.96 (m, 8), 4.12 (s, 3), 4.18 (q, 2), 5.16 (m, 1), 7.56 (t, 1), 7.66 (s, 1), 7.74 (t, 1), 8.10 (d, 1), 8.20 (d, 1H), 9.06 (d, 1) ppm;

2-[(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.30 (m, 6), 2.80-3.10 (m, 3), 3.40 (m, 1), 3.60 (m, 1), 4.00-4.40 (m, 9), 7.55 (m, 1), 7.65 (s, 1), 7.78 (m, 1), 8.10 (d, 1), 8.20 (d, 1), 9.10 (m, 1) ppm;

5 2-[(4-(2-methyl-5-chlorophenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 2.20 (s, 3), 2.85 (m, 4), 3.60 (m, 4), 4.10 (s, 3), 4.30 (m, 2), 7.0 (m, 1), 7.20 (m, 1), 7.60 (s, 1), 7.65 (m, 1), 7.80 (m, 1), 8.05 (d, 1), 8.20 (d, 1), 8.95 (m, 1) ppm;

10 2-[(4-benzylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 2.30-2.43 (m, 4), 3.40-3.56 (m, 6), 4.10 (s, 3), 4.23 (d, 2), 7.20-7.16 (m, 5), 7.60 (s, 1), 7.65 (t, 1), 7.83 (t, 1), 8.06 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

15 2-[(4-ethylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.98 (t, 3), 2.30-2.40 (m, 6), 3.48 (m, 4), 4.12 (s, 3), 4.22 (d, 2), 7.59 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.96 (t, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-((2-chlorobenzyl)carbonyl)aminopentyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 1.40-2.00 (m, 8), 3.20-3.80 (m, 8), 4.10 (s, 3), 4.15 (q, 2), 4.95 (m, 1), 5.20 (m, 2), 7.21 (m, 2), 7.38 (m, 2), 7.55 (m, 1), 7.63 (s, 1), 7.75 (m, 1), 8.05 (d, 1), 8.20 (d, 1), 8.95 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(benzyloxycarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 2.81 (m, 1), 3.20 (m, 1), 3.40-3.65 (m, 8), 4.15 (m, 5), 5.15 (m, 2), 5.60 (m, 1), 7.30 (m, 5), 7.55 (m, 1), 7.75 (m, 1), 8.00 (d, 1), 8.20 (d, 1), 8.95 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 2.05 (m, 1), 2.25 (m, 1), 2.45-2.65 (m, 2), 3.40-3.80 (m, 8), 4.10-4.20 (m, 5), 5.15 (m, 2), 5.23 (m, 1), 7.35 (m, 5), 7.55 (dd, 1), 7.63 (s, 1), 7.75 (dd, 1), 8.05 (dd, 1), 8.20 (dd, 1), 9.00 (dd, 1) ppm;

35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-phenylethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 2.63 (m, 1), 3.05 (m, 2), 3.20 (m, 4), 3.30 (m, 2), 3.45 (m, 2), 3.62 (m, 1), 4.15 (m, 5), 5.38 (m, 1), 7.30 (m, 5), 7.56 (d, 1), 7.75 (dd, 1), 8.05 (d, 1), 8.20 (d, 1), 8.98 (m, 1) ppm;

40 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(benzyloxy)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 3.23 (m, 8), 3.80 (m, 2), 4.15 (m, 5),

4.58 (d, 2), 5.40 (m, 1), 7.24 (m, 5), 7.55 (dd, 1), 7.62 (s, 3), 7.75 (dd, 1), 8.05 (d, 1), 8.20 (dd, 1), 8.98 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-methylpropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.05 (m, 6), 1.30 (m, 3), 2.20 (m, 1), 3.40-3.80 (m, 8), 4.15-4.20 (m, 5), 5.0 (m, 1), 7.58 (m, 1), 7.65 (s, 1), 7.78 (m, 1), 8.05 (d, 1), 8.20 (d, 1), 8.90 (m, 1) ppm;

5 2-[(4-(1,1-dimethylethoxy)carbonylmethyl)piperazin-1-yl]carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.39 (s, 9), 2.50-2.60 (m, 4), 3.16 (s, 2), 3.47 (m, 4), 4.12 (s, 3), 4.22 (d, 2), 7.59 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.96 (t, 1) ppm;

10 2-[(4-(methoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 2.50-2.60 (m, 4), 3.26 (m, 2), 3.47 (m, 4), 3.60 (s, 3), 4.14 (s, 3), 4.23 (d, 2), 7.59 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.96 (t, 1) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 2.82 (dd, 1), 3.18 (dd, 1), 3.40-3.75 (m, 8), 4.14 (m, 5), 5.58 (m, 1), 7.58 (dd, 1), 7.80 (s, 1), 7.73 (dd, 1), 8.01 (d, 1), 8.20 (d, 1), 8.98 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 1.99 (m, 1), 2.23 (m, 1), 2.41-2.63 (m, 2), 3.40-3.82 (m, 8), 4.10 (s, 3), 4.15 (q, 2), 5.35 (m, 1), 7.58 (dd, 1), 7.62 (s, 1), 7.73 (dd, 1), 8.08 (d, 1), 8.19 (d, 1), 9.15 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-aminopentyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.22 (t, 3), 2.85 (dd, 1), 3.17 (dd, 1), 3.40-3.75 (m, 8), 4.15 (m, 5), 5.58 (m, 1), 7.56 (dd, 1), 7.61 (s, 1), 7.75 (dd, 1), 8.05 (d, 1), 8.20 (d, 1), 8.98 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-hydroxyethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 3.40-3.80 (m, 8), 3.92 (m, 1), 4.03 (m, 1), 4.15 (m, 5), 5.20 (m, 1), 7.58 (d, 1), 7.63 (s, 1), 7.75 (dd, 1), 8.05 (d, 1), 8.21 (d, 1), 9.15 (dd, 1) ppm;

35 2-[(4-(carboxymethyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 2.48-2.60 (m, 4), 3.17 (s, 2), 3.46 (m, 4), 4.08 (s, 3), 4.18 (d, 2), 7.56 (s, 1), 7.62 (t, 1), 7.80 (t, 1), 8.01 (d, 1), 8.16 (d, 1), 8.92 (t, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
(ethoxycarbonyl)methoxyquinoline; NMR (DMSO-d₆) 1.20 (m, 6), 3.3-3.5 (m, 8),

4.04 (q, 2), 4.2-4.3 (m, 4), 5.3 (s, 2), 7.5 (s, 1), 7.7 (t, 1), 7.8 (t, 1), 8.1 (d, 1), 8.13 (d, 1), 8.98 (m, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
5 (carboxy)methoxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 3.3-3.5 (m, 8), 4.04 (q, 2), 4.25 (d, 2), 5.1 (s, 2), 7.5 (s, 1), 7.7 (t, 1), 7.85 (t, 1), 8.03 (d, 1), 8.13 (d, 1), 8.95 (m, 1) ppm;

2-[(4-methylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR
10 (DMSO-d₆) 2.58 (s, 3), 2.71-7.93 (m, 4), 3.67 (m, 4), 4.13 (s, 3), 4.26 (d, 2), 7.60 (s, 1), 7.66 (t, 1), 7.84 (t, 1), 8.06 (d, 1), 8.21 (d, 1), 8.94 (t, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-ethoxyquinoline;
15 NMR (DMSO-d₆) 1.21 (t, 3), 1.48 (t, 3), 3.30-3.60 (m, 8), 4.06 (q, 2), 4.28 (d, 2), 4.42 (q, 2), 7.57 (s, 1), 7.66 (t, 1), 7.85 (t, 1), 8.07 (d, 1), 8.21 (d, 1), 8.95 (t, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
20 (aminocarbonyl)methoxyquinoline; NMR (DMSO-d₆) 1.20 (t, 3), 3.30-3.50 (m, 8), 4.05 (q, 2), 4.25 (d, 2), 4.90 (s, 2), 7.50 (s, 1), 7.70 (t, 1), 7.86 (t, 1), 8.03 (d, 1), 8.40 (d, 1), 8.95 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(aminocarbonyl)ethyl]aminocarbonyl-4-
25 methoxyquinoline; NMR (CDCl₃) 1.30 (t, 3), 2.80 (dd, 1), 3.00 (dd, 1), 3.40-3.80 (m, 8), 4.15 (m, 5), 5.60 (m, 2), 6.15 (m, 1), 7.60 (m, 2), 7.75 (m, 1), 8.0 (d, 1), 8.20 (d, 1), 9.0 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(aminocarbonyl)propyl]aminocarbonyl-
30 4-methoxyquinoline; NMR (CDCl₃) 1.30 (t, 3), 2.0 (m, 1), 2.20-2.50 (m, 3), 3.40-3.80 (m, 8), 4.15 (m, 5), 5.20 (m, 1), 5.50 (m, 1), 6.25 (m, 1), 7.60 (m, 2), 7.75 (m, 1), 8.10 (d, 1), 8.20 (d, 1), 9.20 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(imidazol-4-yl)ethyl]aminocarbonyl-4-
35 methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 3.10-3.30 (m, 2), 3.20-3.65 (m, 8), 4.10 (m, 5), 5.40 (m, 1), 6.90 (s, 1), 7.55-7.60 (m, 3), 7.70 (t, 1), 8.02 (d, 1), 8.20 (d, 1), 9.0 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(indol-3-yl)ethyl]aminocarbonyl-4-
40 methoxyquinoline; NMR (CDCl₃) 1.20 (t, 3), 2.25 (m, 1), 2.90 (m, 2), 3.20 (m, 2), 3.40 (m, 4), 3.60 (m, 1), 4.05 (q, 2), 4.15 (s, 3), 5.50 (m, 1), 7.20 (m, 3), 7.35 (d, 1), 7.55 (m, 1), 7.70 (s, 1), 7.80 (m, 2), 8.10 (d, 1), 8.20 (m, 2), 9.10 (d, 1) ppm;

2-[(3-(benzyloxy)carbonyl-4-(ethoxycarbonyl)piperazin-1-
45 yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.28 (m, 3),

2.82 (m, 1), 3.28 (m, 3), 3.88 (m, 1), 4.18 (s, 3), 4.22 (m, 4), 4.60 (m, 3), 5.20 (m, 2), 7.42 (m, 1), 7.22 (m, 2), 7.28 (m, 3), 7.60 (t, 1), 7.64 (s, 1), 7.68 (t, 1), 8.12 (d, 1), 8.22 (d, 1H), 9.18 (s, 1) ppm;

2-[(3-carboxy-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.28 (m, 3), 2.82 (m, 1), 3.26 (m, 4H), 3.88 (m, 1), 4.12 (s, 3), 4.46 (m, 5), 7.42 (m, 1), 7.56 (s, 1), 7.64 (t, 1), 8.00 (d, 1), 8.20 (d, 1), 9.18 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(benzyloxycarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (m, 3), 2.85 (dd, 1), 3.20 (m, 1), 3.40-3.80 (m, 8), 4.15 (m, 5), 5.15 (m, 2), 5.60 (m, 1), 7.35 (m, 5), 7.59 (m, 1), 7.62 (m, 1), 7.75 (m, 1), 8.05 (m, 1), 8.21 (m, 1), 8.90 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-4-(1,1-dimethylethoxy)carbonylbutyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 1.22 (s, 9), 1.70-2.00 (m, 6), 2.30 (dd, 1), 3.40-3.80 (m, 8), 4.15 (m, 5), 5.18 (m, 1), 7.55 (d, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.05 (d, 1), 8.20 (d, 1), 8.95 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-4-carboxybutyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.30-1.90 (m, 6), 2.25 (m, 2), 3.25-3.63 (m, 8), 4.05 (m, 2), 4.15 (s, 3), 5.05 (m, 1), 7.61 (s, 1), 7.65 (dd, 1), 7.85 (dd, 1), 8.10 (d, 1), 8.20 (d, 1), 8.95 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.30-1.90 (m, 6), 2.25 (m, 2), 3.25-3.63 (m, 8), 4.05 (m, 2), 4.15 (s, 3), 5.05 (m, 1), 7.61 (s, 1), 7.65 (dd, 1), 7.85 (dd, 1), 8.10 (d, 1), 8.20 (d, 1), 8.95 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-hydroxyquinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.83 (m, 1), 1.92 (m, 1), 2.24 (m, 2), 3.30-3.70 (m, 8), 4.03 (q, 2), 4.93 (m, 1), 6.94 (s, 1), 7.35 (t, 1), 7.64 (t, 1), 7.86 (d, 1), 8.09 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-ethoxyquinoline; NMR (DMSO-d₆) 1.16 (t, 3), 1.46 (t, 3), 1.85 (m, 1), 2.10 (m, 1), 2.45 (m, 2), 3.3-3.6 (m, 8), 4.02 (q, 2), 4.37 (q, 2), 5.00 (s, 2), 5.05 (m, 1), 7.30 (m, 5), 7.53 (s, 1), 7.63 (t, 1), 7.80 (t, 1), 8.04 (d, 1), 8.17 (d, 1), 9.90 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-ethoxyquinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.46 (t, 3), 1.82 (m, 1), 2.00 (m, 1),

2.30 (m, 2), 3.3-3.7 (m, 8), 4.00 (q, 2), 4.40 (q, 2), 5.04 (m, 1), 7.53 (s, 1), 7.63 (t, 1), 7.80 (t, 1), 8.04 (d, 1), 8.20 (d, 1), 9.90 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃)

5 1.23 (t, 3), 2.05 (m, 1), 2.23 (m, 1), 2.58 (m, 2), 3.40-3.80 (m, 8), 4.15 (s, 3), 4.16 (q, 2), 5.17 (m, 1), 5.25 (m, 1), 7.15 (m, 5), 7.56 (dd, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.0 (d, 1), 8.21 (d, 1), 9.05 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 2.00 (m, 1), 2.23 (m, 1), 2.41-2.63 (m, 2), 3.40-3.82 (m, 8), 4.12 (s, 3), 4.15 (q, 2), 5.35 (m, 1), 7.58 (dd, 1), 7.60 (s, 1), 7.75 (dd, 1), 8.10 (d, 1), 8.20 (d, 1), 9.19 (d, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-((1,1-dimethylethoxy)carbonyl)ethyl]-aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 1.45 (s, 9), 2.78 (dd, 1), 2.99 (s, 3), 3.10 (m, 1), 3.40-3.82 (m, 8), 4.18 (q, 2), 4.20 (s, 3), 5.95 (m, 1), 7.05 (s, 1), 7.65 (dd, 1), 7.90 (dd, 1), 8.30 (m, 2) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 2.20-2.40 (m, 2), 2.50-2.82 (m, 2), 3.02 (s, 3), 3.30-3.80 (m, 8), 4.03 (s, 3), 4.15 (q, 2), 5.15 (m, 2), 5.63 (m, 1), 7.00 (s, 1), 7.35 (m, 5), 7.55 (dd, 1), 7.75 (dd, 1), 7.98 (d, 1), 8.20 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl][methyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 2.17-2.35 (m, 2), 2.52 (m, 1), 3.03 (s, 3), 3.35 (m, 8), 4.05 (s, 3), 4.15 (q, 2), 5.62 (m, 1), 7.00 (s, 1), 7.5 (dd, 1), 7.73 (dd, 1), 8.05 (d, 1), 8.20 (d, 1) ppm;

25 2-[1-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.45 (s, 9), 2.01 (m, 1), 2.22 (m, 1), 2.40-2.60 (m, 2), 3.20-3.80 (m, 11), 4.12 (s, 3), 5.25 (m, 1), 7.58 (dd, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.10 (d, 1), 8.21 (d, 1), 9.05 (d, 1) ppm;

30 2-[(4-(2-carboxyethyl)carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 2.40-2.60 (m, 4), 3.41-3.60 (m, 8), 4.13 (s, 3), 4.27 (d, 2), 7.61 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.05 (d, 1), 8.23 (d, 1), 8.97 (t, 1) ppm;

35 2-[(4-(5-(ethoxycarbonyl)pentyl)carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 1.38 (m, 2), 1.60-1.78 (m, 6), 2.36

(m, 4), 3.51-3.78 (m, 8), 4.11 (m, 5), 4.27 (d, 2), 7.57 (t, 1), 7.65 (s, 1), 7.76 (t, 1), 8.09 (d, 1), 8.23 (d, 1), 9.12 (m, 1) ppm;

2-[(4-(5-carboxypentyl)carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.24 (m, 2), 1.43 (m, 4), 2.13 (m, 2), 2.27 (m, 2), 3.40-3.52 (m, 8), 4.08 (s, 3), 4.24 (d, 2), 7.56 (s, 1), 7.63 (t, 1), 7.79 (t, 1), 8.01 (d, 1), 8.17 (d, 1), 8.92 (m, 1) ppm;

2-[(2,4-di(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-carboxy-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxy)methoxyquinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.84 (m, 1), 2.04 (m, 1), 2.30 (m, 2), 3.31-3.71 (m, 8), 4.03 (q, 2), 5.05 (m, 1), 5.13 (s, 2), 7.47 (s, 1), 7.68 (t, 1), 7.85 (t, 1), 8.09 (d, 1), 8.23 (d, 1), 8.95 (d, 1) ppm;

15 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-n-propoxyquinoline; NMR (DMSO-d₆) 1.06 (t, 3), 1.17 (t, 3), 1.90 (m, 2), 3.30-3.55 (m, 8), 4.04 (q, 2), 4.25 (d, 2), 4.30 (q, 2), 7.57 (s, 1), 7.64 (t, 1), 7.84 (t, 1), 8.03 (d, 1), 8.20 (d, 1), 8.93 (m, 1) ppm;

20 2-[1-(piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.00 (m, 1), 2.25 (m, 1), 2.40-2.60 (m, 2), 2.90 (m, 1), 2.95 (m, 1), 3.60-3.75 (m, 7), 4.12 (s, 3), 5.22 (m, 1), 7.55 (dd, 1), 7.63 (s, 1), 7.75 (dd, 1), 8.0 (d, 1), 8.21 (d, 1), 9.05 (d, 1) ppm;

25 2-[1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.02 (m, 1), 2.30 (m, 1), 2.40-2.62 (m, 2), 3.70 (s, 3), 3.80-5.04 (m, 8), 4.14 (s, 3), 5.30 (m, 1), 6.55 (m, 1), 7.55 (dd, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.10 (d, 1), 8.21 (d, 1), 8.35 (d, 2), 9.05 (d, 1) ppm;

30 2-[1-(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.38 (s, 9), 2.00 (m, 1), 2.23 (m, 1), 2.40-2.61 (m, 2), 3.25-3.80 (m, 11), 4.12 (s, 3), 2.25 (m, 1), 7.5 (dd, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.07 (d, 1), 8.21 (d, 1), 9.01 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 2.00 (m, 1), 2.22 (m, 1), 2.40-2.61 (m, 2), 3.40-3.80 (m, 11), 4.11 (s, 3),

4.17 (q, 2), 5.23 (m, 1), 7.56 (dd, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.10 (d, 1), 8.21 (d, 1), 9.02 (d, 1) ppm;

2-[1-(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.38 (s, 9), 1.98 (m, 1), 2.22 (m, 1), 2.41-2.62 (m, 2), 3.33-3.90 (m, 8), 4.09 (s, 3), 4.11 (q, 2), 5.30 (m, 1), 7.5 (dd, 1), 7.58 (s, 1), 7.73 (dd, 1), 8.05 (d, 1), 8.11 (d, 1), 9.07 (d, 1) ppm;

5 2-[1-(4-(aminocarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.00 (m, 1), 2.2 (m, 1), 2.40-2.61 (m, 2), 3.40-3.90 (m, 11), 4.13 (s, 3), 5.22 (m, 1), 7.58 (dd, 1), 7.61 (s, 1), 7.75 (dd, 1), 8.09 (d, 1), 8.21 (d, 1), 9.00 (d, 1) ppm;

10 2-[1-(4-(benzoxazol-2-yl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.01 (m, 1), 2.23 (m, 1), 2.41-2.62 (m, 2), 3.63-3.98 (m, 11), 4.13 (s, 3), 5.21 (m, 1), 7.04 (dd, 1), 7.18 (dd, 1), 7.25 (d, 1), 7.38 (d, 1), 7.57 (dd, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.09 (d, 1), 8.11 (d, 1), 9.02 (d, 1) ppm;

15 2-[1-(4-(benzthiazol-2-yl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.02 (m, 1), 2.30 (m, 1), 2.41-2.65 (m, 1), 3.60-3.95 (m, 11), 4.12 (s, 3), 5.31 (m, 1), 7.10 (dd, 1), 7.35 (dd, 1), 7.57 (m, 2), 7.61 (m, 1), 7.75 (dd, 1), 8.08 (d, 1), 8.21 (d, 1), 9.02 (d, 1) ppm;

20 2-[1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.02 (m, 1), 2.25 (m, 1), 2.42-2.70 (m, 2), 3.63-4.08 (m, 8), 4.1 (s, 3), 5.40 (m, 1), 6.50 (m, 1), 7.55 (dd, 1), 7.62 (s, 1), 7.75 (dd, 1), 8.10 (d, 1), 8.19 (d, 1), 8.31 (d, 2), 9.21 (d, 1) ppm;

25 2-[1-(4-(aminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.85 (m, 1), 2.05 (m, 1), 2.35 (m, 2), 3.20-3.63 (m, 11), 4.13 (s, 3), 5.08 (m, 1), 6.08 (br s, 1), 7.61 (s, 1), 7.65 (dd, 1), 7.86 (dd, 1), 8.08 (d, 1), 8.20 (d, 1), 8.98 (d, 1) ppm;

30 2-[1-(4-(benzoxazol-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.96 (m, 1), 2.13 (m, 1), 2.38 (m, 2), 3.58-3.85 (m, 8), 4.16 (s, 3), 5.18 (m, 1), 7.02 (dd, 1), 7.79 (dd, 1), 7.31 (d, 1), 7.41 (d, 1), 7.61 (s, 1), 7.65 (dd, 1), 8.85 (dd, 1), 8.12 (d, 1), 8.20 (d, 1), 8.99 (d, 1) ppm;

35 2-[1-(4-(benzthiazol-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.96 (m, 1), 2.15 (m, 1), 2.38 (m, 2), 3.58-

3.90 (m, 8), 4.16 (s, 3), 5.15 (m, 1), 7.05 (dd, 1), 7.28 (dd, 1), 7.46 (d, 1), 7.81 (s, 1), 7.65 (dd, 1), 7.78 (d, 1), 7.82 (dd, 1), 8.10 (d, 1), 8.19 (d, 1), 8.98 (d, 1) ppm;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
5 (ethoxycarbonyl)propoxy)quinoline; NMR (DMSO-d₆) 1.14 (t, 3), 1.18 (t, 3), 2.14
(m, 2), 2.47 (q, 2), 3.30-3.55 (m, 8), 4.04 (q, 2), 4.25 (d, 2), 4.36 (q, 2), 7.56 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.03 (d, 1), 8.19 (d, 1), 8.93 (m, 1) ppm;
10 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
carboxypropoxy)quinoline; NMR (DMSO-d₆) 1.17 (t, 3), 2.11 (m, 2), 2.47 (q, 2),
3.30-3.55 (m, 8), 4.04 (q, 2), 4.25 (d, 2), 4.37 (q, 2), 7.56 (s, 1), 7.64 (t, 1), 7.83
(t, 1), 8.03 (d, 1), 8.20 (d, 1), 8.93 (m, 1) ppm;
15 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
(ethoxycarbonyl)prop-2-en-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.20 (t, 3), 3.30-3.55 (m, 8), 4.04 (q, 2), 4.15 (q, 2), 4.25 (d, 2), 5.20 (s, 1), 6.23 (d, 1),
7.14 (d, 1), 7.60 (s, 1), 7.68 (t, 1), 7.83 (t, 1), 8.03 (d, 1), 8.30 (d, 1), 8.93 (m, 1)
15 ppm;
20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
((methoxycarbonyl)methyl)thioethyl]aminocarbonyl-4-methoxyquinoline; NMR
(CDCl₃) 1.30 (t, 3), 3.0 (m, 1), 3.30 (m, 1), 3.30-3.45 (m, 2), 3.50-3.80 (m, 8), 3.75
(s, 3), 4.15 (m, 5), 5.45 (m, 1), 7.60 (t, 1), 7.65 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.20 (d,
20 1), 9.0 (d, 1) ppm;
25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
(carboxymethyl)thioethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.30
(t, 3), 3.0 (m, 1), 3.30 (m, 1), 3.30-3.50 (m, 2), 3.50-3.80 (m, 8), 4.10 (m, 5), 5.45
(m, 1), 7.55 (m, 1), 7.65 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.20 (d, 1), 9.0 (d, 1) ppm;
25 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(tetrahydro-2-
oxofuran-3-yl)oxyquinoline; NMR (CDCl₃) 1.28 (t, 3), 2.58 (m, 1), 3.00 (m, 1),
3.55 (m, 6), 3.70 (m, 2), 4.18 (q, 2), 4.37 (m, 2), 4.47 (m, 1), 4.60 (m, 1), 5.40 (t,
1), 7.60 (q, 1), 7.75 (s, 1), 7.80 (t, 1), 8.12 (d, 1), 8.26 (d, 1), 9.10 (m, 1) ppm;
30 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-carboxy-3-
hydroxypropoxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 2.20 (m, 2), 3.30-3.55 (m,
6), 3.68 (m, 2), 4.04 (q, 2), 4.25 (d, 2), 5.20 (t, 1), 7.40 (s, 1), 7.70 (t, 1), 7.85 (t,
1), 8.03 (d, 1), 8.24 (d, 1), 8.96 (m, 1) ppm;
30 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1,1-
di(ethoxycarbonyl)methoxy)quinoline; NMR (CDCl₃) 1.28-1.40 (m, 9), 3.55 (m, 6),

3.70 (m, 2), 4.18 (q, 2), 4.38 (m, 6), 5.60 (s, 1), 7.57 (s, 1), 7.65 (t, 1), 7.80 (t, 1),
8.13 (d, 1), 8.42 (d, 1), 9.06 (m, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1,1-
5 di(carboxy)methoxy)quinoline; NMR (DMSO-d₆) 1.20 (t, 3), 3.20-3.60 (m, 8), 4.08
(q, 2), 4.30 (d, 6), 5.90 (s, 1), 7.54 (s, 1), 7.75 (t, 1), 7.90 (t, 1), 8.10 (d, 1), 8.30
(d, 1), 8.98 (m, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-
10 (ethoxycarbonyl)ethoxy)quinoline; NMR (CDCl₃) 1.28 (t, 6), 1.8 (d, 3), 3.52 (m, 6),
3.70 (m, 2), 4.17-4.36 (m, 6), 5.16 (q, 1), 7.52 (s, 1), 7.60 (t, 1), 7.76 (t, 1), 8.10
(d, 1), 8.34 (d, 1), 9.06 (m, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-
15 carboxyethoxy)quinoline; NMR (CDCl₃) 1.25 (t, 3), 1.83 (d, 3), 3.50 (m, 6), 3.65
(m, 2), 4.17 (q, 2), 4.35 (m, 2), 5.23 (q, 1), 7.58 (m, 2), 7.70 (t, 1), 8.02 (d, 1),
8.32 (d, 1), 9.16 (m, 1) ppm;

15 2-[(3-(methoxycarbonyl)methyl-4-(ethoxycarbonyl)piperazin-1-
yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.18 (t, 3),
2.22-2.42 (m, 2), 2.74 (m, 1), 2.96 (m, 1), 3.16 (d, 1), 3.68 (s, 3), 3.80 (m, 2),
4.08 (q, 2), 4.12 (s, 3), 4.34 (m, 6), 7.58 (t, 1), 7.62 (s, 1), 7.68 (t, 1), 8.08 (d, 1),
8.22 (d, 1), 8.96 (d, 1) ppm;

20 2-[(3-(carboxy)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 2.22-2.42 (m, 2), 2.74 (m, 1), 2.96
(m, 1), 3.16 (d, 1), 3.80 (m, 2), 4.06 (q, 2), 4.12 (s, 3), 4.34 (m, 6), 7.60 (s, 1),
7.62 (t, 1), 7.84 (t, 1), 8.06 (d, 1), 8.19 (d, 1), 9.06 (m, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-
(methoxycarbonyl)pentyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.30
(t, 3), 1.50 (m, 2), 1.70 (m, 2), 1.80 (m, 1), 1.90 (m, 1), 2.30 (m, 2), 3.40-3.80 (m,
8), 3.65 (s, 3), 4.15 (m, 5), 5.18 (m, 1), 7.60 (m, 1), 7.65 (s, 1), 7.75 (m, 1), 8.10
(d, 1), 8.20 (d, 1), 8.95 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-(carboxy)pentyl]aminocarbonyl-4-
methoxyquinoline; NMR (CDCl₃) 1.30 (t, 3), 1.50 (m, 2), 1.65-1.95 (m, 4), 2.18
(m, 2), 3.40-3.80 (m, 8), 4.15 (m, 5), 5.20 (m, 1), 7.55 (m, 1), 7.65 (s, 1), 7.75 (m,
1), 8.05 (d, 1), 8.20 (d, 1), 9.0 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-
hydroxyphenyl)methyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-(carboxy)prop-1-en-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 3.25 (d, 2), 3.30-3.55 (m, 8), 4.02 (q, 2), 4.25 (d, 2), 5.20-5.40 (m, 1), 7.13 (d, 1), 7.64 (s, 1), 7.75 (t, 1), 7.90 (t, 1), 8.10 (d, 1), 8.30 (d, 1), 9.00 (m, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-8-methoxy-4-hydroxyquinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.84-2.12 (m, 2), 2.37-2.48 (m, 2), 3.31-3.72 (m, 8), 4.04 (m, 5), 4.98 (m, 1), 7.25 (s, 1), 7.28 (d, 1), 7.42 (t, 1), 7.66 (d, 1) ppm;

10 2-[(2-(methoxycarbonyl)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.26 (t, 3), 2.60-3.22 (m, 4), 3.38-4.22 (m, 1), 3.64 (s, 3), 3.76 (m, 2), 4.06 (m, 4), 4.18 (s, 3), 4.34 (m, 3), 7.62 (t, 1), 7.66 (s, 1), 7.94 (t, 1), 8.06 (d, 1), 8.18 (d, 1), 9.12 (m, 1) ppm;

15 2-[(2-(carboxy)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.16 (t, 3), 2.24 (dd, 1), 2.58 (m, 1), 2.62 (d, 1), 2.80 (m, 1), 3.16 (m, 2), 3.76 (d, 1), 4.06 (m, 4), 4.18 (s, 3), 4.34 (m, 6), 7.60 (s, 1), 7.62 (t, 1), 7.84 (t, 1), 8.06 (d, 1), 8.18 (d, 1), 8.98 (m, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(tetrahydro-2-oxofuran-3-yl)oxyquinoline; NMR (CDCl₃) 1.26 (t, 3), 2.00 (m, 1), 2.24 (m, 1), 2.40-2.60 (m, 3), 3.00 (m, 1), 3.40-3.80 (m, 11), 4.16 (q, 2), 4.44 (m, 1), 4.60 (m, 1), 5.25 (m, 1), 5.38 (q, 1), 7.60 (t, 1), 7.72 (s, 1), 7.78 (t, 1), 8.12 (d, 1), 8.24 (d, 1), 9.00 (m, 1) ppm;

25 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(methoxycarbonyl)propoxy)quinoline; NMR (CDCl₃) 1.20 (t, 3), 1.30 (t, 3), 2.20 (m, 2), 3.55 (m, 6), 3.70 (m, 2), 3.80 (s, 3), 4.20 (q, 2), 4.39 (d, 2), 5.04 (t, 1), 7.50 (s, 1), 7.60 (t, 1), 7.77 (t, 1), 8.10 (d, 1), 8.35 (d, 1), 9.06 (m, 1) ppm;

30 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(carboxy)propoxy)quinoline; NMR (DMSO-d₆) 1.10 (t, 3), 1.20 (t, 3), 2.10 (m, 2), 3.30-3.60 (m, 8), 4.06 (q, 2), 4.26 (d, 2), 5.20 (t, 1), 7.45 (s, 1), 7.70 (t, 1), 7.90 (t, 1), 8.08 (d, 1), 8.30 (d, 1), 8.96 (m, 1) ppm;

35 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline; NMR (CDCl₃) 1.20-1.30 (m, 6), 1.80 (s, 6), 3.55 (m, 6), 3.70 (m, 2), 4.16 (q, 2), 4.25 (q, 2), 4.34 (d, 2), 7.38 (s, 1), 7.57 (t, 1), 7.74 (t, 1), 8.08 (d, 1), 8.28 (d, 1), 9.02 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-hydroxy-1-carboxypropoxy)quinoline; NMR (DMSO-d₆) 1.20 (m, 3), 1.86 (m, 1), 2.05 (m, 1), 2.20 (m, 2), 2.30 (m, 2), 3.30-3.60 (m, 6), 3.68 (m, 4), 4.06 (q, 2), 5.05 (m, 1), 5.22 (q, 1), 7.43 (s, 1), 7.70 (t, 1), 7.90 (t, 1), 8.10 (d, 1), 8.26 (d, 1), 8.95 (m, 1) ppm;

5 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-methyl-1-(carboxy)ethoxy)quinoline; NMR (CDCl₃) 1.26 (t, 3), 1.90 (s, 6), 3.55 (m, 6), 3.70 (m, 2), 4.16 (q, 2), 4.42 (d, 2), 7.43 (s, 1), 7.55 (t, 1), 7.60 (t, 1), 7.90 (d, 1), 8.24 (d, 1), 9.03 (m, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(methoxycarbonyl)methoxyquinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.90 (m, 1), 2.06 (m, 1), 2.38 (m, 2), 3.30-3.50 (m, 6), 3.52 (s, 3), 3.62 (m, 2), 3.72 (s, 3), 4.03 (q, 2), 5.03 (m, 1), 5.24 (s, 2), 7.50 (s, 1), 7.70 (t, 1), 7.87 (t, 1), 8.10 (d, 1), 8.23 (d, 1), 8.95 (m, 1) ppm;

15 2-[1-(2-methyl-4-(benzyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.24-1.36 (m, 6), 1.43 (s, 9), 1.92-2.52 (m, 8), 2.67-3.14 (m, 4), 3.40-3.63 (m, 3), 4.13 (s, 3), 4.24-4.80 (m, 2), 5.18 (m, 1), 7.34 (m, 5), 7.57 (t, 1), 7.65 (s, 1), 7.73 (t, 1), 8.10 (d, 1), 8.23 (d, 1), 9.03 (m, 1) ppm;

20 2-[1-(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.17-1.40 (m, 6), 2.00 (m, 1), 2.20 (m, 1), 2.40-2.60 (m, 2), 3.30-3.40 (m, 3), 3.70 (s, 3), 4.00-4.24 (m, 7), 4.40-4.80 (m, 2), 5.20 (m, 1), 7.57 (t, 1), 7.65 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.23 (d, 1), 9.03 (m, 1) ppm;

25 2-[1-(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.17-1.40 (m, 6), 2.00 (m, 1), 2.20 (m, 1), 2.45-2.64 (m, 2), 3.00-3.40 (m, 3), 4.00-4.24 (m, 8), 4.40-4.50 (m, 1), 5.25 (m, 1), 7.56 (t, 1), 7.65 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.21 (d, 1), 9.20 (m, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-methyl-1-(methoxycarbonyl)ethoxy)quinoline; NMR (CDCl₃) 1.28 (t, 3), 1.80 (d, 6), 2.00 (m, 1), 2.22 (m, 1), 2.51 (m, 2), 3.40-3.80 (m, 14), 4.17 (q, 2), 5.23 (m, 1), 7.35 (s, 1), 7.57 (t, 1), 7.75 (t, 1), 8.10 (d, 1), 8.26 (d, 1), 8.96 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-methyl-1-carboxyethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonylnaphthalene; NMR (CDCl₃) 1.30 (t, 3), 1.90 (m, 1), 2.25 (m, 1), 2.50-2.70 (m, 2), 3.40-3.75 (m, 8), 4.18 (q, 2), 5.20 (m, 2), 5.30 (m, 1), 7.40 (m, 6), 7.55 (m, 2), 7.90 (m, 4), 8.35 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonylnaphthalene; NMR (CDCl₃) 1.30 (t, 3), 1.80 (m, 1), 2.20 (m, 1), 2.50 (m, 2), 3.40-3.80 (m, 8), 4.10 (q, 2), 5.30 (m, 1), 7.50 (m, 2), 7.65 (m, 1), 7.80 (m, 4), 8.30 (s, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonylnaphthalene; NMR (CDCl₃) 1.30 (t, 3), 3.40-3.80 (m, 8), 4.18 (q, 2), 4.35 (d, 2), 7.40-7.60 (m, 3), 7.92 (m, 3), 8.40 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 2.82 (m, 1), 3.36 (m, 5), 3.64 (m, 6), 3.06 (m, 2), 4.02 (s, 3), 4.12 (m, 2), 5.38 (m, 1), 6.80 (t, 1), 6.98 (d, 1), 7.18 (m, 3), 7.58 (t, 1), 7.62 (s, 1), 7.68 (t, 1), 8.16 (d, 1), 8.22 (d, 1), 8.32 (s, 1), 9.08 (d, 1) ppm;

2-[(4-(2-hydroxy-3-chloropyridin-5-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-acetamidophenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((2-methoxyethoxy)methyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-methoxycarbonylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-aminoquinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.85 (m, 1), 2.05 (m, 1), 2.30 (m, 2), 3.25-3.65 (m, 8), 4.0 (q, 2), 5.05 (m, 1), 6.10 (m, 1), 6.80 (d, 1), 7.25 (d, 1), 7.50 (t, 1), 7.90 (d, 1), 8.70 (d, 1), 8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonylpropyl)aminocarbonyl-4-(1-ethoxycarbonyl)ethoxy]quinoline; NMR (CDCl₃) 1.22-1.35 (m, 6), 1.48 (s, 9), 1.80 (d, 3), 1.97 (m, 1), 2.17 (m, 1), 2.40 (m, 2), 3.40-3.80 (m, 8), 4.18 (q, 2),

4.26 (m, 2), 5.10-5.30 (m, 2), 7.30 (d, 1), 7.60 (t, 1), 7.78 (t, 1), 8.10 (d, 1), 8.32 (d, 1), 8.96 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-ethoxycarbonyl)ethoxy)quinoline; NMR (CDCl₃) 1.28 (m, 6), 1.80 (d, 3), 1.97 (m, 1), 2.23 (m, 1), 2.57 (m, 2), 3.40-3.80 (m, 8), 4.17 (q, 2), 4.27 (m, 2), 5.07 (q, 2), 5.31 (m, 1), 7.50 (d, 1), 7.62 (t, 1), 7.78 (t, 1), 8.10 (d, 1), 8.34 (d, 1), 9.16 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)ethoxy)quinoline; NMR (CDCl₃) 1.26 (m, 6), 1.78 (d, 3), 1.97 (m, 1), 2.23 (m, 1), 2.52 (m, 2), 3.40-3.80 (m, 11), 4.18 (q, 2), 4.24 (m, 2), 5.10-5.30 (m, 2), 7.50 (d, 1), 7.58 (t, 1), 7.76 (t, 1), 8.10 (d, 1), 8.35 (d, 1), 8.97 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)-2-methylpropoxy)quinoline; NMR (CDCl₃) 1.17-1.34 (m, 9), 2.00 (m, 1), 2.23 (m, 1), 2.51 (m, 2), 3.40-3.80 (m, 11), 4.18 (q, 2), 4.25 (m, 2), 4.84 (m, 1), 5.23 (m, 1), 7.48 (d, 1), 7.60 (t, 1), 7.77 (t, 1), 8.10 (d, 1), 8.26 (d, 1), 8.98 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxy-2,2-dimethylpropoxy)quinoline; NMR (CDCl₃) 1.17-1.30 (m, 9), 1.90 (m, 1), 2.16 (m, 1), 2.34-2.60 (m, 2), 3.40-3.80 (m, 8), 4.15 (q, 2), 4.87 (m, 1), 5.35 (m, 1), 7.50 (d, 1), 7.58 (t, 1), 7.71 (m, 1), 8.07 (m, 1), 8.26 (m, 1), 9.10 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(cyanomethoxy)quinoline; NMR (CDCl₃) 1.27 (t, 3), 1.98 (m, 1), 2.23 (m, 1), 2.53 (m, 2), 3.40-3.80 (m, 11), 4.17 (q, 2), 5.10 (s, 2), 5.24 (m, 1), 7.66 (t, 1), 7.71 (s, 1), 7.80 (t, 1), 8.18 (d, 1), 8.21 (d, 1), 9.01 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-methyl-1-(methoxycarbonyl)ethoxy)quinoline; NMR (CDCl₃) 1.26 (t, 3), 1.43 (s, 9), 1.83 (d, 6), 1.97 (m, 1), 2.17 (m, 1), 2.40 (m, 2), 3.40-3.80 (m, 11), 4.18 (q, 2), 5.23 (m, 1), 7.35 (s, 1), 7.57 (t, 1), 7.75 (t, 1), 8.10 (d, 1), 8.26 (d, 1), 8.96 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-methyl-1-(methoxycarbonyl)ethoxy)quinoline; NMR (CDCl₃) 1.26 (t, 3), 1.82 (d,

6), 1.97 (m, 1), 2.21 (m, 1), 2.56 (m, 2), 3.40-3.80 (m, 11), 4.18 (q, 2), 5.33 (m, 1), 7.30 (s, 1), 7.60 (t, 1), 7.80 (t, 1), 8.14 (d, 1), 8.29 (d, 1), 9.19 (d, 1) ppm;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-
5 oxy)quinoline; NMR (CDCl₃) 1.22 (t, 3), 1.23 (t, 3), 1.90-2.23 (m, 4), 2.38 (m, 2), 2.64 (m, 2), 2.94 (m, 2), 3.40-3.80 (m, 8), 4.17 (q, 2), 4.22 (q, 2), 5.23 (m, 1), 7.28 (s, 1), 7.58 (t, 1), 7.76 (t, 1), 8.10 (d, 1), 8.32 (d, 1), 8.96 (d, 1) ppm;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-
10 (ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.04 (t, 3), 1.18 (t, 3), 1.84 (m, 1), 1.95-2.01 (m, 3), 2.31 (m, 2), 2.62 (m, 2), 2.81 (m, 2), 3.30-3.66 (m, 8), 4.03 (q, 2), 4.14 (q, 2), 5.01 (m, 1), 6.99 (s, 1), 7.68 (t, 1), 7.86 (t, 1), 8.08 (d, 1), 8.28 (d, 1), 8.89 (d, 1) ppm;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-
15 carboxyethoxy)quinoline; NMR (DMSO-d₆) 1.07 (t, 3), 1.867 (d, 3), 1.85 (m, 1), 2.04 (m, 1), 2.30 (m, 2), 3.30-3.70 (m, 8), 4.06 (q, 2), 5.03 (m, 1), 5.30 (m, 1), 7.42 (s, 1), 7.67 (t, 1), 7.86 (t, 1), 7.78 (t, 1), 8.08 (d, 1), 8.24 (d, 1), 8.96 (d, 1) ppm;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-
20 carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.19 (t, 3), 1.85 (m, 1), 2.04 (m, 3), 2.33 (m, 2), 2.60 (m, 2), 2.83 (m, 2), 3.30-3.70 (m, 8), 4.06 (q, 2), 5.03 (m, 1), 7.08 (s, 1), 7.70 (t, 1), 7.90 (t, 1), 8.10 (d, 1), 8.32 (d, 1), 9.15 (d, 1) ppm;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
25 (methoxycarbonyl)propyl]aminocarbonyl-4-(dimethylaminocarbonyl)methoxyquinoline; NMR (CDCl₃) 1.26 (t, 3), 1.98 (m, 1), 2.24 (m, 1), 2.53 (m, 2), 3.05 (s, 3), 3.13 (s, 3), 3.40-3.80 (m, 11), 4.17 (q, 2), 5.02 (q, 2), 5.24 (m, 1), 7.56 (s, 1), 7.59 (t, 1), 7.76 (t, 1), 8.12 (d, 1), 8.35 (d, 1), 9.01 (d, 1) ppm;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(
30 dimethylaminocarbonyl)methoxyquinoline; NMR (CDCl₃) 1.26 (t, 3), 1.98 (m, 1), 2.22 (m, 1), 2.53 (m, 2), 3.04 (s, 3), 3.13 (s, 3), 3.40-3.80 (m, 8), 4.17 (q, 2), 5.03 (s, 2), 5.33 (m, 1), 7.56 (s, 1), 7.59 (t, 1), 7.76 (t, 1), 8.08 (d, 1), 8.32 (d, 1), 9.11 (d, 1) ppm;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
35 (methoxycarbonyl)propyl]aminocarbonyl-4-(oxiranyl)methoxyquinoline; NMR (DMSO-d₆) 1.27 (t, 3), 1.98 (m, 1), 2.24 (m, 1), 2.40-2.60 (m, 2), 2.85 (m, 1), 3.00

(m, 1), 3.40-3.80 (m, 11), 4.16 (q, 2), 4.21 (m, 1), 4.62 (m, 1), 7.59 (t, 1), 7.63 (s, 1), 7.76 (t, 1), 8.10 (d, 1), 8.27 (d, 1), 9.02 (d, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 2.62 (m, 1), 3.20 (m, 3), 3.36 (m, 2), 3.46 (m, 2), 3.64 (m, 1), 4.12 (s, 3), 3.06 (m, 2), 5.38 (m, 1), 6.78 (dd, 1), 6.82 (d, 1), 6.92 (s, 1), 7.18 (t, 1), 7.52 (t, 1), 7.62 (s, 1), 7.68 (t, 1), 8.16 (d, 1), 8.20 (d, 1), 8.90 (d, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-5-nitroquinoline; NMR (CDCl₃) 1.30 (m, 3), 2.0 (m, 1), 2.25 (m, 1), 2.55 (m, 2), 3.40-3.80 (m, 8), 4.15 (m, 2), 5.15 (m, 2), 5.30 (m, 1), 7.30 (m, 5), 7.85 (m, 1), 8.45 (m, 3), 8.90 (m, 1), 9.15 (m, 1) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-5-nitroquinoline; NMR (CDCl₃) 1.30 (t, 3), 1.95 (m, 1), 2.25 (m, 1), 2.45 (m, 2), 3.40-3.80 (m, 8), 4.20 (q, 2), 5.40 (m, 1), 7.90 (m, 1), 8.40-8.50 (m, 3), 9.00 (m, 1), 9.20 (m, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((ethoxycarbonyl)methoxycarbonyl)propyl]aminocarbonyl-5-aminoquinoline; NMR (CDCl₃) 1.30 (t, 6), 2.10 (m, 1), 2.30 (m, 1), 2.65 (m, 2), 3.40-3.80 (m, 8), 4.20 (m, 4), 4.60 (m, 2), 5.30 (m, 1), 6.90 (d, 1), 7.55 (m, 1), 7.65 (m, 1), 8.20 (d, 1), 8.30 (d, 1), 9.0 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(2,2,2-trifluoroethoxy)quinoline; NMR (CDCl₃) 1.27 (t, 3), 2.00 (m, 1), 2.24 (m, 1), 2.51 (m, 2), 3.40-3.78 (m, 11), 4.16 (q, 2), 4.64 (m, 2), 5.26 (m, 1), 7.60-7.78 (m, 2), 7.85 (t, 1), 8.15-8.35 (m, 2), 9.01 (m, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(oxiranyl)methoxyquinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.85 (m, 1), 2.03 (m, 1), 2.33 (m, 2), 3.30-3.57 (m, 6), 3.64 (m, 2), 4.04 (q, 2), 4.37 (m, 1), 4.58 (m, 1), 5.07 (m, 1), 7.63 (s, 1), 7.72 (t, 1), 7.86 (t, 1), 8.10 (d, 1), 8.32 (d, 1), 9.02 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methylsulfonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(1,2,4-triazol-3-yl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.15 (t, 3), 3.15 (m, 1), 3.23-3.40 (m, 8),

4.01 (q, 2), 4.10 (s, 3), 5.38 (m, 1), 7.55 (s, 1), 7.63 (dd, 1), 7.81 (dd, 1), 8.05 (d, 1), 8.18 (d, 1), 8.36 (br s, 1), 9.15 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(carboxy)methoxyquinoline; NMR (CDCl₃) 1.26 (t, 3), 1.97 (m, 1), 2.18 (m, 1), 2.48 (m, 2), 3.40-3.80 (m, 11), 4.16 (q, 2), 5.07 (q, 2), 5.24 (m, 1), 7.61 (t, 1), 7.65 (s, 1), 7.78 (t, 1), 8.09 (d, 1), 8.26 (d, 1), 9.05 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(ethoxycarbonylmethylaminocarbonyl)methoxyquinoline; NMR (CDCl₃) 1.28 (m, 6), 1.97 (m, 1), 2.24 (m, 1), 2.43-2.58 (m, 2), 3.43-3.78 (m, 11), 4.16 (m, 4), 4.28 (q, 2), 4.86 (s, 2), 5.27 (m, 1), 7.13 (m, 1), 7.65 (m, 2), 7.80 (t, 1), 8.17 (d, 1), 8.27 (d, 1), 8.98 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(3,3,3-trifluoropropoxy)quinoline; NMR (CDCl₃) 1.27 (t, 3), 1.97 (m, 1), 2.23 (m, 1), 2.51 (m, 2), 2.79 (m, 2), 3.41-3.80 (m, 11), 4.17 (q, 2), 4.57 (t, 2), 5.26 (m, 1), 7.58 (t, 1), 7.63 (s, 1), 7.77 (t, 1), 8.12 (d, 1), 8.22 (d, 1), 9.02 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3,3,3-trifluoropropoxy)quinoline; NMR (CDCl₃) 1.27 (t, 3), 1.99 (m, 1), 2.23 (m, 1), 2.54 (m, 2), 2.79 (m, 2), 3.41-3.80 (m, 8), 4.18 (q, 2), 4.56 (t, 2), 5.26 (m, 1), 7.58 (t, 1), 7.64 (s, 1), 7.77 (t, 1), 8.13 (d, 1), 8.21 (d, 1), 9.013 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-cyanoethoxy)quinoline; NMR (CDCl₃) 1.27 (t, 3), 1.98 (d, 3), 2.00 (m, 1), 2.24 (m, 1), 2.54 (m, 2), 3.40-3.80 (m, 11), 4.17 (q, 2), 5.20-5.40 (m, 2), 7.64 (t, 1), 7.80 (m, 2), 8.18 (m, 2), 8.98 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(benzylaminocarbonyl)methoxyquinoline; NMR (CDCl₃) 1.27 (t, 3), 1.98 (m, 1), 2.23 (m, 1), 2.53 (m, 2), 3.40-3.80 (m, 11), 4.16 (q, 2), 4.61 (d, 2), 4.88 (s, 2), 5.26 (m, 1), 7.78 (t, 1), 7.28-7.40 (m, 5), 7.61 (t, 1), 7.65 (s, 1), 7.77 (t, 1), 8.14 (d, 1), 8.16 (d, 1), 9.01 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-tetrazol-5-yethoxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.85 (m, 3), 2.03 (m,

1), 2.31 (m, 2), 3.30-3.70 (m, 8), 4.05 (q, 2), 5.03 (m, 1), 6.47 (m, 1), 7.71 (m, 2),
7.84 (t, 1), 8.08 (d, 1), 8.27 (d, 1), 8.92 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
(benzylaminocarbonyl)methoxyquinoline; NMR (DMSO-d₆) 1.19 (t, 3), 1.90 (m,
5 1), 2.07 (m, 1), 2.37 (m, 2), 3.30-3.73 (m, 8), 4.04 (q, 2), 4.39 (d, 2), 5.01 (s, 2),
5.08 (m, 1), 7.20-7.38 (m, 5), 7.58 (s, 1), 7.71 (t, 1), 7.88 (t, 1), 8.10 (d, 1), 8.43
(d, 1), 8.86 (m, 1), 8.97 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
(carboxy)methylamino)carbonylmethoxyquinoline; NMR (CDCl₃) 1.24 (t, 3), 1.91
10 (m, 1), 2.16 (m, 1), 2.43-2.58 (m, 2), 3.41-3.78 (m, 8), 4.12 (m, 4), 4.77 (s, 2),
5.27 (m, 1), 7.45 (m, 1), 7.55 (m, 1), 7.64 (t, 1), 7.94 (d, 1), 8.04 (d, 1), 9.04 (d,
1) ppm;

2-[1-(3-(2-methylpropyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
carboxypropyl]aminocarbonyl-4-methoxyquinoline;

15 2-[1-(3-(1-methylethyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-benzyl-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(4-hydroxybenzyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-
20 carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
methoxyquinoline;

2-[1-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃)
25 1.47 (s, 9), 2.01 (m, 1), 2.24 (m, 1), 2.34 (s, 3), 2.42 (m, 2), 3.14-3.34 (m, 4),
3.74-3.93 (m, 4), 4.13 (s, 3), 5.31 (m, 1), 6.75 (m, 3), 7.16 (t, 1), 7.57 (t, 1), 7.66
(s, 1), 7.74 (t, 1), 8.10 (d, 1), 8.23 (d, 1), 9.03 (d, 1) ppm;

2-[1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃)
30 1.44 (s, 9), 1.98 (m, 1), 2.23 (m, 1), 2.43 (m, 2), 3.51-3.90 (m, 8), 4.13 (s, 3), 5.30
(m, 1), 6.66 (m, 2), 7.57 (m, 2), 7.65 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.23 (m, 2),
9.04 (d, 1) ppm;

2-[1-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 1.89 (m, 1), 2.08 (m, 1), 2.24 (s, 3), 2.32 (m,
35 2), 3.10-3.26 (m, 4), 3.65 (m, 2), 3.79 (m, 2), 4.13 (s, 3), 5.07 (m, 1), 6.64 (d, 1),

6.80 (m, 2), 7.12 (t, 1), 7.61 (s, 1), 7.66 (t, 1), 7.85 (t, 1), 8.10 (d, 1), 8.18 (d, 1),
8.97 (d, 1) ppm;

2-[1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 1.88 (m, 1), 2.08 (m, 1), 2.34 (m, 2), 3.51-
5 3.72 (m, 6), 3.78 (m, 2), 4.13 (s, 3), 5.16 (m, 1), 6.66 (m, 1), 6.85 (d, 1), 7.56 (t,
1), 7.61 (s, 1), 7.67 (t, 1), 7.85 (t, 1), 8.08-8.21 (m, 3), 8.97 (d, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
(methoxycarbonyl)propyl]aminocarbonyl-4-(3,4,4-trifluorobut-3-en-1-
oxy)quinoline; NMR (CDCl₃) 1.26 (t, 3), 1.98 (m, 1), 2.24 (m, 1), 2.52 (m, 2), 2.92
15 (m, 2), 2.97 (m, 2), 3.41-3.78 (m, 11), 4.16 (q, 2), 4.45 (t, 2), 5.24 (m, 1), 7.58 (t,
1), 7.63 (s, 1), 7.74 (t, 1), 8.10 (d, 1), 8.17 (d, 1), 9.01 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3,4,4-
trifluorobut-3-en-1-oxy)quinoline; NMR (CDCl₃) 1.25 (t, 3), 1.98 (m, 1), 2.24 (m,
1), 2.56 (m, 2), 2.92 (m, 2), 2.97 (m, 2), 3.41-3.78 (m, 8), 4.16 (q, 2), 4.44 (t, 2),
15 5.31 (m, 1), 7.58 (t, 1), 7.63 (s, 1), 7.74 (t, 1), 8.10 (d, 1), 8.17 (d, 1), 9.17 (d, 1)
ppm;

25 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.22 (t, 3), 1.31 (t, 3),
2.13 (m, 2), 2.63 (m, 2), 2.94 (m, 2), 3.57 (m, 6), 3.68 (m, 2), 4.17 (q, 2), 4.24 (q,
20 2), 4.35 (d, 2), 7.16 (s, 1), 7.60 (t, 1), 7.76 (t, 1), 8.10 (d, 1), 8.34 (d, 1), 9.03 (t, 1)
ppm;

30 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-
(carboxy)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.22 (t, 3), 2.03 (m, 2), 2.59
(m, 2), 2.82 (m, 2), 3.30-3.60 (m, 8), 4.04 (q, 2), 4.23 (d, 2), 7.08 (s, 1), 7.71 (t,
25 1), 7.90 (t, 1), 8.07 (d, 1), 8.28 (d, 1), 8.94 (t, 1) ppm;

35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
(tetrazol-5-yl)methoxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.86 (m, 1), 2.08 (m,
1), 2.26 (m, 2), 3.44 (m, 6), 3.64 (m, 2), 4.04 (q, 2), 5.06 (m, 1), 5.88 (s, 1), 7.70
(t, 3), 7.78 (s, 1), 7.84 (t, 1), 8.10 (d, 1), 8.26 (d, 1), 8.90 (d, 1) ppm;

40 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-
hydroxyethoxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.84 (m, 1), 2.14 (m, 1),
2.14 (m, 2), 3.40 (m, 6), 3.64 (m, 2), 3.86 (m, 2), 4.04 (q, 2), 4.36 (m, 2), 5.08 (m,
1), 7.58 (s, 1), 7.68 (t, 3), 7.84 (t, 1), 8.08 (d, 1), 8.18 (d, 1), 8.90 (d, 1) ppm;

45 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-
(carboxymethyl)aminoquinoline; NMR (DMSO-d₆) 1.10 (t, 3), 1.80 (m, 1), 2.0 (m,

1), 2.25 (m, 2), 3.20-3.60 (m, 8), 4.0 (m, 4), 5.0 (m, 1), 6.40 (d, 1), 7.30 (d, 1),
7.50 (m, 1), 7.95 (d, 1), 8.70 (d, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(methoxycarbonyl)ethoxy)quinoline;
5 NMR (CDCl₃) 1.27 (t, 3), 1.77 (d, 3), 1.98 (m, 1), 2.23 (m, 1), 2.48 (m, 2), 3.40-
3.80 (m, 14), 4.16 (q, 2), 5.14-5.30 (m, 2), 7.48 (s, 1), 7.60 (t, 1), 7.76 (t, 1), 8.10
(d, 1), 8.32 (d, 1), 8.98 (t, 1) ppm and NMR (CDCl₃) 1.27 (t, 3), 1.78 (d, 3), 1.98
(m, 1), 2.23 (m, 1), 2.48 (m, 2), 3.40-3.80 (m, 14), 4.16 (q, 2), 5.14-5.30 (m, 2),
7.48 (s, 1), 7.60 (t, 1), 7.76 (t, 1), 8.10 (d, 1), 8.32 (d, 1), 8.98 (t, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-
(carboxy)ethoxy)quinoline; NMR (DMSO) 1.24 (t, 3), 1.71 (d, 3), 1.85 (m, 1), 2.03
(m, 1), 2.32 (m, 2), 3.30-3.71 (m, 8), 4.06 (q, 2), 5.06 (m, 1), 5.34 (m, 1), 7.46 (s,
1), 7.71 (t, 1), 7.89 (t, 1), 8.10 (d, 1), 8.27 (d, 1), 8.98 (m, 1) ppm and NMR (DMSO)
15 1.18 (t, 3), 1.71 (d, 3), 1.86 (m, 1), 2.03 (m, 1), 2.32 (m, 2), 3.30-3.73 (m, 8), 4.06
(q, 2), 5.06 (m, 1), 5.34 (m, 1), 7.46 (s, 1), 7.71 (t, 1), 7.89 (t, 1), 8.10 (d, 1), 8.27 (d,
1), 8.98 (m, 1) ppm;

2-[1-(3-(1-methylethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR
20 (CDCl₃) 0.76-0.98 (m, 6), 1.26 (m, 3), 1.38-1.70 (m, 12), 1.96 (m, 1), 2.24 (m, 1),
2.32-2.50 (m, 2), 2.71-3.47 (m, 3), 4.01-4.31 (m, 7), 4.32-4.60 (m, 2), 5.15-5.33
(m, 1), 7.56 (t, 1), 7.64 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.24 (d, 1), 9.03 (m, 1) ppm
25 and NMR (CDCl₃) 0.77-0.98 (m, 6), 1.26 (m, 3), 1.38-1.70 (m, 12), 1.96 (m, 1),
2.24 (m, 1), 2.32-2.50 (m, 2), 2.71-3.45 (m, 3), 4.01-4.27 (m, 7), 4.32-4.60 (m, 2),
5.15-5.33 (m, 1), 7.56 (t, 1), 7.64 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.24 (d, 1), 9.03
(m, 1) ppm;

2-[1-(3-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO) 0.73-0.98 (m,
6), 1.15-1.57 (m, 6), 1.78-2.20 (m, 2), 2.34 (m, 2), 2.65-3.44 (m, 3), 3.80-4.38 (m,
9), 5.01-5.18 (m, 1), 7.61 (s, 1), 7.66 (t, 1), 7.87 (t, 1), 8.10 (d, 1), 8.22 (d, 1),
30 8.96 (m, 1) ppm and NMR (DMSO) 0.73-0.98 (m, 6), 1.16-1.60 (m, 6), 1.82-2.17
(m, 2), 2.34 (m, 2), 2.67-3.42 (m, 3), 3.80-4.36 (m, 9), 5.01-5.18 (m, 1), 7.61 (s,
1), 7.66 (t, 1), 7.87 (t, 1), 8.10 (d, 1), 8.22 (d, 1), 8.96 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-methoxyquinoline; NMR
35 (CDCl₃) 1.30 (t, 3), 1.45 (s, 9), 2.0 (m, 1), 2.20 (m, 1), 2.40 (m, 2), 3.40-3.80 (m,

8), 4.10 (s, 3), 4.20 (q, 2), 5.20 (m, 1), 7.50 (d, 1), 7.65 (s, 1), 8.15 (m, 2), 8.95 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-methoxyquinoline; NMR (CDCl₃) 1.30 (t, 3), 2.0 (m, 1), 2.20 (m, 1), 2.60 (m, 2), 3.40-3.90 (m, 8), 4.20 (m, 5), 5.35 (m, 1), 7.60 (m, 1), 7.70 (m, 1), 8.20 (m, 2), 9.20 (m, 1) ppm;

5 2-[1-(2-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 0.88-1.10 (m, 6), 1.26 (m, 3), 1.38-1.62 (m, 12), 1.96 (m, 1), 2.21 (m, 1), 2.32-2.50 (m, 2), 2.61-3.42 (m, 3), 3.92-4.80 (m, 9), 5.15-5.30 (m, 1), 7.57 (t, 1), 7.65 (s, 1), 7.75 (t, 1), 8.10 (d, 1), 8.24 (d, 1), 8.92 (m, 1) ppm;

10 2-[1-(2-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 0.88-1.10 (m, 6), 1.27 (m, 3), 1.35-1.60 (m, 3), 1.80-2.24 (m, 2), 2.48-2.65 (m, 2), 2.84-3.11 (m, 2), 3.37 (m, 1), 3.94-4.80 (m, 9), 5.25 (m, 1), 7.59 (t, 1), 7.64 (s, 1), 7.80 (t, 1), 8.14 (d, 1), 8.23 (d, 1), 9.16 (m, 1) ppm and NMR (CDCl₃) 0.88-1.08 (m, 6), 1.25 (m, 3), 1.35-1.62 (m, 3), 1.78-2.26 (m, 2), 2.41-2.62 (m, 2), 2.80-3.42 (m, 3), 3.92-4.85 (m, 9), 5.18-5.33 (m, 1), 7.56 (t, 1), 7.63 (s, 1), 7.74 (t, 1), 8.10 (d, 1), 8.21 (d, 1), 9.12 (m, 1) ppm;

15 20 2-[1-(3-(1-methylethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.67-1.23 (m, 9), 1.73-2.11 (m, 3), 2.32 (m, 2), 2.74-2.98 (m, 2), 3.10-3.37 (m, 2), 3.72 (m, 1), 3.80-4.53 (m, 8), 5.07 (m, 1), 7.58 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.07 (d, 1), 8.18 (d, 1), 8.88 (m, 1) ppm;

25 25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.19 (t, 3), 1.28 (t, 3), 1.95-2.25 (m, 4), 2.40-2.70 (m, 4), 2.96 (m, 2), 3.40-3.80 (m, 11), 4.17 (q, 2), 4.23 (q, 2), 5.24 (m, 1), 7.14 (s, 1), 7.60 (t, 1), 7.87 (t, 1), 8.10 (d, 1), 8.32 (d, 1), 8.94 (d, 1) ppm;

30 30 2-[1-(4-(3-chlorophenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.35 (s, 9), 1.84 (m, 1), 2.03 (m, 1), 2.31 (m, 2), 3.12-3.34 (m, 4), 3.63 (m, 2), 3.75 (m, 2), 4.12 (s, 3), 5.07 (m, 1), 6.78 (d, 1), 6.92 (d, 1), 6.96 (s, 1), 7.21 (t, 1), 7.57 (s, 1), 7.65 (t, 1), 7.84 (t, 1), 8.07 (d, 1), 8.17 (d, 1), 8.92 (d, 1) ppm;

2-[1-(4-(3-methylphenyl)-3-methylpiperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 0.95-1.13 (m, 3), 1.47 (s, 9), 2.02 (m, 1), 2.21-2.57 (m, 5), 3.08-4.45 (m, 10), 5.27 (m, 1), 6.74 (m, 3), 7.16 (m, 1), 7.57 (m, 1), 7.65 (s, 1), 7.75 (t, 1), 8.12 (d, 1), 8.22 (d, 1), 9.04 (m, 1) ppm;

2-[1-(4-(3-chlorophenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.02 (m, 1), 2.24 (m, 1), 2.57 (m, 2), 3.18-3.32 (m, 4), 3.77-3.91 (m, 4), 4.15 (s, 3), 5.33 (m, 1), 6.79 (d, 1), 7.87 (m, 2), 7.18 (t, 1), 7.57 (t, 1), 7.66 (s, 1), 7.77 (t, 1), 8.12 (d, 1), 8.24 (d, 1), 9.25 (d, 1) ppm;

2-[1-(piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(piperidin-4-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-di(acetyl)aminoquinoline; NMR (CDCl₃) 1.30 (t, 3), 2.0 (m, 1), 2.30 (m, 1), 2.35 (s, 3), 2.40 (s, 3), 2.60 (m, 2), 3.40-3.85 (m, 8), 4.20 (q, 2), 5.35 (m, 1), 7.50 (d, 1), 7.85 (m, 1), 8.15 (d, 1), 8.35 (m, 1), 8.65 (m, 2), 9.15 (m, 1) ppm;

2-[1-(3-methyl-4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.82-0.91 (m, 3), 1.78 (m, 1), 2.02 (m, 1), 2.18-2.56 (m, 5), 3.07-3.35 (m, 1), 3.40-3.95 (m, 4), 4.02-4.41 (m, 5), 5.03 (m, 1), 7.08 (m, 1), 7.26 (m, 3), 7.57 (m, 2), 7.76 (m, 1), 8.01-8.13 (m, 2), 9.18 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-acetamidoquinoline; NMR (CDCl₃) 1.30 (m, 3), 2.0 (m, 1), 2.20 (m, 1), 2.40 (s, 3), 2.60 (m, 2), 3.40-3.85 (m, 8), 4.20 (m, 2), 5.35 (m, 1), 7.60-7.80 (m, 3), 8.40 (m, 1), 9.0 (m, 2) ppm;

2-[1-(3-(1-hydroxyethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.27-1.38 (m, 6), 1.46 (s, 9), 1.94 (m, 1), 2.17 (m, 1), 2.44 (m, 2), 2.92 (m, 1), 3.27-3.60 (m, 2), 3.90-4.63 (m, 9), 5.26 (m, 1), 7.56 (t, 1), 7.63 (s, 1), 7.73 (t, 1), 8.09 (d, 1), 8.22 (d, 1), 8.93 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-4-(1-tetrazol-5-yethoxy)quinoline; NMR (DMSO-d₆) 1.07-1.18 (m, 6), 1.87 (m, 4), 2.05 (m, 1), 2.37 (m, 2), 3.32-3.68 (m, 8), 3.95-4.06 (m, 4), 5.03 (m, 1), 6.47 (m, 1), 7.67 (m, 2), 7.85 (t, 1), 8.07 (d, 1), 8.27 (d, 1), 8.93 (d, 1) ppm;

2-[1-(3-(1-hydroxyethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.18 (m, 6), 1.78 (m, 1), 2.01 (m, 1), 2.32 (m, 2), 2.77 (m, 1), 3.27-3.43 (m, 2), 3.80-4.41 (m, 9), 5.06 (m, 1), 7.56 (m, 1), 7.63 (t, 1), 7.83 (t, 1), 8.08 (m, 1), 8.18 (m, 1), 8.93 (m, 1) ppm and NMR (DMSO-d₆) 1.05-1.23 (m, 6), 1.82 (m, 1), 2.01 (m, 1), 2.30 (m, 2), 2.84 (m, 1), 3.03-3.23 (m, 2), 3.40-4.41 (m, 9), 5.04 (m, 1), 7.56 (s, 1), 7.63 (t, 1), 7.83 (t, 1), 8.08 (d, 1), 8.18 (d, 1), 8.93 (m, 1) ppm;

2-[1-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxy)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.84 (m, 1), 2.03 (m, 3), 2.25 (s, 3), 2.35 (m, 2), 2.58 (m, 2), 2.83 (m, 2), 3.10-3.24 (m, 4), 3.62-3.85 (m, 4), 5.11 (m, 1), 6.64 (d, 1), 6.77 (m, 2), 7.08 (s, 1), 7.12 (d, 1), 7.71 (t, 1), 7.88 (t, 1), 8.11 (d, 1), 8.27 (d, 1), 8.92 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.23 (t, 3), 1.27 (t, 3), 1.46 (s, 9), 1.96 (m, 1), 2.16 (m, 3), 2.37 (m, 2), 2.94 (m, 2), 3.41-3.79 (m, 8), 4.17 (q, 2), 4.24 (q, 2), 5.19 (m, 1), 7.13 (s, 1), 7.54 (d, 1), 8.13 (s, 1), 8.25 (d, 1), 8.87 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.05 (t, 3), 1.18 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.60 (m, 2), 2.79 (m, 2), 3.35-3.65 (m, 8), 4.05 (q, 2), 4.16 (q, 2), 5.00 (m, 1), 6.99 (s, 1), 7.72 (d, 1), 8.15 (s, 1), 8.30 (d, 1), 8.88 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.18 (t, 3), 1.25 (m, 6), 1.97 (m, 1), 2.09 (m, 1), 2.21 (m, 2), 2.48 (m, 2), 2.62 (m, 2), 2.94 (m, 2), 3.42-3.78 (m, 8), 4.12-4.26 (m, 6), 5.23 (m, 1), 7.13 (s, 1), 7.60 (t, 1), 7.75 (t, 1), 8.07 (d, 1), 8.33 (d, 1), 8.92 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.85 (m, 1), 1.98 (m, 3), 2.30 (m, 2), 2.58 (m, 2), 2.78 (m, 2), 3.35-3.62 (m, 8), 4.05 (q, 2), 4.96 (m, 1), 7.03 (s, 1), 7.70 (d, 1), 8.15 (s, 1), 8.25 (d, 1), 8.88 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-methoxyquinoline; NMR (CDCl₃) 1.30 (t, 3), 2.0 (m, 1), 2.20 (m, 1), 2.60

(m, 2), 3.40-3.85 (m, 8), 4.10 (s, 3), 4.20 (q, 2), 5.30 (m, 1), 7.60 (m, 2), 8.0 (s, 1), 9.10 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxy-3-(diethylamino)propoxy)quinoline; NMR (DMSO-d₆) 1.18 (m, 9), 1.83 (m, 1), 2.02 (m, 1), 2.31 (m, 2), 2.48 (m, 2), 3.22-3.68 (m, 14), 4.04 (q, 2), 5.03 (m, 1), 5.46 (m, 1), 7.47 (s, 1), 7.71 (t, 1), 7.88 (t, 1), 8.10 (d, 1), 8.31 (d, 1), 8.94 (m, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.15 (t, 3), 1.90 (m, 1), 2.10 (m, 3), 2.40 (m, 2), 2.60 (m, 2), 2.80 (m, 2), 3.40-3.70 (m, 8), 4.05 (q, 2), 5.10 (m, 1), 7.0 (s, 1), 7.60 (s, 1), 8.0 (s, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.80-1.95 (m, 1), 2.00 (m, 2), 2.30 (m, 2), 2.60 (m, 2), 2.80 (m, 2), 3.30-3.75 (m, 8), 4.05 (q, 2), 15 5.00 (m, 1), 7.15 (s, 1), 7.85 (d, 1), 8.10 (d, 1), 8.25 (s, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.10 (t, 3), 1.98 (m, 2), 2.30-2.63 (m, 3), 2.75-2.87 (m, 3), 3.28-3.50 (m, 8), 3.94 (q, 2), 5.17 (m, 1), 7.64 (t, 1), 7.80 (t, 1), 8.01 (d, 1), 8.22 (d, 1), 9.10 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1,1-di(ethoxycarbonyl)methoxy)quinoline; NMR (CDCl₃) 1.04-1.18 (m, 9), 1.96 (m, 1), 2.23 (m, 1), 2.53 (m, 2), 3.40-3.80 (m, 8), 4.15 (q, 2), 4.37 (m, 4), 5.24 (m, 1), 5.57 (s, 1), 7.53 (s, 1), 7.63 (t, 1), 7.78 (t, 1), 8.11 (d, 1), 8.41 (d, 1), 8.98 (d, 1) 25 ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1,1-di(carboxy)methoxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.84 (m, 1), 2.00 (m, 1), 2.30 (m, 2), 3.35-3.65 (m, 8), 4.01 (q, 2), 5.02 (m, 1), 5.88 (s, 1), 7.47 (s 1), 7.70 (t, 1), 7.90 (t, 1), 8.10 (d, 1), 8.27 (d, 1), 8.94 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.14 (t, 3), 1.83 (m, 1), 2.02 (m, 3), 2.28 (m, 2), 2.54 (s, 3), 2.56 (m, 2), 2.78 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.03 (q, 2), 5.00 (m, 1), 7.02 (s, 1), 7.68 (dd, 1), 7.95 (d, 1), 8.14 (s, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-nitro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.88 (m, 1), 2.06 (m, 3), 2.30 (m, 2), 2.69 (m, 2), 2.83 (m, 2), 3.30-3.65 (m, 8), 4.05 (q, 2), 5.02 (m, 1), 7.19 (s, 1), 8.32 (d, 1), 8.59 (d, 1), 8.64 (s, 1), 9.02 (d, 1), 9.06 (s, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-amino-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.84 (m, 1), 2.01 (m, 3), 2.30 (m, 2), 2.65 (m, 2), 2.78 (m, 2), 3.30-3.65 (m, 8), 4.05 (q, 2), 5.00 (m, 1), 6.92 (s, 1), 7.19 (m, 2), 7.92 (d, 1), 8.79 (m, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.55 (m, 2), 2.77 (m, 2), 2.88 (s, 3), 3.40 (m, 6), 3.62 (m, 2), 4.03 (q, 2), 4.98 (m, 1), 6.93 (s, 1), 7.42 (d, 1), 7.65 (t, 1), 7.86 (d, 1), 8.85 (d, 1) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-(benzyloxy)-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.22 (t, 3), 1.28 (t, 3), 1.46 (s, 9), 1.95 (m, 1), 1.99-2.24 (m, 3), 2.38 (m, 2), 2.62 (m, 2), 2.94 (m, 2), 3.41-3.80 (m, 8), 4.20 (m, 4), 5.22 (m, 1), 5.25 (s, 2), 7.06 (s, 1), 7.18-7.58 (m, 7), 8.13 (d, 1), 8.92 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-hydroxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.22 (t, 3), 1.28 (t, 3), 1.46 (s, 9), 1.77 (m, 1), 1.95-2.24 (m, 3), 2.42 (m, 2), 2.59 (m, 2), 2.94 (m, 2), 3.46-3.83 (m, 8), 4.21 (m, 4), 5.22 (m, 1), 6.95 (s, 1), 7.07 (d, 1), 7.34 (s, 1), 8.04 (d, 1), 8.85 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(benzyloxy)-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.85 (m, 1), 1.94-2.17 (m, 3), 2.32 (m, 2), 2.57 (m, 2), 2.81 (m, 2), 3.31-3.72 (m, 8), 4.05 (q, 4), 5.05 (m, 1), 5.26 (s, 2), 6.96 (s, 1), 7.35-7.61 (m, 7), 8.19 (d, 1), 8.88 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.85 (m, 1), 2.02 (m, 3), 2.30 (m, 2), 2.55 (m, 2), 2.80 (m, 2), 3.35-3.65 (m, 8), 4.05 (q, 2), 5.00 (m, 1), 6.90 (s, 1), 7.20 (d, 1), 7.30 (s, 1), 8.10 (d, 1), 8.85 (d, 1), 10.40 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-*n*-
propoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.03 (t, 3), 1.18
(t, 3), 1.82 (m, 3), 2.03 (m, 3), 2.31 (m, 2), 2.57 (m, 2), 2.77 (m, 2), 3.34-3.68 (m,
8), 4.06 (q, 2), 2.13 (q, 2), 5.03 (m, 1), 6.84 (s, 1), 7.33 (d, 1), 7.43 (d, 1), 8.14 (d,
1), 8.87 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
(carboxy)methoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t,
3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.60 (m, 2), 2.80 (m, 2), 3.30-3.62 (m, 8),
4.05 (q, 2), 4.94 (s, 2), 5.02 (m, 1), 6.93 (s, 1), 7.40 (m, 2), 8.20 (d, 1), 8.90 (d, 1)
ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxybutyl]aminocarbonyl-4-(1-
carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.05 (d, 3), 1.19 (t, 3), 1.65 (m
1), 2.0 (m, 3), 2.40-2.60 (m, 2), 2.80 (m, 2), 3.30-3.75 (m, 8), 4.05 (q, 2), 4.99 (m,
1), 7.02 (s, 1), 7.70 (t, 1), 7.85 (t, 3), 8.10 (d, 1), 8.25 (d, 1), 8.95 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
(diethylamino)ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆)
1.18-1.33 (m, 9), 1.82 (m, 1), 2.03 (m, 3), 2.31 (m, 2), 2.57 (m, 2), 2.80 (m, 2),
3.24-3.71 (m, 14), 4.06 (q, 2), 4.57 (m, 2), 5.07 (m, 1), 6.97 (s, 1), 7.37 (d, 1),
7.56 (s, 1), 8.23 (d, 1), 8.86 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
methoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.82
(m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.56 (m, 2), 2.79 (m, 2), 3.35-3.65 (m, 8), 3.92 (s,
3), 4.02 (q, 2), 5.00 (m, 1), 6.95 (s, 1), 7.30 (d, 1), 7.42 (s, 1), 8.15 (d, 1), 8.85 (d,
1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(2-
carboxy-4-hydroxypyrrolidin-1-yl)ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;
NMR (DMSO-d₆) 1.19 (t, 3), 1.82-2.18 (m, 6), 2.31 (m, 2), 2.57 (m, 2), 2.81 (m,
2), 3.31-3.83 (m, 10), 4.04 (q, 2), 4.21-4.42 (m, 6), 5.05 (m, 1), 6.96 (s, 1), 7.36
(t, 1), 7.46 (d, 1), 8.17 (d, 1), 8.88 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-8-
methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.72
(m, 1), 1.85 (m, 1), 1.92 (m, 2), 2.12 (m, 2), 2.30 (m, 2), 2.70 (s, 3), 2.72 (m, 2),
3.40 (m, 8), 3.62 (m, 2), 4.02 (q, 2), 4.98 (m, 1), 7.10 (s, 1), 7.46 (t, 1), 7.60 (6,
1), 8.04 (d, 1), 8.95 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(diethylamino)methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.16 (t, 3), 2.18 (t, 6), 1.83 (m, 1), 2.04 (m, 3), 2.28 (m, 2), 2.58 (m, 2), 2.84 (m, 2), 3.18 (m, 4), 3.40 (m, 6), 3.62 (m, 2), 4.04 (q, 2), 4.58 (s, 2), 5.00 (m, 1), 7.06 (s, 1), 7.98 (d, 1), 87.82 (d, 1), 8.42 (s, 1), 8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(diethylamino)methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.14 (t, 3), 1.18 (t, 6), 1.83 (m, 1), 2.04 (m, 3), 2.28 (m, 2), 2.58 (m, 2), 2.80 (m, 2), 3.18 (m, 4), 3.40 (m, 6), 3.62 (m, 2), 4.04 (q, 2), 4.58 (s, 2), 5.00 (m, 1), 7.06 (s, 1), 7.78 (d, 1), 8.34 (s, 1), 8.38 (d, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(benzyloxy)-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.83 (m, 1), 1.94-2.08 (m, 3), 2.29 (m, 2), 2.57 (m, 2), 2.80 (m, 2), 3.31-3.67 (m, 8), 4.02 (q, 4), 4.98 (m, 1), 5.27 (s, 2), 7.00 (s, 1), 7.35-7.64 (m, 7), 8.01 (d, 1), 8.81 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(carboxy)methoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.83 (m, 1), 2.02 (m, 3), 2.28 (m, 2), 2.56 (m, 2), 2.78 (m, 2), 3.30-3.70 (m, 8), 4.03 (q, 2), 4.86 (s, 2), 4.98 (m, 1), 7.01 (s, 1), 7.44 (s, 1), 7.56 (d, 1), 8.03 (d, 1), 8.82 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.29 (t, 3), 1.80 (m, 1), 1.98 (m, 3), 2.30 (m, 2), 2.58 (m, 2), 2.78 (m, 2), 3.30-3.63 (m, 8), 4.02 (q, 2), 4.19 (q, 2), 4.98 (m, 1), 7.00 (s, 1), 7.47 (m, 2), 7.98 (d, 1), 8.80 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.82 (m, 1), 1.98 (m, 3), 2.30 (m, 2), 2.58 (m, 2), 2.79 (m, 2), 3.35-3.65 (m, 8), 3.91 (s, 3), 4.02 (q, 2), 4.98 (m, 1), 7.01 (s, 1), 7.30 (m, 1), 7.98 (d, 1), 8.80 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(1-methylethoxy)-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.35 (d, 6), 1.83 (m, 1), 2.01 (m, 3), 2.28 (m, 2), 2.57 (m, 2), 2.78 (m, 2), 3.30-

3.70 (m, 8), 4.04 (q, 2), 4.84 (m, 1), 4.98 (m, 1), 7.00 (s, 1), 7.47 (d, 1), 7.51 (s, 1), 7.97 (d, 1), 8.82 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.2 (t, 3), 1.9 (m, 3), 2.0-2.15 (m, 3), 2.4 (m, 2), 2.6 (m, 2), 2.9 (m, 2), 3.3-3.75 (m, 8), 5.1 (m, 1), 7.0 (s, 1), 7.4 (t, 1), 7.7 (d, 1), 8.3 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(trifluoromethyl)-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.84 (m, 1), 2.04 (m, 3), 2.28 (m, 2), 2.60 (m, 2), 2.80 (m, 2), 2.86 (s, 3), 3.44 (m, 6), 3.62 (m, 2), 4.03 (q, 2), 5.00 (m, 1), 7.18 (s, 1), 7.96 (d, 1), 8.42 (s, 1), 8.46 (d, 1), 8.94 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.19 (t, 3), 2.00 (m, 1), 2.15 (m, 1), 2.35 (m, 1), 2.60 (m, 2), 2.80 (m, 2), 2.90-3.05 (m, 2), 3.30-3.65 (m, 8), 4.05 (q, 2), 5.10 (m, 1), 7.05 (s, 1), 7.70 (t, 1), 7.90 (t, 1), 7.95 (s, 1), 8.10 (d, 1), 8.30 (d, 1), 9.05 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-(aminocarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.25 (t, 3), 1.80 (m, 1), 2.00 (m, 2), 2.30 (m, 2), 2.15 (m, 1), 2.30-2.50 (m, 3), 2.60 (m, 1), 2.80 (m, 1), 3.00 (m, 1), 3.40-3.75 (m, 8), 4.15 (q, 2), 5.24 (m, 1), 6.20 (s, 1), 6.90 (s, 1), 7.15 (s, 1), 7.55 (d, 1), 8.10 (s, 1), 8.20 (d, 1), 9.00 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(hydroxymethyl)-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.82 (m, 1), 3.00 (m, 3), 2.30 (m, 2), 2.58 (m, 2), 2.78 (m, 2), 3.30-3.65 (m, 8), 4.02 (q, 2), 4.70 (s, 2), 5.00 (m, 1), 7.00 (s, 1), 7.60 (d, 1), 8.00 (s, 1), 8.20 (d, 1), 8.92 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-ethyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.25 (t, 2), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.56 (m, 2), 2.82 (m, 4), 3.40 (m, 6), 3.62 (m, 2), 4.00 (q, 2), 5.00 (m, 1), 6.98 (s, 1), 7.55 (dd, 1), 7.85 (s, 1), 8.15 (d, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-cyano-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.83 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.60 (m, 2), 2.80 (m, 2), 3.30-3.62 (m, 8), 4.05 (q, 2), 5.00 (m, 1), 7.14 (s, 1), 7.98 (d, 1), 8.40 (d, 1), 8.64 (s, 1), 8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-cyano-
4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.84 (m, 1),
2.02 (m, 3), 2.28 (m, 2), 2.67 (m, 2), 2.78 (m, 2), 3.30-3.70 (m, 8), 4.03 (q, 2),
5.02 (m, 1), 7.12 (s, 1), 7.96 (t, 1), 8.25 (d, 1), 8.40 (d, 1), 8.92 (d, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-nitro-4-
(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.30 (t, 3), 1.90 (m, 1), 2.0-
2.30 (m, 4), 2.50 (m, 2), 2.70 (m, 1), 2.95 (m, 2), 3.40-3.85 (m, 8), 4.10 (q, 2),
5.20 (m, 1), 7.10 (s, 1), 8.25 (m, 1), 8.45 (d, 1), 8.80 (s, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-
carboxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.30 (t, 3), 1.90
(m, 1), 2.15 (m, 3), 2.45 (m, 3), 2.50 (m, 1), 2.99 (m, 2), 3.40-3.80 (m, 8), 4.15 (q,
2), 5.20 (m, 1), 7.20 (s, 1), 8.10 (d, 1), 8.30 (d, 1), 9.0 (s, 1) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-amino-
4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.25 (t, 3), 1.9-2.25 (m, 4),
2.45 (m, 2), 2.6 (m, 2), 2.95 (m, 2), 3.4-3.8 (m, 8), 4.10 (q, 2), 5.15 (m, 1), 6.8 (s,
1), 7.0 (s, 1), 7.1 (d, 1), 8.05 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
(trifluoromethoxy)-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t,
3), 1.85 (m, 1), 2.02 (m, 3), 2.28 (m, 2), 2.58 (m, 2), 2.78 (m, 2), 3.36 (m, 4), 3.48
(m, 2), 3.63 (m, 2), 4.02 (q, 2), 5.00 (m, 1), 7.06 (s, 1), 7.68 (dd, 1), 7.98 (s, 1),
8.38 (d, 1), 8.92 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-4-
(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.05 (t, 3), 1.15 (t,
3), 2.00 (m, 2), 2.15 (m, 1), 2.25 (m, 1), 2.60 (m, 2), 2.75-3.00 (m, 4), 3.25-3.61
(m, 8), 4.03 (q, 2), 4.15 (q, 2), 5.05 (m, 1), 6.95 (s, 1), 7.65 (t, 2), 7.85 (t, 2), 8.05
(d, 2), 8.25 (d, 2), 9.05 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-7-
methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 2.00
(m, 2), 2.15 (m, 1), 2.25 (m, 1), 2.55 (s, 3), 2.60 (m, 2), 2.75-3.00 (m, 4), 3.25-
3.61 (m, 8), 4.03 (q, 2), 4.15 (q, 2), 5.05 (m, 1), 6.95 (s, 1), 7.50 (d, 1), 7.88 (s,
1), 8.15 (d, 2), 9.05 (d, 2) ppm;

35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
((trifluoromethyl)sulfonylamino)propyl]aminocarbonyl-7-methyl-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.05 (t, 3), 1.15 (t, 3),
1.90-2.10 (m, 4), 2.5 (s, 3), 2.60 (m, 2), 2.80 (m, 2), 3.15-3.60 (m, 10), 4.00 (q, 2),

4.15 (q, 2), 5.05 (m, 1), 6.95 (s, 1), 7.55 (d, 2), 7.85 (s, 1), 8.17 (d, 2), 9.03 (d, 2),
9.41 (br t, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

((trifluoromethyl)sulfonylamino)propyl]aminocarbonyl-7-methyl-4-(1-
5 carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.90-2.10 (m, 4),
2.5 (s, 3), 2.60 (m, 2), 2.80 (m, 2), 3.15-3.60 (m, 10), 4.00 (q, 2), 4.15 (q, 2), 5.05
(m, 1), 6.95 (s, 1), 7.55 (d, 2), 7.85 (s, 1), 8.17 (d, 2), 9.03 (d, 2), 9.41 (br t, 1)
ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-
10 trifluoromethoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.17 (t,
3), 1.85 (m, 1), 2.02 (m, 3), 2.28 (m, 2), 2.60 (m, 2), 2.68 (m, 2), 3.40 (m, 6), 3.63
(m, 2), 4.02 (q, 2), 4.98 (m, 1), 7.08 (s, 1), 7.85 (dd, 1), 8.10 (s, 1), 8.22 (d, 1),
8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
15 methyl-4-(1-tetrazol-5-ylethoxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.80-1.88
(m, 4), 2.00 (m, 1), 2.30 (m, 2), 2.55 (s, 3), 3.35-3.65 (m, 8), 4.02 (q, 2), 5.01 (m,
1), 6.42 (q, 1), 7.55 (d, 1), 7.60 (d, 1), 7.88 (s, 1), 8.16 (d, 1), 8.88 (m, 1) ppm;
and NMR (DMSO-d₆) 1.18 (t, 3), 1.78-1.82 (m, 4), 2.00 (m, 1), 2.30 (m, 2), 2.55
(s, 3), 3.35-3.62 (m, 8), 4.05 (q, 2), 5.04 (m, 1), 6.44 (m, 1), 7.55 (d, 1), 7.60 (s,
20 1), 7.88 (s, 1), 8.16 (d, 1), 8.88 (d, 1), 12.16 (s, 1) ppm; and NMR (DMSO-d₆)
1.18 (t, 3), 1.78-1.90 (m, 4), 2.00 (m, 1), 2.30 (m, 2), 2.55 (s, 3), 3.35-3.65 (m, 8),
4.02 (q, 2), 5.00 (m, 1), 6.45 (q, 1), 7.55 (d, 1), 7.62 (s, 1), 7.88 (s, 1), 8.16 (d, 1),
8.88 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-acetyl-
25 4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.85 (m, 2),
2.00 (m, 3), 2.30 (m, 2), 2.60 (m, 2), 2.75 (s, 3), 2.80 (m, 2), 3.40 (m, 6), 3.65 (m,
2), 4.05 (m, 2), 5.05 (m, 1), 7.15 (s, 1), 8.10 (d, 1), 8.35 (d, 1), 8.70 (s, 1), 8.92
(d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-
30 ethoxycarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.25 (t, 3),
1.35 (t, 3), 2.0 (m, 2), 2.20 (m, 2), 2.45 (m, 2), 2.60 (m, 2), 2.90 (m, 2), 3.40-3.80
(m, 8), 4.10 (q, 2), 4.40 (q, 2), 5.20 (m, 1), 7.20 (s, 1), 7.60 (d, 1), 7.85 (m, 1),
8.20 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-
35 methyl-4-(tetrazol-5-yl)methoxyquinoline; NMR (DMSO-d₆) 1.13 (t, 3), 1.81 (m,

1), 1.98 (m, 1), 2.37 (m, 2), 2.50 (s, 3), 2.56 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.00 (q, 2), 5.00 (m, 1), 5.85 (s, 1), 7.50 (dd, 1), 7.67 (s, 1), 7.85 (s, 1), 8.14 (d, 1), 8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-ethyl-5 4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.16 (t, 3), 1.27 (t, 2), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.56 (m, 2), 2.84 (m, 4), 3.40 (m, 6), 3.64 (m, 2), 4.03 (q, 2), 4.98 (m, 1), 7.02 (s, 1), 7.72 (dd, 1), 8.00 (d, 1), 8.02 (d, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-acetyl-10 4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-15 carboxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.30 (t, 3), 2.20 (m, 4), 2.50 (m, 2), 2.70 (m, 2), 2.95 (m, 2), 3.40-3.80 (m, 8), 4.15 (q, 2), 5.20 (m, 1), 7.20 (s, 1), 8.20 (d, 1), 8.40 (d, 1), 8.75 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-20 aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.19 (t, 3), 1.85 (m, 2), 2.00 (m, 3), 2.30 (m, 2), 2.58 (m, 2), 2.80 (m, 2), 3.40 (m, 6), 3.60 (m, 2), 4.05 (m, 2), 5.00 (m, 1), 7.05 (s, 1), 7.60 (br s, 1), 8.15 (d, 1), 8.30 (d, 1), 8.38 (br s, 1), 8.80 (s, 1), 8.94 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-25 methyl-4-(1-methyl-1-carboxyethoxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.61 (s, 3), 1.63 (s, 3), 1.75 (m, 1), 2.00 (m, 1), 2.5 (s, 4), 3.15-3.63 (m, 8), 4.02 (q, 2), 5.05 (m, 1), 7.30 (s, 1), 7.50 (d, 2), 7.85 (s, 1), 8.10 (d, 1), 8.95 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-30 dimethoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.30 (t, 3), 2.20 (m, 4), 2.45 (m, 2), 2.65 (m, 2), 2.90 (m, 2), 3.40-3.80 (m, 8), 4.0 (s, 6), 4.10 (q, 2), 5.20 (m, 1), 7.05 (s, 1), 7.45 (s, 1), 7.55 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-35 6-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.04 (t, 3), 1.15 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.55 (s, 3), 2.60 (m, 2), 2.67 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.02 (q, 2), 4.15 (q, 2), 4.98 (m, 1), 6.95 (s, 1), 8.15 (s, 1), 8.22 (s, 1), 8.83 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-35 6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.85 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.55 (s, 3), 2.57 (m, 2), 2.67 (m, 2), 3.40 (m, 6),

3.62 (m, 2), 4.0 (q, 2), 4.98 (m, 1), 7.00 (s, 1), 8.12 (s, 1), 8.20 (s, 1), 8.83 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.52 (s, 3), 2.57 (m, 2), 2.67 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.02 (q, 2), 4.98 (m, 1), 7.00 (s, 1), 8.09 (s, 1), 8.21 (s, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.20 (t, 3), 1.30 (t, 3), 2.20 (m, 4), 2.45 (m, 2), 2.70 (m, 2), 3.0 (m, 2), 3.40-3.80 (m, 8), 4.0 (s, 6), 4.15 (q, 2), 4.25 (q, 2), 5.20 (m, 1), 7.05 (s, 1), 7.50 (s, 1), 7.60 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(carboxy)ethoxy)quinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.65 (d, 3), 1.83 (m, 1), 2.04 (m, 1), 2.32 (m, 2), 2.56 (s, 3), 3.35-3.70 (m, 8), 4.05 (q, 2), 5.04 (m, 1), 5.28 (m, 1), 7.37 (s, 1), 7.55 (d, 1), 7.88 (s, 1), 8.13 (d, 1), 8.90 (d, 1) ppm; and NMR (DMSO-d₆) 1.18 (t, 3), 1.65 (d, 3), 1.84 (m, 1), 2.00 (m, 1), 2.30 (m, 2), 2.55 (s, 3), 3.35-3.65 (m, 8), 4.02 (q, 2), 5.01 (m, 1), 6.28 (q, 1), 7.38 (s, 1), 7.50 (d, 1), 7.87 (s, 1), 8.12 (d, 1), 8.90 (m, 1) ppm; and NMR (DMSO-d₆) 1.18 (t, 3), 1.65 (d, 3), 1.84 (m, 1), 2.00 (m, 1), 2.30 (m, 2), 2.55 (s, 3), 3.35-3.65 (m, 8), 4.02 (q, 2), 5.01 (m, 1), 6.35 (q, 1), 7.36 (s, 1), 7.50 (d, 1), 7.86 (s, 1), 8.12 (d, 1), 8.90 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.02 (t, 3), 1.18 (t, 3), 1.81 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.48 (s, 3), 2.60 (m, 2), 2.79 (m, 2), 3.35-3.65 (m, 8), 4.02 (q, 2), 4.15 (q, 2), 5.00 (m, 1), 6.85 (s, 1), 7.85 (d, 1), 8.05 (d, 1), 8.82 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.81 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.48 (s, 3), 2.58 (m, 2), 2.79 (m, 2), 3.35-3.62 (m, 8), 4.05 (q, 2), 5.00 (m, 1), 7.03 (s, 1), 7.84 (d, 1), 8.05 (d, 1), 8.84 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.87 (m, 1), 2.00 (m, 4), 2.30 (m, 2), 2.58 (m, 2), 2.80 (m, 2), 3.40 (m, 6), 3.60 (m, 2), 4.05

(m, 2), 5.00 (m, 1), 7.08 (s, 1), 7.78 (m, 1), 7.92 (d, 1), 8.38 (m, 1), 8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinolline; NMR (DMSO-d₆) 1.02 (t, 3), 1.15 (t, 3), 1.85 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.54 (s, 3), 2.53 (m, 2), 2.67 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.02 (q, 2), 4.15 (q, 2), 4.98 (m, 1), 6.97 (s, 1), 8.10 (s, 1), 8.23 (s, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-fluoro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.04 (t, 3), 1.18 (t, 3), 1.83 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.62 (m, 2), 2.78 (m, 2), 3.35-3.65 (m, 8), 4.03 (q, 2), 4.16 (q, 2), 5.00 (m, 1), 7.00 (s, 1), 8.17 (d, 1), 8.37 (d, 1), 8.82 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.58 (m, 2), 2.79 (m, 2), 3.35-3.65 (m, 8), 4.05 (q, 2), 5.00 (m, 1), 7.05 (s, 1), 8.15 (d, 1), 8.35 (d, 1), 8.84 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-bromo-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.19 (t, 3), 1.85 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.55 (m, 2), 2.80 (m, 2), 3.38 (m, 6), 3.62 (m, 2), 4.05 (m, 2), 4.95 (m, 1), 7.05 (s, 1), 7.82 (d, 1), 8.20 (d, 1), 8.30 (s, 1), 8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(tetrazol-5-yl)ethyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.19 (t, 3), 2.00 (m, 2), 2.50 (s, 3), 2.50-2.60 (m, 2), 2.80 (m, 2), 3.30-3.60 (m, 8), 4.00 (q, 2), 5.40 (m, 1), 6.95 (s, 1), 7.0 (d, 2), 7.88 (s, 1), 8.15 (d, 1), 9.25 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.02 (t, 3), 1.18 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.58 (m, 2), 2.79 (m, 2), 3.35-3.65 (m, 8), 3.93 (s, 3), 4.05 (q, 2), 4.13 (q, 2), 5.00 (m, 1), 6.88 (s, 1), 7.30 (d, 1), 7.43 (s, 1), 8.16 (d, 1), 8.84 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-hydroxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.02 (t, 3), 1.15 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.55 (m, 2), 2.77 (m, 2), 3.30-3.65 (m, 8), 4.02 (q, 2), 4.15 (q, 2), 4.96 (m, 1), 6.80 (s, 1), 7.20 (d, 1), 7.27 (s, 1), 8.10 (d, 1), 8.84 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.55 (m, 2), 2.76 (m, 2), 3.35-3.65 (m, 8), 4.02 (q, 2), 4.96 (m, 1), 6.86 (s, 1), 7.20 (d, 1), 7.28 (s, 1), 8.09 (d, 1), 8.85 (d, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.05 (t, 3), 1.15 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.46 (s, 6), 2.57 (m, 2), 2.79 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.05 (q, 2), 4.12 (q, 2), 4.98 (m, 1), 6.92 (s, 1), 7.92 (s, 1), 8.02 (s, 1), 8.92 (d, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.81 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.45 (s, 6), 2.55 (m, 2), 2.75 (m, 2), 3.40 (m, 6), 3.62 (m, 2), 4.05 (q, 2), 5.00 (m, 1), 6.98 (s, 1), 7.98 (s, 1), 8.14 (s, 1), 8.84 (d, 1) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.08 (t, 3), 1.17 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.62 (m, 2), 2.70 (m, 2), 3.40 (m, 6), 3.60 (m, 2), 4.02 (q, 2), 4.04 (s, 3), 4.15 (q, 2), 4.98 (m, 1), 6.95 (s, 1), 7.58 (s, 1), 8.18 (s, 1), 8.78 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methoxy-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.17 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.28 (m, 2), 2.58 (m, 2), 2.76 (m, 2), 3.38 (m, 6), 3.62 (m, 2), 4.02 (q, 2), 4.04 (s, 3), 4.98 (m, 1), 7.02 (s, 1), 7.60 (s, 1), 8.18 (s, 1), 8.80 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.26 (t, 3), 2.0 (s, 3), 2.1-2.2(m, 4), 2.4 (m, 2), 2.6(m, 2), 2.9 (m, 2), 3.5-3.8 (m, 8), 4.10 (q, 2), 5.18(m, 1), 7.2 (s, 1), 8.25 (s, 1), 8.42 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)propoxy)quinoline; NMR (DMSO-d₆) 1.05 (t, 3), 1.15 (m, 6), 1.82 (m, 1), 2.04 (m, 3), 2.28 (m, 2), 2.53 (s, 3), 3.38 (m, 6), 3.64 (m, 2), 4.05 (q, 2), 4.18 (q, 2), 5.00 (m, 1), 5.28 (m, 1), 7.36 (s, 1), 7.52 (dd, 1), 7.88 (s, 1), 8.15 (d, 1), 8.90 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxypropoxy)quinoline; NMR (DMSO-d₆) 1.15 (t, 3), 1.25 (t, 3),

35

1.82 (m, 1), 2.05 (m, 3), 2.30 (m, 2), 2.53 (s, 3), 3.42 (m, 6), 3.64 (m, 2), 4.05 (q, 2), 5.02 (m, 1), 5.12 (m, 1), 7.35 (s, 1), 7.52 (dd, 1), 7.88 (s, 1), 8.14 (d, 1), 8.90 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)-2-methylpropoxy)quinoline; NMR (DMSO-d₆) 1.05 (m, 9), 1.82 (m, 1), 1.85 (m, 1), 2.05 (m, 1), 2.25 (m, 2), 2.35 (m, 1), 2.52 (s, 3), 3.42 (m, 6), 3.64 (m, 2), 4.04 (q, 2), 4.15 (q, 2), 5.02 (m, 1), 5.13 (m, 1), 7.33 (s, 1), 7.55 (d, 1), 7.88 (s, 1), 8.15 (d, 1), 8.88 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxy-2-methylpropoxy)quinoline; NMR (DMSO-d₆) 1.10 (t, 6), 1.15 (t, 3), 1.82 (m, 1), 1.85 (m, 1), 2.05 (m, 1), 2.30 (m, 2), 2.35 (m, 1), 2.53 (s, 3), 3.40 (m, 6), 3.64 (m, 2), 4.03 (q, 2), 5.00 (m, 2), 7.35 (s, 1), 7.52 (d, 1), 7.88 (s, 1), 8.1 (d, 1), 8.92 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-difluoro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.26 (t, 3), 2.0 (s, 3), 2.1-2.25 (m, 4), 2.45 (m, 2), 2.65 (m, 2), 2.95 (m, 2), 3.45-3.80 (m, 8), 4.15 (q, 2), 5.2 (m, 1), 7.2 (s, 1), 7.96 (dd, 1), 8.10 (dd, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-fluoro-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.25 (t, 3), 2.0 (m, 1), 2.05-2.20 (m, 4), 2.45 (m, 2), 2.5 (s, 3), 2.65 (m, 2), 2.95 (m, 2), 3.4-3.8 (m, 8), 4.15 (q, 2), 5.1 (m, 1), 7.1 (s, 1), 7.65 (d, 1), 8.18 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-fluoro-6-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.15 (t, 3), 1.3 (t, 3), 2.0 (m, 1), 2.05-2.25 (m, 3), 2.45 (m, 2), 2.55 (s, 3), 2.65 (m, 2), 2.90 (m, 2), 3.4-3.8 (m, 8), 4.15 (q, 2), 4.21 (q, 2), 5.2 (m, 1), 7.06 (s, 1), 7.7 (d, 1), 8.2 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.18 (t, 3), 1.25 (m, 6), 1.90-2.25 (m, 4), 2.93-2.65 (m, 7), 2.90-3.00 (m, 2), 3.40-3.80 (m, 8), 4.10-4.23 (m, 6), 5.21 (m, 1), 7.03 (s, 3), 7.40 (d, 1), 7.85 (s, 1), 8.18 (d, 1), 8.93 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.16 (t, 3), 1.25 (t, 3), 2.0 (m, 1), 2.18 (m, 3), 2.46 (m, 2), 2.70 (m, 2), 2.95 (m, 2), 3.4-3.8 (m, 8), 4.15 (q, 2), 4.25 (q, 2), 5.2 (m, 1), 7.1 (s, 1), 8.3 (s, 1), 8.4 (s, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.18 (t, 3), 1.25 (m, 6), 1.94 (m, 1), 2.03-2.24 (m, 3), 2.41-2.52 (m, 5), 2.62 (m, 2), 2.93 (m, 2), 3.41-3.78 (m, 8), 4.11-4.26 (m, 6), 5.21 (m, 1), 7.07 (s, 1), 7.82 (d, 1), 7.93 (d, 1), 8.86 (d, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.09 (t, 3), 1.17 (t, 3), 1.84 (m, 1), 2.94-2.07 (m, 3), 2.36 (m, 2), 2.48 (s, 3), 2.56 (m, 2), 2.77 (m, 2), 3.28-3.64 (m, 8), 3.98 (q, 2), 4.02 (q, 2), 4.98 (m, 1), 7.01 (s, 1), 7.84 (d, 1), 8.05 (d, 1), 8.83 (d, 1) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.06-1.18 (m, 9), 1.84 (m, 1), 2.94-2.07 (m, 3), 2.36 (m, 2), 2.48 (s, 3), 2.57 (m, 2), 2.77 (m, 2), 3.28-3.64 (m, 8), 4.02 (q, 2), 4.83 (m, 1), 4.98 (m, 1), 7.01 (s, 1), 7.84 (d, 1), 8.05 (d, 1), 8.82 (d, 1) ppm;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.10 (t, 3), 1.18 (t, 3), 1.85 (m, 1), 2.00 (m, 3), 2.35 (m, 2), 2.41-2.60 (m, 2), 2.78 (m, 2), 3.30-3.62 (m, 8), 4.00 (m, 4), 5.00 (m, 1), 6.98 (s, 3), 7.50 (d, 1), 7.83 (s, 1), 8.15 (d, 1), 8.82 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.05-1.20 (m, 9), 1.79-1.93 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.51 (m, 4), 2.78 (m, 2), 3.23-3.61 (m, 10), 4.02 (q, 2), 4.82 (m, 1), 4.98 (m, 1), 6.98 (s, 1), 7.53 (d, 1), 7.85 (d, 1), 8.82 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.12 (t, 3), 1.16 (t, 3), 1.18 (t, 3), 1.86 (m, 1), 1.96 (m, 2), 2.32 (m, 2), 2.56 (s, 3), 2.60 (m, 2), 2.80 (m, 2), 3.40 (m, 10), 3.98 (q, 2), 4.00 (q, 2), 4.16 (q, 2), 5.00 (m, 1), 6.96 (s, 1), 8.12 (s, 1), 8.22 (s, 1), 8.82 (d, 1) ppm;

35

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.12 (t, 3), 1.16 (t, 3), 1.86 (m, 1), 1.96 (m, 2), 2.02 (m, 3), 2.36 (m, 2), 2.56 (s, 3), 2.58 (m, 2), 3.40 (m, 10), 4.02 (q, 2), 4.08 (m, 2), 5.00 (m, 1), 7.00 (s, 1), 8.18 (s, 1), 5 8.22 (s, 1), 8.84 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.12 (d, 6), 1.20 (m, 5), 1.96 (m, 1), 2.56 (s, 3), 2.64 (m, 2), 2.76 (m, 2), 3.40 (m, 9), 2.75 (m, 2), 3.64 (m, 2), 10 4.05 (q, 2), 4.82 (m, 1), 5.00 (m, 1), 7.00 (s, 1), 8.18 (s, 1), 8.24 (s, 1), 8.84 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.02 (t, 3), 1.09 (t, 3), 1.18 (t, 3), 1.85 (m, 1), 2.02 (m, 3), 2.35 (m, 2), 2.42 (br s, 6), 2.58 (m, 2), 2.80 (m, 2), 3.23-3.62 (m, 8), 3.95-4.05 (m, 4), 4.15 (q, 2), 5.00 20 (m, 1), 6.92 (s, 1), 7.83 (s, 1), 7.99 (s, 1), 8.80 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.08-1.20 (m, 6), 1.81 (m, 1), 2.00 (m, 2), 2.25-2.40 (m, 12), 2.78 (m, 2), 3.25-3.80 (m, 8), 4.00 (m, 4), 5.00 (m, 1), 8.97 (s, 1), 7.82 (s, 1), 7.98 (s, 1), 8.82 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.03-1.20 (m, 9), 1.81 (m, 1), 2.00 (m, 2), 2.30-2.40 (m, 12), 2.78 (m, 2), 3.20-3.40 (m, 8), 4.02 (m, 2), 4.83 (m, 1), 5.00 (m, 1), 8.97 (s, 1), 7.82 (s, 1), 7.98 (s, 1), 8.80 (d, 1) ppm;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.20 (t, 3),

1.30 (t, 3), 2.0 (m, 1), 2.20 (m, 3), 2.45 (m, 2), 2.70 (m, 2), 2.95 (m, 2), 3.40-3.80 (m, 8), 4.10 (m, 4), 5.20 (m, 1), 7.20 (s, 1), 8.30 (s, 1), 8.40 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.25 (m, 9), 2.0 (m, 1), 2.20 (m, 3), 2.40 (m, 2), 2.65 (m, 2), 2.95 (m, 2), 3.40-3.80 (m, 8), 4.10 (q, 2), 4.95 (m, 1), 5.15 (m, 1), 7.20 (s, 1), 8.25 (s, 1), 8.40 (s, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CDCl₃) 1.20 (t, 3), 1.30 (t, 6), 1.95 (m, 1), 2.05-2.25 (m, 3), 2.45 (m, 2), 2.65 (m, 2), 2.95 (m, 2), 3.40-3.80 (m, 8), 4.20 (q, 4), 4.25 (q, 2), 5.20 (m, 1), 7.10 (s, 1), 8.25 (s, 1), 8.40 (s, 1), 8.85 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline; NMR (DMSO-d₆) 1.08 (t, 3), 1.16 (t, 3), 1.74 (s, 6), 1.82 (m, 1), 2.00 (m, 1), 2.28 (m, 2), 2.52 (s, 3), 3.40 (m, 2), 3.62 (m, 2), 4.04 (q, 2), 4.14 (q, 2), 5.02 (m, 1), 7.18 (s, 1), 7.50 (dd, 1), 7.86 (s, 1), 8.08 (d, 1), 8.86 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline; NMR (DMSO-d₆) 1.98 (t, 3), 1.22 (t, 3), 1.80 (br s, 6), 1.98 (m, 1), 2.15 (m, 1), 2.42 (m, 2), 2.61 (s, 3), 3.38-3.70 (m, 8), 4.08 (m, 4), 5.10 (m, 1), 7.18 (s, 1), 7.59 (d, 1), 7.97 (s, 1), 8.19 (d, 1), 8.99 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methylthio-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.20 (t, 3), 1.25 (t, 3), 1.95 (m, 1), 2.20 (m, 3), 2.40 (m, 2), 2.65 (s, 3), 2.70 (m, 2), 2.95 (m, 2), 3.40-3.80 (m, 8), 4.10 (q, 2), 4.20 (q, 2), 5.20 (m, 1), 7.10 (s, 1), 7.70 (m, 1), 8.0 (m, 2) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methylthio-4-(1-carboxycyclobut-1-oxy)quinoline; NMR (CD₃OD) 1.30 (t, 3), 2.0 (m, 1), 2.20 (m, 3), 2.40 (m, 2), 2.60 (s, 3), 2.70 (m, 2), 2.95 (m, 2), 3.40-3.80 (m, 8), 4.10 (q, 2), 5.20 (m, 1), 7.20 (s, 1), 7.70 (d, 1), 8.0 (m, 2) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-cyclohexyl-1-carboxymethoxy)quinoline; NMR (CD₃OD) 1.25 (t, 3), 1.30-1.40 (m, 4), 1.55 (m, 1), 1.75 (m, 1), 1.85-2.00 (m, 5), 2.20 (m, 2), 2.50 (m, 2), 2.60 (s, 3), 3.40-3.80 (m, 8), 4.15 (q, 2), 4.95 (m, 1), 5.20 (m, 1), 7.45 (s, 1),

7.55 (d, 1), 7.90 (s, 1), 8.25 (d, 1) ppm and NMR (CD₃OD) 1.25 (t, 3), 1.30-1.40 (m, 4), 1.55 (m, 1), 1.75 (m, 1), 1.90-2.00 (m, 5), 2.20 (m, 2), 2.45 (m, 2), 2.60 (s, 3), 3.40-3.80 (m, 8), 4.15 (q, 2), 4.95 (m, 1), 5.20 (m, 1), 7.45 (s, 1), 7.55 (m, 1), 7.90 (s, 1), 8.20 (m, 1) ppm;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-cyclohexyl-1-(methoxycarbonyl)methoxy)quinoline; NMR (CD₃OD) 1.20 (t, 3), 1.25 (m, 4), 1.50 (m, 1), 1.70 (m, 1), 1.80 (m, 4), 1.90 (m, 1), 2.10 (m, 2), 2.40 (m, 2), 2.55 (s, 3), 3.40-3.80 (m, 8), 3.70 (s, 3), 4.05 (q, 2), 5.05 (m, 1), 5.15 (m, 1), 7.45 (s, 1), 7.55 (d, 1), 7.85 (s, 1), 8.20 (d, 1) ppm and NMR (CD₃OD) 1.22 (t, 3), 1.25 (m, 4), 1.45 (m, 1), 1.70 (m, 1), 1.90 (m, 4), 2.0 (m, 1), 2.20 (m, 2), 2.45 (m, 2), 2.60 (s, 3), 3.40-3.80 (m, 8), 3.78 (s, 3), 4.10 (q, 2), 5.10 (m, 1), 5.25 (m, 1), 7.50 (s, 1), 7.60 (d, 1), 7.90 (s, 1), 8.25 (d, 1) ppm;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(methoxycarbonyl)cyclobut-1-oxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.82 (m, 1), 2.00 (m, 3), 2.30 (m, 2), 2.56 (s, 3), 2.59 (m, 3), 2.80 (m, 2), 3.30-3.50 (m, 6), 3.60 (m, 2), 3.64 (s, 3), 4.04 (q, 2), 4.98 (m, 1), 6.92 (s, 1), 7.55 (d, 1), 7.90 (s, 1), 8.17 (d, 1), 8.87 (d, 1) ppm;

15 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(1-methylethoxycarbonyl)cyclobut-1-oxy)quinoline;

20 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.26 (t, 3), 1.74 (s, 6), 1.82 (m, 1), 2.00 (m, 1), 2.30 (m, 2), 2.54 (s, 3), 3.40 (m, 2), 3.62 (m, 2), 4.04 (q, 2), 4.16 (q, 2), 5.52 (m, 1), 7.10 (s, 1), 8.1 (s, 1), 8.18 (s, 1), 8.82 (d, 1) ppm;

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.72 (2s, 6), 1.84 (m, 1), 2.00 (m, 1), 2.30 (m, 2), 2.54 (s, 3), 3.36 (m, 1), 3.40 (m, 1), 3.48 (m, 1), 3.64 (m, 1), 4.06 (q, 2), 5.02 (m, 1), 7.30 (s, 1), 8.08 (s, 1), 8.16 (s, 1), 8.86 (d, 1) ppm;

30 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonylquinoline; NMR (DMSO-d₆) 1.17 (t, 3), 3.34-3.57 (m, 8), 4.06 (q, 3), 4.28 (d, 2), 7.74 (t, 1), 7.90 (t, 1), 8.06-18 (m, 3), 8.60 (d, 1), 8.98 (t, 1) ppm;

35 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-hydroxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 3.30-3.48 (m, 8), 4.04 (q, 2), 4.20 (d, 2), 6.75 (m, 1), 7.40 (m, 1), 7.70 (t, 1), 7.92 (d, 1), 8.06 (d, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(*n*-propylsulfonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
NMR (DMSO-d₆) 0.94 (t, 3), 1.67 (m, 2), 3.02 (t, 2), 3.10-3.35 (m, 4), 3.57 (m, 4),
4.13 (s, 3), 4.26 (d, 2), 7.60 (s, 1), 7.66 (t, 1), 7.84 (t, 1), 8.04 (d, 1), 8.19 (d, 1),
5 8.96 (t, 1) ppm;

2-[(4-(2,5-dibromophenyl)sulfonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 3.20-3.30 (m, 4), 3.58 (m, 4), 4.10 (s, 3),
4.25 (d, 2), 7.57 (s, 1), 7.64 (t, 1), 7.80 (m, 3), 8.02 (d, 1), 8.06 (s, 1), 8.18 (d, 1),
8.94 (t, 1) ppm;

10 2-[(4-(2,6-difluorophenyl)sulfonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 3.10-3.20 (m, 4), 3.60 (m, 4), 4.10 (s, 3),
4.23 (d, 2), 7.34 (t, 1), 7.58 (s, 1), 7.64 (t, 1), 7.75-7.82 (m, 2), 8.02 (d, 1), 8.18
(d, 1), 8.88 (t, 1) ppm;

15 2-[(4-(3-bromophenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;

2-[(4-(4-ethylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 2.60 (m, 2), 3.30-3.65 (m, 8), 4.12
(s, 3), 4.24 (d, 2), 7.26 (d, 2), 7.35 (d, 2), 7.60 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04
(d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

20 2-[(4-(4-*n*-propylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (CDCl₃) 0.94 (t, 3), 1.65 (m, 2), 2.62 (t, 2), 3.50-3.80 (m,
8), 4.15 (s, 3), 4.38 (d, 2), 7.24 (d, 2), 7.36 (d, 2), 7.56 (t, 1), 7.65 (s, 1), 7.75 (t,
1), 8.08 (d, 1), 8.23 (d, 1), 9.08 (t, 1) ppm;

25 2-[(4-(4-*n*-butylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline;

2-[(4-(phenoxyethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 3.40-3.60 (m, 8), 4.13 (s, 3), 4.26 (d, 2), 4.84
(s, 2), 6.93 (m, 3), 7.26 (m, 2), 7.60 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.06 (d, 1), 8.18
(d, 1), 8.94 (t, 1) ppm;

30 2-[(4-(2,2-dimethylpropyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (CDCl₃) 1.07 (s, 9), 2.32 (s, 2), 3.53-3.77 (m, 8), 4.15 (s,
3), 4.38 (d, 2), 7.57 (t, 1), 7.65 (s, 1), 7.74 (t, 1), 8.09 (d, 1), 8.13 (d, 1), 9.09 (t, 1)
ppm;

35 2-[(4-(2-ethoxycarbonylethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 1.15 (t, 3), 2.51 (m, 2), 2.60 (m, 2), 3.44-3.56

(m, 8), 4.01 (q, 2), 4.11 (s, 3), 4.27 (d, 2), 7.57 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

2-[(4-(*n*-propyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.86 (t, 3), 1.51 (m, 2), 2.30 (m, 2), 3.40-3.58 (m, 8), 4.14 (s, 3), 4.27 (d, 2), 7.60 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.96 (t, 1) ppm;

2-[(4-(*n*-pentyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.82 (t, 3), 1.23 (m, 6), 1.44 (m, 2), 2.30 (m, 2), 3.40-3.56 (m, 8), 4.12 (s, 3), 4.25 (d, 2), 7.60 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

2-[(4-(furan-2-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 3.63 (m, 2), 3.83 (m, 6), 4.14 (s, 3), 4.39 (d, 1), 6.53 (m, 1), 7.08 (d, 1), 7.53 (d, 1), 7.57 (t, 1), 7.65 (s, 1), 7.74 (t, 1), 8.09 (d, 1), 8.13 (d, 1), 9.10 (t, 1) ppm;

15 2-[(4-(thien-2-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 3.63 (m, 2), 3.83 (m, 6), 4.14 (s, 3), 4.38 (d, 1), 7.08 (m, 1), 7.35 (d, 1), 7.52 (d, 1), 7.58 (t, 1), 7.66 (s, 1), 7.74 (t, 1), 8.09 (d, 1), 8.13 (d, 1), 9.08 (t, 1) ppm;

2-[(4-(2-phenylcyclopropyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

20 2-[(4-(2-bromo-5-methoxyphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 3.10-3.20 (m, 2), 3.48-3.72 (m, 6), 3.75 (s, 3), 4.10 (s, 3), 4.25 (d, 2), 6.85 (m, 2), 7.57-7.66 (m, 3), 7.83 (m, 1), 8.02 (d, 1), 8.18 (d, 1), 8.96 (t, 1) ppm;

25 2-[(4-(*n*-butyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.82 (t, 3), 1.23 (m, 4), 1.44 (m, 2), 2.30 (m, 2), 3.40-3.60 (m, 8), 4.12 (s, 3), 4.25 (d, 2), 7.60 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

30 2-[(4-(3-trifluoromethoxyphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 3.52-3.94 (m, 8), 4.15 (s, 3), 4.39 (d, 2), 7.25-7.41 (m, 3), 7.48 (d, 1), 7.58 (t, 1), 7.64 (s, 1), 7.75 (t, 1), 8.08 (d, 1), 8.13 (d, 1), 9.08 (t, 1) ppm;

2-[(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.23 (s, 9), 3.24-3.33 (m, 4), 3.44 (m, 4),

4.12 (s, 3), 4.14 (d, 2), 5.88 (s, 1), 7.57 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.03 (d, 1),
8.17 (d, 1), 8.92 (t, 1) ppm;

2-[(4-((1-methylethyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (CDCl₃) 1.17 (d, 6), 3.36-3.78 (m, 8), 3.98 (m, 1), 4.12
5 (s, 3), 4.36 (d, 3), 7.58 (t, 1), 7.66 (s, 1), 7.75 (t, 1) ppm;

2-[(4-((n-propyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 0.80 (t, 3), 1.39 (m, 2), 2.95 (m, 2), 3.30-3.46
(m, 8), 4.13 (s, 3), 4.25 (d, 2), 6.57 (t, 1), 7.60 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04
(d, 1), 8.18 (d, 1), 8.96 (t, 1) ppm;

10 2-[(4-((n-butyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (CDCl₃) 0.92 (t, 3), 1.37 (m, 2), 1.52 (m, 2), 3.26 (m, 2),
3.40 (m, 2), 3.56 (m, 4), 3.64 (m, 2), 4.14 (s, 3), 4.26 (d, 2), 7.56 (t, 1), 7.66 (s,
1), 7.73 (t, 1), 8.10 (d, 1), 8.24 (d, 1), 9.10 (t, 1) ppm;

15 2-[(4-((n-hexyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 0.82 (t, 3), 1.23 (m, 6), 1.38 (m, 2), 2.97 (m,
2), 3.30-3.48 (m, 8), 4.12 (s, 3), 4.25 (d, 2), 6.54 (t, 1), 7.60 (s, 1), 7.64 (t, 1),
7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

20 2-[(4-((n-pentyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 0.82 (t, 3), 1.23 (m, 4), 1.38 (m, 2), 2.97 (m,
2), 3.28-3.48 (m, 8), 4.12 (s, 3), 4.26 (d, 2), 6.53 (t, 1), 7.60 (s, 1), 7.64 (t, 1),
7.83 (t, 1), 8.04 (d, 1), 8.18 (d, 1), 8.94 (t, 1) ppm;

25 2-[(4-((ethoxycarbonyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (DMSO-d₆) 1.18 (t, 3), 3.30-3.48 (m, 8), 4.06 (q, 2), 4.12
(s, 3), 4.25 (d, 2), 6.57 (t, 1), 7.59 (s, 1), 7.64 (t, 1), 7.83 (t, 1), 8.04 (d, 1), 8.18
(d, 1), 8.96 (t, 1) ppm;

30 2-[(4-(morpholin-4-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-
methoxyquinoline; NMR (CDCl₃) 3.35 (m, 8), 3.58 (m, 2), 3.71 (m, 6), 4.14 (s, 3),
4.37 (d, 2), 7.56 (t, 1), 7.65 (s, 1), 7.74 (t, 1), 8.07 (d, 1), 8.13 (d, 1), 9.09 (t, 1)
ppm;

2-[(4-(pyridin-2-yl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
NMR (CDCl₃) 3.57 (m, 2), 3.69 (m, 4), 3.84 (m, 2), 4.15 (s, 3), 4.41 (d, 2), 6.70
(m, 2), 7.56 (m, 2), 7.67 (s, 1), 7.76 (t, 1), 8.10 (d, 1), 8.22 (d, 1), 9.15 (t, 1) ppm;

2-[(4-(3-chlorophenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
NMR (CDCl₃) 3.25 (m, 4), 3.67 (m, 2), 3.86 (m, 2), 4.15 (s, 3), 4.19 (d, 2), 6.81

(d, 1), 6.91 (m, 2), 7.22 (t, 1), 7.57 (t, 1), 7.68 (s, 1), 7.74 (t, 1), 8.11 (d, 1), 8.23 (d, 1), 9.14 (t, 1) ppm;

2-[(3-methyl-4-(3-methylphenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 0.83-0.95 (dd, 3), 2.23 (s, 3), 2.85-3.18 (m, 2), 3.30-4.42 (m, 10), 6.57 (d, 1), 6.68 (m, 2), 7.08 (t, 1), 7.60 (s, 1), 7.65 (t, 1), 7.84 (t, 1), 8.07 (d, 1), 8.18 (d, 1), 8.96 (t, 1) ppm; and

5 2-[(4-(3-methylphenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 2.35 (s, 3), 3.22 (m, 4), 3.66 (m, 2), 3.87 (m, 2), 4.15 (s, 3), 4.38 (d, 2), 6.77 (m, 3), 7.18 (t, 1), 7.57 (t, 1), 7.69 (s, 1), 7.75 (t, 1), 8.11 (d, 1), 8.22 (d, 1), 9.17 (t, 1) ppm.

10

EXAMPLE 3

Compounds of formula (Ic)

A. To a solution of 2-((carboxy)methylcarbonylamino)naphthalene (1.2 g, 5.2 mmol) in CH₂Cl₂ (40 mL) was added triethylamine (2.2 mL, 15.6 mmol) and 1-hydroxybenzotriazole (HOBT) (0.84 g, 6.2 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (1.2 g, 6.2 mmol). After 5 minutes, 1-ethoxycarbonylpiperazine (0.84 mL, 5.3 mmol) was added and the reaction was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford an oil, which was dissolved in ethyl acetate, and washed with saturated NaHCO₃, 1M NaHSO₄ and brine. The organic layer was evaporated *in vacuo* to afford 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonylaminonaphthalene (1.2 g), as a solid that was used without further purification.

15

20

B. In a similar manner, the following compounds of formula (Ic) were prepared:

25

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-5-hydroxynaphthalene; NMR (DMSO-d₆) 1.17 (t, 3), 3.28-3.60 (m, 10), 4.04 (q, 2), 6.72 (d, 1), 7.22 (m, 2), 7.24 (d, 1), 8.02 (d, 1), 8.17 (s, 1) ppm;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-4-methoxynaphthalene; NMR (DMSO-d₆) 1.17 (t, 3), 3.30-3.60 (m, 10), 3.93 (s, 3), 4.03 (q, 2), 7.03 (s, 1), 7.34 (t, 1), 7.43 (t, 1), 7.73 (d, 1), 7.82 (s, 1), 8.01 (d, 1) ppm;

30

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]amino-5-(carboxymethoxy)naphthalene; NMR (DMSO-d₆) 1.17 (t, 3), 3.30-3.60 (m, 10), 4.03 (q, 2), 6.73 (d, 1), 7.36 (m, 2), 7.52 (d, 1), 8.13 (d, 1), 8.21 (s, 1) ppm;

35

2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-5-(3-
(ethoxycarbonyl)propoxy)naphthalene; NMR (CDCl₃) 1.25 (m, 6), 2.24 (m, 2),
2.61 (t, 2), 3.52-3.71 (m, 10), 4.17 (m, 6), 6.73 (d, 1), 7.36 (m, 2), 7.45 (d, 1), 8.21
(m, 2), 9.93 (s, 1) ppm;

5 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-5-(3-
carboxypropoxy)naphthalene; NMR (DMSO-d₆) 1.17 (t, 3), 2.04 (m, 2), 3.30-3.60
(m, 10), 4.03 (q, 2), 4.12 (t, 2), 6.79 (m, 1), 7.34 (m, 2), 7.47 (d, 1), 8.07 (d, 1), 8.21
(s, 1), 10.29 (s, 1) ppm and;

10 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-4-
(carboxymethoxy)naphthalene.

EXAMPLE 4

Compounds of formula (Id)

A. NaH 95% (15 mg, 0.6 mmol) was suspended in DMF (5 mL). A
15 solution of 2-[((4-(ethoxycarbonyl)piperazin-1-
yl)carbonylmethyl)carbonyl]aminonaphthalene (160 mg, 0.43 mmol) in DMF (1 mL)
was added dropwise. The reaction mixture was stirred at ambient temperature. After
5 minutes, a solution of methyl 3-(bromomethyl) benzoate (99 mg, 0.43 mmol) in DMF
(0.5 mL) was added. The reaction was quenched by water (100 mL) after 15 minutes,
20 then extracted with ethyl acetate (80 mL). The organic layer was evaporated *in vacuo*.
Purification by flash column on silica gel afforded a solid, 2-[(1-(4-
(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(methoxycarbonyl)phenyl)ethyl)carbonyl]-
aminonaphthalene (195 mg, 0.38 mmol).

B. In a similar manner, the following compounds of formula (Id) were
25 prepared:

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(tetrahydro-2-oxofuran-3-
yl)methyl)carbonyl]aminonaphthalene; NMR (CDCl₃) 1.24 (t, 3), 2.31-2.78 (m, 2),
3.41-3.90 (m, 10), 4.16 (q, 2), 4.28 (m, 1), 4.44 (m, 1), 7.42-7.56 (m, 3), 7.80 (m,
3), 8.23 (s, 1) ppm;

30 2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxy-4-
hydroxybutyl)carbonyl]aminonaphthalene; NMR (CDCl₃) 1.25 (t, 3), 2.02 (m, 2),
2.34 (m, 1), 3.37 (m, 2), 3.57 (m, 2), 3.71-3.90 (m, 4), 3.95-4.12 (m, 2), 4.17 (q, 2),
4.25 (d, 1), 7.36 (d, 1), 7.56 (m, 2), 7.80 (s, 1), 7.91 (m, 2), 7.97 (d, 1) ppm;

35 2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-
(ethoxycarbonyl)ethyl)carbonyl]aminonaphthalene; NMR (DMSO-d₆) 1.27 (m,

6), 2.87 (m, 2), 3.32-3.62 (m, 8), 4.03 (m, 4), 4.18 (m, 1), 7.38 (t, 1), 7.43 (t, 1),
7.56 (d, 1), 7.83 (m, 3), 8.22 (s, 1) ppm; and

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-(methoxycarbonyl)phenyl)ethyl)carbonyl]aminonaphthalene. NMR (DMSO-d₆)

5 1.16 (t, 3), 3.17-3.36 (m, 6), 3.42-3.58 (m, 4), 3.79 (s, 3), 3.98 (q, 2), 4.17 (m, 1),
7.42 (m, 5), 7.80 (m, 5), 8.17 (s, 1) ppm.

C. To a solution of 2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(methoxycarbonyl)phenyl)ethyl)carbonyl]aminonaphthalene (110 mg, 0.2 mmol) in THF (8 mL) was added a solution of LiOH (27 mg, 0.6 mmol) in water (6 mL). The reaction 10 mixture was stirred at ambient temperature. After 5 hours, the reaction mixture was acidified to pH 2-3 by 2N NaHSO₄, then extracted with ethyl acetate (3 x 10 mL). The organic layer was dried over Na₂SO₄ and evaporated *in vacuo* to afford 2-[(1-(4-ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-carboxyphenyl)ethyl)carbonyl]aminonaphthalene (90 mg, 0.18 mmol); NMR (DMSO-d₆)

15 1.25 (t, 3), 3.10-3.30 (m, 6), 3.40-3.60 (m, 4), 3.97 (q, 2), 4.14 (t, 1), 7.35-7.55 (m, 5),
7.70-7.87 (m, 5), 8.14 (s, 1), 10.12 (s, 1) ppm.

D. In a similar manner, the following compounds were made:

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl)carbonyl]aminonaphthalene; NMR (CDCl₃) 1.27 (t, 3), 3.01 (m, 1),
20 3.32 (m, 2), 3.54 (m, 2), 3.81 (m, 3), 4.06 (m, 2), 4.17 (q, 2), 4.25 (m, 1), 7.34 (d, 1),
7.57 (m, 2), 7.79 (s, 1), 7.88 (m, 2), 7.94 (d, 1) ppm;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-carboxyphenyl)ethyl)carbonyl]aminonaphthalene; NMR (DMSO-d₆) 1.14 (t, 3),
25 3.17-3.33 (m, 6), 3.42-3.56 (m, 4), 3.98 (q, 2), 4.16 (m, 1), 7.37-7.47 (m, 5), 7.80 (m, 5), 8.16 (s, 1) ppm; and

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl(methyl)carbonyl]amino-4-hydroxyquinoline; NMR (CDCl₃) 1.26 (t, 3), 3.43-3.63 (m, 8), 1.17 (q, 2), 5.93 (s, 1), 7.24-7.35 (m, 3), 7.57 (t, 1), 8.23 (d, 1) ppm.

30

EXAMPLE 5

Compounds of formulae (Q), (If) and (Ig)

A. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline (380 mg, 0.75 mmol) in CH₂Cl₂ cooled to -30°C was added triethylamine (0.12 mL, 1.12 mmol) and dimethylamino pyridine 35 (20 mg, 1.6 mmol) and the reaction mixture was stirred for 10 minutes.

Trifluoromethanesulfonic anhydride (0.19 mL, 1.12 mmol) was added and the reaction mixture was slowly warmed to ambient temperature. The solvent was evaporated under reduced pressure and residue was purified by flash chromatography (ethyl acetate:hexane-30:70) to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(trifluoromethylsulfonyl)oxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline as a yellow oil (320 mg).

5 B. In a similar manner, the following compounds were made:
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-(trifluoromethylsulfonyl)oxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

10 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(trifluoromethylsulfonyl)oxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;
and
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-(trifluoromethylsulfonyl)oxyphenyl)methyl]aminocarbonyl-4-methoxyquinoline.

15 C. Carbon monoxide was bubbled for 10 minutes to a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(trifluoromethylsulfonyl)oxyphenyl)-ethyl]aminocarbonyl-4-methoxyquinoline (320 mg, 0.50 mmol) in a mixture of DMSO(3 mL), MeOH (2 mL) and triethylamine (0.2 mL). Palladium acetate (60 mg) and 2',2'-bis(diphenylphosphino)-1,1-binaphthyl (200 mg) was added and reaction mixture was

20 heated to 70°C for 45 minutes. The reaction mixture was cooled to ambient temperature, filtered through celite and concentrated under reduced pressure. Flash column chromatography (methanol:CH₂Cl₂, 1:99) afforded 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-methoxycarbonylphenyl)ethyl]aminocarbonyl-4-methoxyquinoline as an orange oil, 220 mg (80%); NMR (CDCl₃) 2.40 (t, 3), 3.4 (m, 10), 3.88 (s, 3), 3.16 (q, 2), 3.18 (s, 3), 5.62 (m, 1), 7.26 (m, 2), 7.48 (m, 2), 7.68 (m, 1), 7.92 (d, 1), 8.04 (d, 1), 8.20 (d, 1), 9.00 (d, 1) ppm.

25 D. In a similar manner, the following compound was made:
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-(1,1-dimethylethoxy)carbonylphenyl)-ethyl]aminocarbonyl-4-methoxyquinoline;
NMR (CDCl₃) 1.23 (t, 3), 1.60 (s, 9), 3.02-3.60 (m, 10), 4.12 (m, 5), 5.40 (m, 1), 7.35 (d, 1), 7.58 (dd, 1), 7.82 (s, 1), 7.75 (dd, 1), 7.92 (d, 1), 8.05 (d, 1), 8.21 (d, 1), 8.99 (d, 1) ppm.

30 E. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-methoxycarbonylphenyl)ethyl]aminocarbonyl-4-methoxyquinoline (220 mg, 0.4 mmol)

in methanol was added a solution of LiOH (3 mL, 0.25 M) and the resulting reaction mixture was stirred at ambient temperature overnight. The product was purified by preparative HPLC and lyophilization to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline as an orange 5 solid, 140 mg (50%); NMR (DMSO-d₆), 1.08 (t, 3), 3.40 (m, 10), 4.00 (q, 2), 4.04 (s, 3), 5.28 (m, 1), 7.26 (t, 1), 7.34 (m, 2), 7.42 (s, 1), 7.82 (m, 2), 8.06 (d, 1), 8.14 (d, 1H), 8.88 (d, 1) ppm.

F. In a similar manner, the following compounds were made:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-10 carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 3.20-4.80 (m, 8), 4.15 (q, 2), 4.30 (s, 3), 5.45 (m, 1), 7.32 (d, 2), 7.81 (dd, 1), 7.83 (s, 1), 7.95 (d, 1), 8.01 (dd, 1), 8.38 (d, 2) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-15 carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4- carboxyphenyl)methyl]aminocarbonyl-4-methoxyquinoline.

EXAMPLE 6

Compounds of formula (Ih)

20 A. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline (200 mg, 0.39 mmol) in DMF (5 mL) was added CsCO₃ (260 mg, 0.8 mmol) and ethyl bromoacetate (120 mg, 0.7 mmol) and the reaction mixture was stirred at ambient temperature for 6 hours. The reaction mixture was partitioned in water and ethyl acetate and extracted with ethyl 25 acetate. Combined organic layers were washed with water, brine, dried over sodium sulfate and concentrated. The residue was purified by preparative HPLC to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(ethoxycarbonyl)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline as a white solid 140 mg (60%); NMR (DMSO-d₆), 1.18 (m, 6), 3.26 (m, 10), 4.00 (q, 2), 4.04 (s, 3), 4.84 (s, 2), 5.26 (m, 1), 6.82 (q, 1), 7.88 (d, 1), 7.48 (s, 1), 7.64 (t, 1), 7.82 (t, 1), 30 8.06 (d, 1), 8.16 (d, 1), 8.86 (d, 1) ppm.

B. In a similar manner, the following compound was prepared:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(ethoxycarbonyl)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline.

C. The compounds prepared in Paragraph A and B and similar compounds were hydrolyzed under standard hydrolysis conditions to yield the following compounds:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-(carboxymethoxy)phenyl)methyl]aminocarbonyl-4-methoxyquinoline;
5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(carboxy)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline; and
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(carboxy)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline.

10

EXAMPLE 7

Compounds of formula (Ij)

A. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-hydroxyethyl]aminocarbonyl-4-methoxyquinoline (50 mg, 0.116 mmol) in tetrahydrofuran (THF) (2 mL) at 0°C was added potassium hexamethyldisilazide (0.232 mL, 0.5 M in toluene, 0.122 mmol). After 5 minutes, ethyl bromoacetate (0.18 mg, 0.174 mmol) was added. The reaction mixture was stirred at 0°C for 1 hour and the reaction was quenched with water. The resultant solution was partitioned between water and ethyl acetate. The organic layer was concentrated *in vacuo* to afford an oil (50 mg). The crude product was purified by elution through silica gel with 4:1 ethyl acetate-hexanes, dissolved in methanol and treated with 200 µL 0.25M lithium hydroxide. The reaction mixture was acidified with 10% HCl and extracted into ethyl acetate and concentrated *in vacuo* to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(carboxy)methoxyethyl]aminocarbonyl-4-methoxyquinoline (20 mg, 35%);

15 NMR (CDCl₃) 1.25 (t, 6), 3.42-3.95 (m, 10), 4.11-4.23 (m, 9), 5.45 (m, 1), 7.55 (t, 1),
20 7.63 (s, 1), 7.76 (t, 1), 8.05 (d, 1), 8.20 (d, 1), 9.05 (d, 1) ppm.

25

B. In a similar manner, other compounds of formula (Ij) are prepared.

C. The compounds prepared above in Paragraph A and B may be further hydrolyzed under standard hydrolysis conditions to yield the following compounds:

30

EXAMPLE 8

Compounds of formulae (II) and (Im)

A. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-hydroxyquinoline (80 mg, 0.17 mmol) in *N,N*-dimethylformamide (DMF) (25 mL) was added cesium carbonate (454 mg, 1.36 mmol)

and *tert*-butyl bromoacetate (102 mg, 0.51 mmol). The reaction mixture was heated at 50°C. After half hour, the reaction was diluted with 200 mL water, then extracted by ethyl acetate (80 mL). The organic layer was separated and dried over sodium sulfate. The solvent was evaporated *in vacuo* to afford an yellow oil. Purification by flash 5 column on silica gel afforded 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((1,1-dimethylethoxy)carbonyl)methoxy]carbonylpropyl]aminocarbonyl-4-((1,1-dimethylethoxy)carbonyl)methoxyquinoline NMR (DMSO-d₆) 1.17 (t, 3), 1.37 (s, 9), 1.42 (s, 9), 1.93 (m, 1), 2.08 (m, 1), 2.48 (m, 2), 3.31-3.71 (m, 8), 4.03 (q, 2), 4.46 (q, 2), 5.07 (m, 3), 7.46 (s, 1), 7.68 (t, 1), 7.85 (t, 1), 8.09 (d, 1), 8.23 (d, 1), 8.95 (d, 1) ppm as a solid 10 (110 mg).

B. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((1,1-dimethylethoxy)carbonyl)methoxy]carbonylpropyl]aminocarbonyl-4-((1,1-dimethylethoxy)carbonyl)methoxyquinoline (38 mg, 0.05 mmol) in 1 mL CH₂Cl₂, was added 2 mL trifluoroacetic acid, then the reaction mixture was stirred at ambient 15 temperature for 3 hours. The reaction mixture was evaporated *in vacuo* to afford an oil. The oil was diluted in water (5 mL), adjusted to pH 4.5 by saturated NaHCO₃, then extracted by ethyl acetate (3 x 10 mL). The organic layer was evaporated *in vacuo* to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((carboxy)methoxycarbonyl)propyl]aminocarbonyl-4-(carboxy)methoxyquinoline as a 20 white solid (30 mg); NMR (DMSO-d₆), 1.16 (t, 3), 1.90 (m, 1), 2.10 (m, 1), 2.45 (m, 2), 3.3-3.9 (m, 8), 4.02 (q, 2), 4.52 (q, 2), 5.04 (m, 1), 5.13 (s, 2), 7.46 (s, 1), 7.68 (t, 1), 7.84 (t, 1), 8.08 (d, 1), 8.23 (d, 1), 9.95 (m, 1) ppm.

C. In a similar manner, similar compounds of the invention are prepared.

25

EXAMPLE 9

Compounds of formula (In)

A. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline (142 mg, 0.30 mmol) in tetrahydrofuran (THF) (5 mL) was added glycine *t*-butyl ester hydrochloride (44 mg, 0.33 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (64 mg, 0.33 mmol), 1-hydroxybenzotriazole (HOBT) (45 mg, 0.33 mmol) and diisopropylethylamine (DIEA) (0.43 g, 0.33 mmol). The reaction was stirred at ambient temperature overnight. The resultant solution was partitioned between water and ethyl acetate. The organic layer was concentrated *in vacuo* to afford an oil. The crude product was 35 purified by elution through silica gel with 20:1 methylene chloride-methanol to afford 2-

[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(((1,1-dimethylethoxycarbonyl)methyl)aminocarbonyl)propyl]aminocarbonyl-4-methoxyquinoline (62 mg, 35%); NMR (CDCl₃) 1.25 (t, 3), 1.50 (s, 9), 2.00 (m, 1), 2.15-2.50 (m, 3), 3.31-3.95 (m, 9), 4.10-4.32 (m, 7), 5.40 (m, 1), 7.59 (t, 1), 7.63 (s, 1), 5 7.75 (t, 1), 8.14 (d, 1), 8.22 (d, 1), 9.41 (d, 1) ppm.

B. The compound prepared above is hydrolyzed under standard conditions to yield the compound 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((carboxymethyl)aminocarbonyl)propyl]aminocarbonyl-4-methoxyquinoline.

C. In a similar manner, similar compounds of the invention are prepared.

10

EXAMPLE 10

Compounds of formula (I_p)

A. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-methoxyquinoline (50 mg, 0.11 mmol) in 15 tetrahydrofuran (THF) (2 mL) was added glycine *t*-butyl ester hydrochloride (20 mg, 0.12 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (23 mg, 0.12 mmol), 1-hydroxybenzotriazole (HOBT) (16 mg, 0.12 mmol) and diisopropylethylamine (DIEA) (0.16 g, 0.12 mmol). The reaction was stirred at ambient temperature overnight. The resultant solution was partitioned between water and ethyl acetate. 20 The organic layer was concentrated *in vacuo* to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-((carboxy)methyl)aminocarbonyl)ethyl]-aminocarbonyl-4-methoxyquinoline as an oil.

B. In a similar manner, the following compounds were prepared:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-((carboxy)methyl)(methyl)aminocarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (DMSO-d₆) 1.20 (t, 3), 2.70-3.85 (m, 13), 3.95-4.21 (m, 4), 4.35 (s, 3), 5.45 (m, 1), 7.83 (dd, 1), 7.98 (s, 1), 8.04 (dd, 1), 8.35 (d, 1), 8.41 (d, 1), 9.78 (m, 1) ppm; and 25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(((1,1-dimethylethoxycarbonyl)methyl)(methyl)aminocarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.23 (t, 3), 1.42 (s, 9), 2.80 (m, 1), 3.07 (s, 3), 3.40-3.80 (m, 8), 4.12 (s, 3), 5.65 (m, 1), 7.58 (dd, 1), 7.63 (s, 1), 7.75 (dd, 1), 30 8.02 (d, 1), 8.21 (d, 1), 8.75 (m, 1) ppm.

EXAMPLE 11

Compounds of formulae (Iq), (Ir) and (Is)

A. To a solution of *N*-*t*-butoxycarbonylhistidine (2g, 7.05 mmol) in THF (30 mL) was added 1-ethoxycarbonylpiperazine (1.36 mL, 1.3 eq.), EDCI (1.65 g, 1.2 eq. 5), HOBr (1.2 g, 1.1 eq.) and the reaction mixture was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford a crude product, which was dissolved in ethyl acetate, washed with saturated NaHCO₃, 1M NaHSO₄ and brine. The organic layer was evaporated. Flash column chromatography with 2%-6% MeOH in CH₂Cl₂ afforded 4-ethoxycarbonyl-1-(1-(*t*-butoxycarbonyl)amino-2-(imidazol-4-10 yl)ethyl)carbonylpiperazine (820 mg). 4-Ethoxycarbonyl-1-(1-(*t*-butoxycarbonyl)amino-2-(imidazol-4-yl)ethyl)carbonylpiperazine (200 mg, 0.5 mmol) was treated with trifluoroacetic acid/methylene chloride (1:1, 2.0 mL) with stirring at ambient temperture for 1 hour. Evaporation gave 4-ethoxycarbonyl-1-(1-amino-2-(imidazol-4-yl)ethyl)carbonylpiperazine, which was treated with methylene chloride 15 and triethylamine (0.5 mL), and the solvents evaporated to again afford 4-ethoxycarbonyl-1-(1-amino-2-(imidazol-4-yl)ethyl)carbonylpiperazine. To a solution of 2-carboxy-4-methoxyquinoline (124 mg, 0.61 mmol) in THF (4 mL) was added a mixture of 4-ethoxycarbonyl-1-(1-amino-2-(imidazol-4-yl)ethyl)carbonylpiperazine, THF (2 mL), and triethylamine (0.1 mL), followed by addition of EDCI (136 mg, 1.4 20 eq.), HOBr (98 mg, 1.4 eq.). The resulting mixture was stirred overnight. The crude product (245 mg, foam) was isolated from the reaction mixture by the same methods employed above. Flash column chromatography with 25%-6% MeOH in methylene chloride afforded 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(imidazol-4-yl)ethyl]aminocarbonyl-4-methoxyquinoline; NMR (CDCl₃) 1.25 (t, 3), 3.10-3.30 (m, 2), 25 3.20-3.65 (m, 9), 4.10 (m, 5), 5.40 (m, 1), 6.90 (s, 1), 7.55-7.60 (m, 3), 7.70 (t, 1), 8.02 (d, 1), 8.20 (d, 1), 9.0 (d, 1) ppm.

B. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(imidazol-4-yl)ethyl]aminocarbonyl-4-methoxyquinoline (69 mg, 0.14 mmol) in DMF (2 mL) was added *t*-butyl bromo acetate (0.026 mL, 1.2 eq.), potassium carbonate (30 mg, 1.5 eq), NaI (2.0 mg, 0.1 eq.). The reaction mixture was heated at 50°C for 1 hour. Evaporation followed by flash column chromatography with 2%-3% MeOH in methylene chloride afforded 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(*t*-butoxycarbonyl)methyl]imidazol-4-yl)ethyl]-aminocarbonyl-4-methoxyquinoline (25 mg) which was treated with neat trifluoroacetic acid (0.5 mL) for 1.5 hours at ambient 35 temperature. Repeated evaporation of the solvents and treatment with methylene

chloride afforded 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(1-(carboxymethyl)imidazol-4-yl)ethyl]-aminocarbonyl-4-methoxyquinoline (27 mg) as a trifluoroacetic acid salt: NMR (DMSO) 1.20 (t, 3), 3.2-3.6 (m, 11), 4.05 (q, 2), 4.1 (s, 3), 5.0 (s, 2), 5.3 (m, 1), 7.45 (s, 1), 7.5 (s, 1), 7.65 (t, 1), 7.8 (t, 1), 8.05 (d, 1), 8.16
5 (d, 1), 8.95 (s, 1) ppm.

C. In a similar manner, similar compounds of the invention are prepared.

EXAMPLE 12

Compounds of formula (Ii)

10 A. To a solution of 4-methoxy-2-carboxyquinoline (102 mg, 0.50 mmol) in CH₂Cl₂ (15 mL) was added triethylamine (0.33 mL, 2.36 mmol) and 1-hydroxybenzotriazole (HOBT) (80 mg, 0.60 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (110 mg, 0.60 mmol). After 5 minutes, 1-ethoxycarbonyl-4-(ethoxycarbonylmethyl)-aminomethylcarbonylpiperazine (150 mg, 0.50 mmol) was
15 added and the reaction mixture was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford an oil, which was dissolved in ethyl acetate, and washed with saturated NaHCO₃, 1M NaHSO₄ and brine. The organic layer was evaporated *in vacuo* and the crude product was purified by flash column to afford 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl](ethoxycarbonylmethyl)-aminocarbonyl-4-methoxyquinoline (30 mg).

20 B. To a solution of 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl](ethoxycarbonylmethyl)aminocarbonyl-4-methoxyquinoline (30 mg, 0.06 mmol) in ethanol (1.0 mL), was added a solution of LiOH (6 mg, 0.12 mmol) in water (1.0 mL). The resulting reaction mixture was stirred at ambient temperature for
25 1 hour. The reaction mixture was acidified to pH 3 by 2N NaHSO₄, extracted by ethyl acetate (3x20 mL), dried over sodium sulfate, and concentrated *in vacuo* to afford 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl](carboxymethyl)aminocarbonyl-4-methoxyquinoline (25 mg) as a solid; NMR (DMSO-d₆), 1.20 (m, 3), 3.20-3.60 (m, 8), 4.00-4.14 (m, 5), 4.20 (s, 1), 4.35 (s, 1), 4.50 (s, 1), 4.70 (s, 1), 7.23 (d, 1), 7.65 (m, 1),
30 7.80-7.94 (m, 2), 8.17 (m, 1) ppm.

C. In a similar manner, other compounds of formula (Ii) are prepared.

EXAMPLE 13

Compounds of formula (Iu)

A. To a solution of 2-[carboxymethylcarbonyl][(1,1-dimethylethoxycarbonyl)methyl]aminonaphthalene (270 mg, 0.78 mmol) in CH_2Cl_2 (50 mL) was added triethylamine (0.33 mL, 2.36 mmol) and 1-hydroxybenzotriazole (HOBT) (128 mg, 0.91 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (238 mg, 1.23 mmol). After 5 minutes, 1-ethoxycarbonylpiperazine (0.12 mL, 0.78 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford an oil, which was dissolved in ethyl acetate, and washed with saturated NaHCO_3 , 1M NaHSO_4 and brine. The organic layer was evaporated *in vacuo* and the crude product was purified by flash column to afford 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][(1,1-dimethylethoxycarbonyl)methyl]aminonaphthalene (147 mg).

B. To a solution of 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][(1,1-dimethylethoxycarbonyl)methyl]aminonaphthalene (147 mg, 0.30 mmol) in CH_2Cl_2 (2.0 mL) was added TFA (3.0 mL). The resulting reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was evaporated *in vacuo* to afford an oil, which was diluted with water (15 mL), adjusted to pH 4.5 by saturated NaHCO_3 , then extracted by ethyl acetate (3x15 mL). The organic layer was evaporated *in vacuo* to afford 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][carboxymethyl]-aminonaphthalene (90 mg) as a solid; NMR (CDCl_3) 1.26 (t, 3), 3.24-3.30 (m, 2), 3.35-3.42 (m, 6), 3.57 (m, 2), 4.14 (q, 2), 4.52 (s, 2), 7.48 (d, 1), 7.58 (m, 2), 7.84-7.94 (m, 4) ppm.

C. In a similar manner, the following compound was made:

2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][carboxymethyl]amino-4-methoxynaphthalene; NMR (CDCl_3) 1.24 (t, 3), 3.32-3.60 (m, 8), 4.02 (s, 3), 4.13 (q, 2), 4.48 (s, 2), 6.82 (s, 1), 7.48 (s, 1), 7.57 (m, 2), 7.79 (d, 1), 8.26 (d, 1) ppm.

EXAMPLE 14

Compounds of formula (Iv) and formula (Iw)

A. A solution of 4-ethoxycarbonyl-1-(1-amino-3-(methoxycarbonyl)propyl)carbonylpiperazine (0.97 g, 3.23 mmol), 2-carboxy-4-chloroquinoline (0.67 g, 3.23 mmol), EDCI (0.68 g, 3.55 mmol) and HOBT (0.48 g, 3.55 mmol) was combined in 30 mL of THF. The reaction mixture was stirred overnight at ambient temperature. The reaction was diluted with ethyl acetate and

washed with water. The organic layer was concentrated to give a dark oil (0.87 g) that was purified by flash chromatography through silica gel with 2:1 ethyl acetate–hexanes to provide 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-chloroquinoline (0.46 g). A solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-chloroquinoline (0.15 g, 0.313 mmol) was dissolved in 5 mL THF and LiOH (0.25 M, 1.9 mL, 0.47 mmol) was added. The reaction mixture was stirred for 2 hours. The reaction mixture was concentrated to an oil, acidified with 10% HCl, extracted into ethyl acetate, and concentrated to provide pure 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-chloroquinoline, (167 mg); NMR 1.20 (t, 3), 1.90 (m, 1), 2.05 (m, 1), 2.35 (m, 2), 3.35-3.60 (m, 8), 3.65 (m, 2), 4.05 (q, 2), 5.07 (m, 1), 7.95 (m, 1), 8.02 (m, 1), 8.23 (s, 1), 8.30 (m, 1), 8.98 (m, 1) ppm.

B. To a solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-chloroquinoline (150 mg, 0.315 mmol) in 15 DMSO (3.0 mL) was added (R)-3-hydroxypiperidine (68 mg, 0.5 mmol) and DIEA (65 mg, 0.5 mL). The mixture was heated at 110°C for 18 hours. The crude reaction mixture was treated with lithium hydroxide (3.0 mL 0.25 M) for 4 hours. The reaction was purified by preparative HPLC to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-hydroxypyrrolidin-1-yl)quinoline (41.0 mg); NMR (DMSO-d₆) 1.2 (t, 3), 2.00-2.20 (m, 4), 2.45 (m, 2), 3.30-3.75 (m, 8), 4.05 (q, 2), 4.60 (s, 1), 5.11 (m, 1), 7.39 (s, 1), 7.65 (m, 1), 7.95 (m, 1), 8.28 (m, 1), 8.58 (br s, 1), 9.75 (m, 1) ppm.

C. In a similar manner, the following compounds were made from the appropriate amine:

25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(morpholin-4-yl)quinoline; NMR (CDCl₃) 1.23 (t, 3), 2.01 (m, 1), 2.20 (m, 1), 2.50-2.63 (m, 2), 3.40-3.80 (m, 8), 3.98 (m, 4), 4.15 (m, 2), 5.25 (m, 1), 7.55 (dd, 1), 7.70 (s, 1), 7.75 (dd, 1), 8.00 (d, 1), 8.20 (d, 1), 9.21 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-30 carboxypiperidin-1-yl)quinoline; NMR (DMSO-d₆) 1.22 (t, 3), 1.65 (m, 1), 1.75-1.98 (m, 3), 2.06 (m, 2), 2.35 (m, 2), 2.82 (m, 1), 2.96 (m, 1), 3.13 (m, 1), 3.38-3.77 (m, 10), 4.06 (q, 2), 5.06 (m, 1), 7.57 (s, 1), 7.64 (t, 1), 7.79 (t, 1), 8.11 (m, 2), 8.94 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-35 ((dimethylamino)carbonylmethyl)(methyl)aminoquinoline; NMR (DMSO-d₆) 1.23

(t, 3), 1.95-2.15 (m, 2), 2.41 (dd, 1), 2.98 (s, 3), 3.05 (s, 3), 3.25-3.75 (m, 11), 4.05 (q, 2), 4.85 (m, 2), 5.05 (m, 1), 7.40 (s, 1), 7.65 (dd, 1), 7.99 (dd, 1), 8.25-8.35 (m, 2), 9.75 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)(methyl)aminoquinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.85-2.05 (m, 2), 2.35 (m, 2), 3.20-3.63 (m, 11), 4.01 (q, 2), 4.65 (s, 2), 5.02 (m, 1), 7.55 (s, 1), 7.63 (dd, 1), 7.95 (dd, 1), 8.25 (dd, 1), 9.65 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-methylpiperazin-1-yl)quinoline; NMR (DMSO-d₆) 1.18 (t, 3), 1.85 (m, 1), 2.05 (m, 1), 2.39 (dd, 2), 2.91 (s, 3), 3.25-3.70 (m, 16), 4.05 (m, 4), 5.15 (m, 1), 7.65 (m, 2), 7.95 (dd, 1), 8.15 (d, 1), 8.22 (d, 1), 9.35 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-hydroxypiperidin-1-yl)quinoline; NMR (DMSO-d₆) 1.23 (t, 3), 1.78 (m, 2), 1.95-2.20 (m, 4), 2.42 (dd, 2), 3.34-3.82 (m, 10), 4.00 (m, 1), 4.05-4.20 (m, 3), 5.15 (m, 1), 7.70 (dd, 1), 7.78 (s, 1), 7.97 (dd, 1), 8.15 (d, 1), 8.35 (d, 1), 9.75 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-(carboxymethyl)piperazin-1-yl)quinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.80-2.00 (m, 2), 2.35 (m, 2), 3.23-3.45 (m, 6), 3.63 (m, 6), 3.80-4.00 (m, 4), 4.02 (q, 2), 4.25 (s, 2), 5.05 (m, 1), 7.70 (m, 2), 7.93 (dd, 1), 8.10 (dd, 1), 8.24 (dd, 1), 9.39 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(carboxymethyl)piperazin-1-yl)quinoline; NMR (DMSO-d₆) 1.20 (t, 3), 1.82-2.10 (m, 2), 2.35 (m, 2), 2.75 (m, 2), 3.25-3.65 (m, 12), 3.90-4.10 (m, 6), 5.05 (m, 1), 7.63 (m, 2), 7.92 (dd, 1), 8.15-8.22 (m, 2), 9.38 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-aminocarbonylpiperidin-1-yl)quinoline; NMR (DMSO-d₆) 1.23 (t, 3), 1.90-2.20 (m, 6), 2.43 (dd, 2), 2.65 (m, 1), 3.35-3.75 (m, 10), 4.05 (q, 2), 4.35 (m, 2), 5.18 (m, 1), 7.70 (dd, 1), 7.75 (s, 1), 7.98 (dd, 1), 8.18 (d, 1), 8.35 (d, 1), 8.78 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(3-ethoxycarbonylpiperidin-1-yl)quinoline; NMR (CDCl₃) 1.26 (m, 6), 1.74-2.08 (m, 4), 2.22 (m, 2), 2.57 (m, 2), 2.82-2.98 (m, 2), 3.16 (m, 1), 3.40-3.82 (m, 13), 4.18 (q, 2), 5.27 (m, 1), 7.55 (t, 1), 7.70 (s, 1), 7.76 (t, 1), 8.03 (d, 1), 8.11 (d, 1), 9.01 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-ethoxycarbonylpiperidin-1-yl)quinoline; NMR (CDCl₃) 1.27 (m, 6), 1.78-2.08 (m, 4), 2.22 (m, 2), 2.57 (m, 2), 2.88 (m, 1), 3.07 (m, 1), 3.28 (m, 1), 3.40-3.82 (m, 10), 4.18 (q, 2), 5.29 (m, 1), 7.57 (t, 1), 7.73 (s, 1), 7.76 (t, 1), 8.05 (d, 1), 8.17 (d, 1), 9.24 (d, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)aminoquinoline; NMR (CD₃OD) 1.25 (t, 3), 2.0 (m, 1), 2.15 (m, 1), 2.45 (m, 2), 3.40-3.80 (m, 8), 3.90 (s, 2), 4.10 (q, 2), 5.20 (m, 1), 7.05 (s, 1), 7.50 (m, 1), 7.65 (m, 1), 7.85 (m, 1), 8.10 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methyl)(2-(dimethylamino)ethyl)aminoquinoline; NMR (DMSO-d₆) 1.21 (t, 3), 1.95-2.16 (m, 2), 2.45 (dd, 2), 2.95 (s, 3), 3.34-3.80 (m, 13), 4.09 (q, 2), 4.20 (m, 1), 5.15 (m, 1), 7.60 (s, 1), 7.75 (dd, 1), 8.02 (dd, 1), 8.30-8.40 (m, 2), 9.65 (d, 1) ppm; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methyl)(2-hydroxyethyl)aminoquinoline. NMR (DMSO-d₆) 1.21 (t, 3), 1.95-2.15 (m, 2), 2.55 (s, 3), 3.30-3.75 (m, 11), 3.90 (m, 2), 4.10 (m, 3), 5.15 (m, 1), 7.61 (m, 2), 7.98 (dd, 1), 8.30 (d, 1), 8.55 (d, 1), 9.75 (d, 1) ppm.

D. To a solution of 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (100 mg, 0.173 mmol) in 4 mL of CH₃CN was added methyl acrylate (20 μ L, 0.217 mmol), palladium acetate (5 mg, 0.0173 mmol), palladium triphenylphosphine (10 mg, 0.035), and DIEA (30 μ L, 0.017 mmol). The reaction was heated at 85°C for 25 hours. Aqueous work-up afforded a crude product, which was dissolved in methylene chloride (5.0 mL). Trifluoroacetic acid (5.0 mL) was added to the solution. After 1 hour, the reaction mixture was concentrated *in vacuo*. The residue was dissolved in lithium hydroxide (5 mL, 0.25 M). After 6 hours, the desired product was purified by preparative HPLC to afford 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-carboxyethenyl)quinoline (34 mg); NMR (DMSO-d₆) 1.15 (t, 3), 1.80 (m, 1), 2.05 (m, 2), 3.15-3.63 (m, 8), 4.02 (q, 2), 5.05 (m, 1), 6.80 (d, 2), 7.75 (t, 1), 7.90 (t, 2), 8.20 (d, 1), 8.30-8.38 (m, 3), 8.99 (d, 1) ppm.

E. In a similar manner, other compounds of formula (iv) and formula (lw) are prepared.

EXAMPLE 15

Compounds of formula (Ix) and formula (Iy)

A. To a mixture of 2,4-dicarboxyquinoline (1.085 g, 5 mmol) in methanol (40 mL) was added chlorotrimethylsilane (TMSCl) (1.41 mL), and the reaction mixture 5 was stirred overnight. The reaction mixture turned into a clear solution. The solvents were evaporated to yield a crude product, 2-carboxy-4-methoxycarbonylquinoline. To a solution of 2-carboxy-4-methoxycarbonylquinoline (151 mg, 0.65 mmol) in THF (10mL) was added 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (181 mg, 1.05 eq.), EDCI (161 mg, 10 1.2 eq.), and HOBt (75 mg, 1.1 eq.), and the resulting reaction mixture was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford a crude product, which was dissolved in ethyl acetate, washed with saturated NaHCO₃, 1M NaHSO₄ and brine. The organic layer was evaporated. Flash column chromatography with 1%-3% MeOH in CH₂Cl₂ afforded 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(methoxycarbonyl)quinoline (146 mg) which was treated with trifluoroacetic acid (TFA) and CH₂Cl₂ (TFA/CH₂Cl₂, 1:1, 1.5 mL) and the resulting reaction mixture was stirred at ambient temperature for 1 hour. Evaporation of the solvents gave 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methoxycarbonyl)quinoline (74 mg). To this was 15 added a mixture of THF:H₂O (2:1, 2 mL) and LiOH (4 eq.). The resulting mixture was stirred at ambient temperature for 1.5 hours. The pH value was adjusted to between pH 3 and pH 4 with 1N HCl solution. Extraction of the organic layers with ethyl acetate was followed by evaporation of the solvents to yield 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-carboxyquinoline (39 mg); NMR 20 (CD₃OD) 1.25 (t, 3), 1.99 (m, 1), 2.2 (m, 1), 2.5 (m, 2), 3.4-3.9 (m, 8), 4.16 (q, 2), 5.25 (m, 1), 7.75 (m, 1), 7.86 (m, 1), 8.25 (m, 3) ppm.

B. Alternatively, 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(methoxycarbonyl)quinoline (200 mg, 0.359 mmol) was treated with LiOH (2 eq.) in a solution of THF:H₂O (3:1, 8 mL). The 25 reaction mixture was stirred at ambient temperature for 5 hours. The pH value was adjusted to between pH 3 and pH 4 with 1N HCl solution. Evaporation of the solvents, extraction with ethyl acetate, washing with H₂O and brine, followed by evaporation and flash column chromatography with 100% ethyl acetate, 1-5% MeOH in ethyl acetate gave 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-carboxyquinoline (106 mg). To a 30 35

solution of 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-carboxyquinoline (500 mg (two batches combined), 0.922 mmol) in THF (10 mL) was added 1-methyl 5-t-butyl ester glutamic acid (300 mg, 1.5 eq), EDCI (216 mg, 1.2eq.), HOBr (140 mg, 1.1 eq.), and 5 the resulting mixture was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford a crude product, which was dissolved in ethyl acetate, washed with saturated NaHCO₃, 1M NaHSO₄ and brine. The organic layer was evaporated. Flash column chromatography with 1%-3% MeOH in CH₂Cl₂ afforded 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline (387 mg); NMR (CDCl₃) 1.28 (t, 3), 1.40 (s, 9), 1.47 (s, 9), 1.83 (m, 1), 2.16 (m, 2), 2.35-2.50 (m, 5), 3.5-3.76 (m, 8), 3.8 (s, 3), 4.18 (q, 2), 4.85 (m, 1), 5.35 (m, 1), 7.15 (d, 1), 7.65 (m, 1), 7.80 (m, 1), 8.20 (d, 1), 8.30 (d, 1), 8.35 (s, 1), 8.70 (d, 1) ppm.

10 C. 2-[1-(4-(Ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline (170 mg, 0.229 mmol) was treated with LiOH (2.0 eq.) in a solution of THF:H₂O (3:1, 12 mL). The reaction mixture was stirred at ambient temperature for 5 hours. The pH value of the reaction 15 mixture was adjusted to between pH 3 and pH4 with 1N HCl solution. The reaction mixture was evaporated *in vacuo* to afford a crude product, which was dissolved in ethyl acetate, washed with H₂O and brine. The solvent was evaporated to give 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-carboxy-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline (150 mg); NMR (CD₃OD) 1.30 (t, 3), 1.40 (s, 9), 1.50 (s, 9), 1.90 (m, 1), 2.15 (m, 2), 2.30-2.50 (m, 5), 3.45-3.90 (m, 8), 4.18 (q, 2), 4.75 (m, 1), 5.25 (m, 1), 7.75 (m, 1), 7.90 (m, 1), 8.25 (m, 3) ppm.

20 D. Alternatively, 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline (41 mg, 0.055 mmol) was treated with trifluoroacetic acid:methylene chloride (1:1, 0.6 mL) at ambient 25 temperature for 2 hours. Evaporation of the reaction mixture, followed by dilution with methylene chloride, and repeated evaporation of the solvent gave 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-carboxypropyl)aminocarbonyl]quinoline (40 mg) as a

trifluoroacetic acid salt; NMR (CD₃OD) 1.25 (t, 3), 1.95 (m, 1), 2.18 (m, 2), 2.40 (m, 1), 2.45-2.55 (m, 4), 3.45-3.92 (m, 11), 4.16 (q, 2), 4.80 (m, 1), 5.25 (m, 1), 7.72 (t, 1), 7.86 (t, 1), 8.21-8.26 (m, 3) ppm.

E. Alternatively, 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-carboxy-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline (136 mg, 0.187 mmol) was treated with trifluoroacetic acid:methylene chloride (1:1, 1.2 mL) at ambient temperature for 1 hour. The solvents were evaporate and resulting residue diluted with methylene chloride, followed by evaporation of the solvent gave 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-[(1,3-dicarboxypropyl)aminocarbonyl]quinoline (112 mg); NMR (CD₃OD) 1.20 (m, 3), 1.90 (m, 1), 2.10 (m, 2), 2.30-2.50 (m, 5), 3.40-3.80 (m, 8), 4.10 (m, 2), 4.70 (m, 1), 5.18 (m, 1), 7.60 (m, 1), 7.80 (m, 1), 8.20 (m, 3) ppm.

F. In a similar manner as described above, the following compounds of the invention were made:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(methoxycarbonylmethyl)aminocarbonylquinoline; NMR (CDCl₃) 1.30 (t, 3), 1.50 (s, 9), 1.85 (m, 1), 2.20 (m, 1), 2.45 (m, 2), 3.55-3.80 (m, 8), 3.85 (s, 3), 4.20 (q, 2), 4.38 (d, 2), 5.35 (m, 1), 7.20 (d, 1), 7.70 (m, 1), 7.85 (m, 1), 8.20 (d, 1), 8.35 (d, 1), 8.38 (s, 1), 8.65 (m, 1) ppm;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(carboxymethyl)aminocarbonylquinoline; NMR (CD₃OD) 1.30 (t, 3), 1.50 (s, 9), 1.90 (m, 1), 2.20 (m, 1), 2.50 (m, 2), 3.45-3.92 (m, 8), 4.18 (q, 2), 4.25 (s, 2), 5.25 (m, 1), 7.75 (m, 1), 7.90 (m, 1), 8.25-8.32 (m, 3) ppm; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)aminocarbonylquinoline; NMR (CD₃OD) 1.30 (t, 3), 1.95 (m, 1), 2.20 (m, 1), 2.50 (m, 2), 3.45-3.90 (m, 8), 4.18 (q, 2), 4.22 (s, 2), 5.25 (m, 1), 7.75 (m, 1), 7.85 (m, 1), 8.25 (m, 3) ppm.

30

EXAMPLE 16

Compounds of formula (Iz)

A. To a solution of 2-carboxy-7-chloro-4-mercaptoquinoline HCl salt (75 mg, 0.31 mmol) in DMF (3 mL) was added MeI (0.0425 mL, 2.5 eq.) and cesium carbonate (340 mg, 3.5 eq.). The resulting reaction mixture was stirred at 70°C overnight. The reaction mixture was diluted with ethyl acetate and washed with water,

brine, and dried over sodium sulfate. The solvent was evaporated. Flash column chromatography with 1%-2% MeOH in methylene chloride afforded 2-(methoxycarbonyl)-7-chloro-4-methylthioquinoline (40 mg). To 2-(methoxycarbonyl)-7-chloro-4-methylthioquinoline (40 mg) was added THF:H₂O (2:1, 2 mL) and LiOH (10 mg, 1.5 eq.). The reaction mixture was stirred for 2 hours. The pH was adjusted to pH 4.5 with 1N HCl. Extraction with ethyl acetate, washing with brine, drying over sodium sulfate and evaporation gave 2-carboxy-7-chloro-4-methylthioquinoline (29 mg). To a solution of 2-carboxy-7-chloro-4-methylthioquinoline (29 mg) in THF (6 mL) and DMF (1mL) was added 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (46 mg, 1.1 eq.), EDCI (28 mg, 1.2 eq.), and HOBT (18 mg, 1.1 eq.). The resulting reaction mixture was stirred at ambient temperature overnight. The reaction mixture was evaporated *in vacuo* to afford a crude product, which was dissolved in ethyl acetate, washed with saturated NaHCO₃, 1M NaHSO₄ and brine. The organic layer was evaporated. Flash column chromatography with 1%-3% MeOH in CH₂Cl₂ afforded the product, 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(methylthio)quinoline (36 mg). The product (32 mg) was treated with TFA:CH₂Cl₂ (1:1, 1 mL) at ambient temperature for 2 hours. The solvents were then evaporated to afford the desired product, 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(methylthio)quinoline; NMR (CDCl₃) 1.35 (t,3), 2.10 (m,1), 2.25 (m,1), 2.55 (m, 2), 2.7 (s, 3), 3.4-3.9 (m, 8), 4.2 (q, 2), 5.3 (m, 1), 7.55 (d, 1), 7.9 (s, 1), 8.02 (d, 1), 8.15 (s, 1) ppm.

B. In a similar manner, the following compound was made:
25 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-(methylthio)quinoline; NMR (CDCl₃) 1.30 (t, 3), 2.0 (m, 1), 2.20 (m, 1), 2.55 (m, 2), 2.60 (s, 3), 3.40-3.80 (m, 8), 4.15 (q, 2), 5.30 (m, 1), 7.60 (s, 1), 7.90 (s, 1), 8.05 (s, 1), 9.05 (m, 1) ppm.

30

EXAMPLE 17

Receptor Binding Studies

The ability of the compounds of the invention to bind to the platelet adenosine diphosphate ("ADP") receptor was tested using human washed platelets and rat washed platelets by displacement assays.

35 Methods:

One day old platelet concentrates were purchased from a local blood bank. The platelet concentrates were spun at 680 g for 10 minutes and the resulting pellets were resuspended in modified Tyrode's buffer (135 mM NaCl, 3.6 mM KCl, 1.8 mM MgCl₂, 9 mM HEPES, 0.18 mg/mL BSA, 4.5 mM glucose, pH 6.6) supplemented by 5 2% acid citrate dextrose (ACD). This platelet suspension was spun at 680 g for 10 minutes and the final pellet was resuspended in platelet binding buffer (20 mM Tris buffer, pH 7.5, 140 mM NaCl, 4 mM KCl, 2 mM MgCl₂, 1 mM EDTA, 0.1% BSA, 5 mM glucose, 2 µg/mL aprotinin, and 2 µg/mL leupeptin).

Platelets were isolated from rat whole blood as described in Example 13 with 10 the final pellet resuspended in platelet binding buffer. The platelet number for binding to rat platelets (5×10^8 per well) was normalized to the number of platelets for binding to human platelet ($4-6 \times 10^8$ per well).

Binding reactions were initiated by mixing [³³P]-2-methylthio-ADP (0.3-0.5 nM), 15 test compounds and washed platelets in 96-well plates. The reactions were kept at ambient temperature for 60 minutes under constant shaking and were stopped by fast-filtration onto 96-well, glass-fiber (GFC) filter plates followed by washing 5 times with ice-cold 50 mM Tris buffer (pH 7.5). The amount of [³³P]-2-methylthio-ADP bound to the filters was measured by scintillation counting. Non-specific binding was determined in the presence of 10 µM unlabelled 2-methylthio-ADP. Competition 20 studies were done using a single concentration of [³³P]-2-methylthio-ADP (0.3 nM) and varying concentrations of test compounds.

Results:

The compounds of the invention, when tested in this assay, demonstrated their ability to inhibit the binding of [³³P]-2-methylthio-ADP binding to the human platelet 25 ADP receptor and the rat platelet ADP receptor.

EXAMPLE 18

ADP-Induced Aggregation *In Vitro* Studies

The compounds of the invention were evaluated as functional antagonists of 30 the platelet ADP receptor using both human and rat washed platelets.

Methods:

Human venous blood was collected from healthy, drug-free volunteers into 1/6 volume 3.2% acid/citrate/dextrose. Whole blood from Nembutal-anesthetized rats was collected from the abdominal aorta into 1/10 volume 3.8% acid/citrate/dextrose.

35 Platelet rich plasma (PRP) was prepared by centrifugation at 800 g for 3-4 successive

1.5-minute intervals, with removal of the PRP after each spin. Alternatively, some PRP preps were performed by centrifugation at 100 g for 15 minutes. Washed platelets were prepared from the PRP by centrifugation at 680 g for 15 minutes and the platelet pellet resuspended in Tyrode's buffer (137 mM NaCl, 2.7 mM KCl, 12 mM 5 NaHCO₃, 0.42 mM NaH₂PO₄, 1 mM MgCl₂, 2 mM CaCl₂, 0.35% BSA, 5.5 mM glucose, 5 mM HEPES, pH 7.35 supplemented with f.c. 10% ACD solution. The platelets were washed a total of two times under these acidic conditions and the platelet pellet 10 collected by centrifugation at 680 g for 15 minutes at ambient temperature. The final platelet pellet was resuspended at 2 X 10⁸ platelets/mL in Tyrode's buffer containing 0.02 units/mL apyrase. This platelet suspension was kept at 37°C for at least 30 minutes prior to studies.

Inhibition of ADP-induced aggregation was measured at 37°C in a 4-channel aggregometer. The platelet suspension (0.5 mL) was stirred at 1200 rpm. Human fibrinogen (400 µg) was added at time zero for 1 minute followed by 2 minute pre- 15 incubation in the presence or absence of antagonist. Platelet aggregation was induced with the addition of 10 or 31.6 µM ADP (submaximal response) in human platelets or 3 or 10 µM ADP (submaximal response) in rat and monitored for 5 minutes. ADP-induced aggregation was quantified by measuring increase in light transmission (%T) compared to Tyrode's buffer control. IC₅₀ values were determined using the 4- 20 parameter equation.

Results:

The compounds of the invention, when tested in this assay, demonstrated the ability to inhibit ADP-induced platelet aggregation *in vitro* in human and rat washed platelets.

25

EXAMPLE 19

Efficacy Assay

Inhibition of thrombus formation by compounds of the invention was evaluated in the rat arterio-venous (A-V) shunt model.

30 Methods:

Male Sprague-Dawley rats (350-400 g, 10-18 per group) were anesthetized with Nembutal (65 mg/kg, i.p.). The left carotid artery and the right jugular vein were each cannulated with a piece of PE-50 tubing (8 cm, siliconized). Fifty minutes after anesthesia, the arterial and venous catheters were connected (A-V shunt) by a piece 35 of shunt tubing (Tygon S-50-HL, 6 cm) that contained a silk thread (6-0 silk suture, 10

cm) coated with collagen (Horm, 100 µg/ml). Blood was allowed to flow through the A-V shunt for 10 minutes. The amount of thrombus deposited on the silk thread was measured as dry weight (24 hours at ambient temperature). A compound of the invention (1, 3 and 10 mg/kg) (as the appropriate salt form) or vehicle (15% DMSO in 5 saline, 1 mL/kg) was injected via the jugular vein catheter 5 minutes before the A-V shunt. Blood samples (1 mL) were taken immediately before the dosing and at the end of the A-V shunt for measurements of *ex vivo* platelet aggregation and plasma levels of the compound of the invention.

Results:

10 When tested in this assay, compounds of the invention demonstrated the ability to dose-dependently inhibit platelet aggregation and thrombus formation in the rat A-V shunt model. Both the inhibition of platelet aggregation and thrombus formation were also parallel in relation to the changes in plasma drug concentrations. Thus, the inhibition of thrombus formation is correlated with the inhibition of platelet aggregation 15 induced by the compound of the invention.

EXAMPLE 20

20 This example illustrates the preparation of representative pharmaceutical compositions for oral administration containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

A.	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	20.0%
	Lactose	79.5%
	Magnesium stearate	0.5%

25 The above ingredients are mixed and dispensed into hard-shell gelatin capsules containing 100 mg each, one capsule would approximate a total daily dosage.

B.	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	20.0%
30	Magnesium stearate	0.9%
	Starch	8.6%
	Lactose	69.6%
	PVP (polyvinylpyrrolidone)	0.9%

35 The above ingredients with the exception of the magnesium stearate are combined and granulated using water as a granulating liquid. The formulation is then

dried, mixed with the magnesium stearate and formed into tablets with an appropriate tabletting machine.

C. Ingredients

5	Compound of the invention	0.1 g
	Propylene glycol	20.0 g
	Polyethylene glycol 400	20.0 g
	Polysorbate 80	1.0 g
	Water	q.s. 100 mL

10 The compound of the invention is dissolved in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient quantity of water is then added with stirring to provide 100 mL of the solution which is filtered and bottled.

D. Ingredients

% wt./wt.

15	Compound of the invention	20.0%
	Peanut Oil	78.0%
	Span 60	2.0%

The above ingredients are melted, mixed and filled into soft elastic capsules.

E. Ingredients

% wt./wt.

20	Compound of the invention	1.0%
	Methyl or carboxymethyl cellulose	2.0%
	0.9% saline	q.s. 100 mL

25 The compound of the invention is dissolved in the cellulose/saline solution, filtered and bottled for use.

EXAMPLE 21

25 This example illustrates the preparation of a representative pharmaceutical formulation for parenteral administration containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

Ingredients

30	Compound of the invention	0.02 g
	Propylene glycol	20.0 g
	Polyethylene glycol 400	20.0 g
	Polysorbate 80	1.0 g
	0.9% Saline solution	q.s. 100 mL

35 The compound of the invention is dissolved in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient quantity of 0.9% saline solution is then

added with stirring to provide 100 mL of the I.V. solution which is filtered through a 0.2 m membrane filter and packaged under sterile conditions.

EXAMPLE 22

5 This example illustrates the preparation of a representative pharmaceutical composition in suppository form containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	1.0%
10	Polyethylene glycol 1000	74.5%
	Polyethylene glycol 4000	24.5%

The ingredients are melted together and mixed on a steam bath, and poured into molds containing 2.5 g total weight.

15

EXAMPLE 23

This example illustrates the preparation of a representative pharmaceutical formulation for insufflation containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

	<u>Ingredients</u>	<u>% wt./wt.</u>
20	Micronized compound of the invention	1.0%
	Micronized lactose	99.0%

The ingredients are milled, mixed, and packaged in an insufflator equipped with a dosing pump.

25

EXAMPLE 24

This example illustrates the preparation of a representative pharmaceutical formulation in nebulized form containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

	<u>Ingredients</u>	<u>% wt./wt.</u>
30	Compound of the invention	0.005%
	Water	89.995%
	Ethanol	10.000%

The compound of the invention is dissolved in ethanol and blended with water. The formulation is then packaged in a nebulizer equipped with a dosing pump.

EXAMPLE 25

This example illustrates the preparation of a representative pharmaceutical formulation in aerosol form containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

5	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	0.10%
	Propellant 11/12	98.90%
	Oleic acid	1.00%

The compound of the invention is dispersed in oleic acid and the propellants.

10 The resulting mixture is then poured into an aerosol container fitted with a metering valve.


While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications

15

20 are intended to be within the scope of the claims appended hereto.

What is claimed is:

1. A compound of formula (I):



wherein:

a and b are independently 1 to 4;

A is =CH- or =N-;

R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, alkoxyalkoxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxy carbonylalkylcarbonyl, alkoxy carbonylalkyl, alkoxy carbonyl, aryl carbonyl, aryloxy carbonyl, aralkoxy carbonyl, cycloalkyl carbonyl, haloalkoxy carbonyl, aminocarbonyl, monoalkylaminocarbonyl, alkoxy carbonylaminocarbonyl, alkylsulfonyl, arylsulfonyl, heterocyclyl, or heterocyclylcarbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminocarbonyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxy carbonylalkyl, aralkoxy carbonylalkyl, carboxyalkoxy carbonylalkyl, alkoxy carbonylalkylthioalkyl, aminocarbonylalkyl, aralkoxy carbonylaminocarbonyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxy carbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, tetrahydrofuranonyl, or heterocyclylalkyl;

R³ is hydrogen, alkyl, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxy carbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyl, carboxyalkenyl, alkoxy carbonylalkenyl, (cycloalkyl)(alkoxy carbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxy carbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxy carbonyl)alkyl)aminocarbonyl,

mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl,
mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylaminocarbonylalkoxy,
monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy,
mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy,
alkoxycarbonylcycloalkoxy, aminocarbonylcycloalkoxy, heterocyclyl,
tetrahydrofuranonyloxy, or heterocyclylalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy,
aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, aloxycarbonyl,
aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino,
carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl,
dialkylaminoalkyl, carboxyalkoxy, aloxycarbonylalkoxy, dialkylaminoalkoxy, and
heterocyclylalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl,
aralkyl, carboxy, aloxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and
alkoxycarbonylalkyl;

R⁶ is -N(R⁷)-C(O)- or -C(O)-N(R⁷)-;

R⁷ is hydrogen, alkyl, carboxyalkyl, or aloxycarbonylalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture;
or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1 wherein:

a is 1 or 2;

b is 1;

A is =N-;

R¹ is aloxycarbonyl;

R² is carboxyalkyl, aloxycarbonylalkyl, carboxyalkoxycarbonylalkyl, or heterocyclylalkyl;

R³ is alkoxy, aloxycarbonylalkoxy, aloxycarbonylcycloalkoxy, carboxyalkoxy,
carboxycycloalkoxy, aminocarbonylcycloalkoxy, heterocyclyl, tetrahydrofuranonyloxy or
heterocyclylalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy,
aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, aloxycarbonyl,
aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino,
carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl,

- 171 -

dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

R⁵ is hydrogen, alkyl or hydroxalkyl;

R⁶ is -N(R⁷)-C(O)-; and

R⁷ is hydrogen or alkyl.

3. The compound of Claim 2 wherein:

a is 1 or 2;

b is 1;

A is =N-;

R¹ is alkoxy carbonyl;

R² is carboxyalkyl, alkoxy carbonylalkyl or heterocyclalkyl;

R³ is alkoxy, alkoxy carbonylcycloalkoxy, carboxycycloalkoxy, tetrahydrofuranonyloxy, heterocycl, or heterocyclalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl and heterocyclalkoxy;

R⁵ is hydrogen, alkyl or hydroxalkyl;

R⁶ is -N(R⁷)-C(O)-; and

R⁷ is hydrogen.

4. The compound of Claim 3 wherein R² is carboxyalkyl.

5. The compound of Claim 4 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(oxiranyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(morpholin-4-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-tetrazol-5-ylethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(tetrazol-5-yl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-aminocarbonylpiperidin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxypiperidin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-ethoxycarbonylpiperidin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-methylpiperazin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-hydroxypyrrolidin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-hydroxypiperidin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-(carboxymethyl)piperazin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(carboxymethyl)piperazin-1-yl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(2-carboxy-4-hydroxypyrrolidin-1-yl)ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(tetrazol-5-yl)methoxyquinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-tetrazol-5-ylethoxy)quinoline.

6. The compound of Claim 3 wherein R² is alkoxy carbonylalkyl.

7. The compound of Claim 6 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(tetrahydro-2-oxofuran-3-yl)oxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(oxiranyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(3-ethoxycarbonylpiperidin-1-yl)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-4-(1-tetrazol-5-ylethoxy)quinoline.

8. The compound of Claim 3 wherein R² is heterocyclalkyl.

9. The compound of Claim 8 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(imidazol-4-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(indol-3-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(1-(carboxymethyl)imidazol-4-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(1,2,4-triazol-3-yl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(tetrazol-1-yl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(tetrazol-5-yl)ethyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline.

10. The compound of Claim 2 wherein:

a is 1 or 2;

b is 1;

A is =N-;

R¹ is alkoxy carbonyl;

R² is carboxyalkyl, alkoxy carbonylalkyl or carboxyalkoxy carbonylalkyl;

R³ is alkoxy, alkoxy carbonylalkoxy, alkoxy carbonylcycloalkoxy, aminocarbonylcycloalkoxy, carboxyalkoxy or carboxycycloalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkyl carbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkyl carbonylamino, di(alkyl carbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, and dialkylaminoalkoxy;

R⁵ is hydrogen, alkyl or hydroxyalkyl;

R⁶ is -N(R⁷)-C(O)-; and

R^7 is hydrogen or alkyl.

11. The compound of Claim 10 wherein:

R^3 is alkoxy carbonylalkoxy;

each R^4 is independently selected from the group consisting of hydrogen, alkyl or halo; and

R^5 is hydrogen.

12. The compound of Claim 11 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(methoxycarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-methyl-1-(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-(ethoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)-2-methylpropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-methyl-1-(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-methyl-1-(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-(methoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)propoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)-2-methylpropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-

methyl-1-(ethoxycarbonyl)ethoxy)quinoline.

13. The compound of Claim 10 wherein:

R^3 is alkoxy carbonylcycloalkoxy or aminocarbonylcycloalkoxy; and

R^5 is hydrogen.

14. The compound of Claim 13 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-

dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-
oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-
oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-7-(benzyloxy)-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-7-hydroxy-4-(1-(ethoxycarbonyl)cyclobut-
1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-
(aminocarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-
fluoro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methoxy-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-hydroxy-4-(1-
(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-fluoro-6-

methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(1-methylethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methoxy-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methylthio-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline; and
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-(methoxycarbonyl)cyclobut-1-oxy)quinoline.

15. The compound of 10 wherein:

R^3 is carboxyalkoxycarbonylalkyl or carboxyalkoxy; and

R^5 is hydrogen.

16. The compound of 15 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((carboxy)methoxycarbonyl)propyl]aminocarbonyl-4-(carboxy)methoxyquinoline
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxy)methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-methyl-1-carboxyethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxy-2,2-dimethylpropoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxyethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(carboxy)methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxyethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxyethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxypropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxy-2-methylpropoxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-methyl-1-carboxyethoxy)quinoline.

17. The compound of Claim 10 wherein:

R^3 is carboxycycloalkoxy; and

R^5 is hydrogen.

18. The compound of Claim 17 wherein each R^4 is independently selected from the group consisting of alkyl, hydroxyalkyl, alkoxy, halo, haloalkyl, and dialkylaminoalkyl.

19. The compound of Claim 18 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-8-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(diethylamino)methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(diethylamino)methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(trifluoromethyl)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(hydroxymethyl)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-ethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-ethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-fluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-bromo-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-difluoro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-fluoro-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(ethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1-methylethoxycarbonyl)propyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethyl-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dichloro-4-(1-carboxycyclobut-1-oxy)quinoline.

20. The compound of Claim 17 wherein each R^4 is independently selected from the group consisting of cyano, nitro, amino, monoalkylamino, and dialkylamino.

21. The compound of Claim 20 selected from the group consisting of the following:
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-nitro-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-amino-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-cyano-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-cyano-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-nitro-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-amino-4-(1-carboxycyclobut-1-oxy)quinoline.

22. The compound of Claim 17 wherein each R^4 is independently selected from the group consisting of alkoxy, aralkoxy, haloalkoxy, hydroxy, alkylthio, carboxyalkoxy, alkoxycarbonylalkoxy and dialkylaminoalkoxy.

23. The compound of Claim 22 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(benzyloxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-n-propoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(carboxy)methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(diethylamino)ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(benzyloxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-hydroxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(carboxy)methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-ethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-(1-methylethoxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-(trifluoromethoxy)-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-trifluoromethoxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,7-dimethoxy-4-(1-carboxycyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-methylthio-4-(1-carboxycyclobut-1-oxy)quinoline.

24. The compound of Claim 17 wherein each R⁴ is independently selected from the group consisting of hydrogen, carboxy, alkoxy carbonyl, aminocarbonyl and alkylcarbonyl.

25. The compound of Claim 24 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxybutyl]aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-carboxy-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-acetyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-ethoxycarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-acetyl-4-(1-carboxycyclobut-1-oxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-carboxy-4-(1-carboxycyclobut-1-oxy)quinoline; and;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-aminocarbonyl-4-(1-carboxycyclobut-1-oxy)quinoline.

26. The compound of Claim 10 wherein:

R^3 is alkoxy; and

R^5 is hydrogen.

27. The compound of Claim 26 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-4-(1,1-dimethylethoxy)carbonylbutyl]-aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-4-carboxybutyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-ethoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-((1,1-dimethylethoxy)carbonyl)ethyl]-aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl][methyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-((1,1-dimethylethoxy)carbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-(methoxycarbonyl)pentyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-(carboxy)pentyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-chloro-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-methoxyquinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-methoxyquinoline.

28. The compound of Claim 10 wherein:

R³ is alkoxy; and

R⁵ is alkyl or hydroxyalkyl.

29. The compound of Claim 28 selected from the group consisting of the following:

2-[1-(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(1-methylethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(2-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(2-(2-methylpropyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(1-methylethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(1-hydroxyethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline; and

2-[1-(3-(1-hydroxyethyl)-4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline.

30. The compound of Claim 1 wherein:

a is 1 or 2;

b is 1;

A is =N-;

R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, alkoxyalkoxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxy carbonylalkylcarbonyl, alkoxy carbonylalkyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, alkoxy carbonylaminocarbonyl, alkylsulfonyl, arylsulfonyl, heterocyclyl, or heterocyclylcarbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminocarbonyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxy carbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxy carbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminocarbonyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, and (carboxyalkyl)(alkyl)aminocarbonylalkyl;

R³ is hydrogen, alkyl, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxycarbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyloxy, carboxyalkenyloxy, alkoxy carbonylalkenyloxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxycarbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxycarbonyl)alkyl)aminocarbonyl, mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy, alkoxy carbonylcycloalkoxy, and aminocarbonylcycloalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl,

aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy, or heterocyclylalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxy carbonyl, aralkoxy carbonyl, carboxyalkyl, or alkoxy carbonylalkyl;

R⁶ is -N(R⁷)-C(O)-; and

R⁷ is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl.

31. The compound of Claim 30 wherein:

R³ is hydrogen or alkoxy;

each R⁴ is independently hydrogen, halo or carboxyalkylamino;

R⁵ is hydrogen or alkyl; and

R⁷ is hydrogen or alkyl.

32. The compound of Claim 31 wherein R¹ is hydrogen, alkyl, aralkyl, carboxyalkyl or alkoxy carbonylalkyl.

33. The compound of Claim 32 selected from the group consisting of the following:

2-[(piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-methyl-4-(4-fluorobenzyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-methyl-4-benzylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-benzylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-ethylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(1,1-dimethylethoxy)carbonylmethyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(carboxymethyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-methylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

and

2-[1-(2-methyl-4-(benzyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline.

34. The compound of Claim 31 wherein R¹ is aryl.

35. The compound of Claim 34 selected from the group consisting of the following:

2-[(4-(2-methyl-5-chlorophenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-chlorophenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-methylphenyl)-3-methylpiperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(3-chlorophenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(3-methyl-4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(3-chlorophenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(3-methyl-4-(3-methylphenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; and
2-[(4-(3-methylphenyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

36. The compound of Claim 31 wherein R¹ is heterocyclyl or heterocyclylcarbonyl.

37. The compound of Claim 36 selected from the group consisting of the following:

2-[1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(benzoxazol-2-yl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(benzthiazol-2-yl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;
2-[1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(benzoxazol-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(benzthiazol-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-hydroxy-3-chloropyridin-5-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(2-methylpropyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(1-methylethyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-benzyl-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(3-(4-hydroxybenzyl)-4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(piperidin-4-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(furan-2-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(thien-2-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(morpholin-4-yl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

and

2-[(4-(pyridin-2-yl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

38. The compound of Claim 31 wherein R¹ is aminocarbonyl, monoalkylaminocarbonyl or alkoxy carbonylaminocarbonyl.

39. The compound of Claim 38 selected from the group consisting of the following:

2-[1-(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(aminocarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(aminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((1,1-dimethylethyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((1-methylethyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((n-propyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((n-butyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((n-hexyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((n-pentyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; and

2-[(4-((ethoxycarbonyl)aminocarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

40. The compound of Claim 31 wherein R¹ is alkylcarbonyl, alkoxyalkoxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, or haloalkoxycarbonyl.

41. The compound of Claim 40 selected from the group consisting of the following:

2-[(4-(trichloromethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(benzyloxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(1-chloroethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(phenoxy carbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-carboxyethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(5-ethoxycarbonyl)pentyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(5-carboxypentyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-acetamidophenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-((2-methoxyethoxy)methyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-methoxycarbonylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(*n*-propylsulfonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2,5-dibromophenyl)sulfonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2,6-difluorophenyl)sulfonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(3-bromophenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-ethylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-*n*-propylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(4-*n*-butylphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(phenoxyethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2,2-dimethylpropyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-ethoxycarbonylethyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(*n*-propyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(*n*-pentyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-phenylcyclopropyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(2-bromo-5-methoxyphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline; and

2-[(4-(*n*-butyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(3-trifluoromethoxyphenyl)carbonylpiperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

42. The compound of Claim 1 wherein:

a is 1 or 2;

b is 1;

A is =N-;

R¹ is alkoxy carbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonyl aminoalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxy carbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonyl aminoalkyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, or (carboxyalkyl)(alkyl)aminocarbonylalkyl;

R³ is hydrogen, alkyl, hydroxy, halo, carboxy alkenyl, alkoxy, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxycarbonyl)alkoxy, carboxy alkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxy alkoxy, cyano alkoxy, halo alkoxy, halo alkenyloxy, carboxy alkenyloxy, alkoxy carbonyl alkenyloxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxy alkylamino, mono(alkoxycarbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxycarbonyl)alkyl)aminocarbonyl, mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylaminocarbonylalkoxy, mono aralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxy cycloalkoxy, alkoxy carbonyl cycloalkoxy, aminocarbonyl cycloalkoxy or tetrahydrofuranonyloxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkyl carbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxy alkylamino, alkyl carbonyl amino, di(alkyl carbonyl)amino, hydroxyalkyl,

dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy, and heterocyclylalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxy carbonyl, aralkoxy carbonyl, carboxyalkyl, and alkoxy carbonylalkyl;

R⁶ is -N(R⁷)-C(O)-; and

R⁷ is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl.

43. The compound of Claim 42 wherein:

R² is hydrogen, alkyl, aryl, aralkyl, hydroxyalkyl, haloalkylsulfonylaminooalkyl, or alkoxy carbonylalkoxy carbonylalkyl; and

R³ is alkyl, halo, carboxyalkenyl, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxy carbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyl oxy, carboxyalkenyl oxy, alkoxy carbonylalkenyl oxy, (cycloalkyl)(alkoxy carbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxy carbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxy carbonyl)alkyl)aminocarbonyl, mono((alkoxy carbonyl)(carboxy)alkyl)aminocarbonyl, mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, mono(alkoxy carbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy, alkoxy carbonylcycloalkoxy, aminocarbonylcycloalkoxy, or tetrahydrofuranonyloxy.

44. The compound of Claim 43 selected from the group consisting of the following:

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(ethoxycarbonyl)methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(carboxy)methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(aminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(((1,1-dimethylethoxy)carbonyl)methoxy)-carbonylpropyl]aminocarbonyl-4-((1,1-dimethylethoxy)carbonyl)methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-(ethoxycarbonyl)propoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-carboxypropoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-(ethoxycarbonyl)prop-2-en-1-oxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(tetrahydro-2-oxofuran-3-yl)oxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-carboxy-3-hydroxypropoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1,1-di(ethoxycarbonyl)methoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1,1-di(carboxy)methoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(ethoxycarbonyl)ethoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-carboxyethoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-(carboxy)prop-1-en-1-oxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(methoxycarbonyl)propoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(carboxy)propoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-methyl-1-(ethoxycarbonyl)ethoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-methyl-1-(carboxy)ethoxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(ethoxycarbonyl)cyclobut-1-oxy)quinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(1-(carboxy)cyclobut-1-oxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

((trifluoromethyl)sulfonylamino)propyl]aminocarbonyl-7-methyl-4-(1-ethoxycarbonyl)cyclobut-1-oxy)quinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

((trifluoromethyl)sulfonylamino)propyl]aminocarbonyl-7-methyl-4-(1-carboxycyclobut-1-oxy)quinoline.

45. The compound of Claim 42 wherein:

R^2 is alkylsulfonylalkyl, aralkoxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxy carbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl; and

R^3 is hydrogen, hydroxy or alkoxy.

46. The compound of Claim 45 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-((2-chlorobenzyloxy)carbonyl)aminopentyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(benzyloxycarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(benzyloxy)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-5-aminopentyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(aminocarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(aminocarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(benzyloxycarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(((carboxy)methyl)aminocarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-ethoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-(1,1-dimethylethoxy)carbonylphenyl)-ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-((methoxycarbonyl)methyl)thioethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(carboxymethyl)thioethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((carboxymethyl)aminocarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(((1,1-dimethylethoxycarbonyl)methyl)aminocarbonyl)propyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(((1,1-dimethylethoxycarbonyl)methyl)(methyl)aminocarbonyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-((carboxy)methyl)aminocarbonyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonyl-5-nitroquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-((ethoxycarbonyl)methoxycarbonyl)propyl]aminocarbonyl-5-aminoquinoline; and

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methylsulfonyl)propyl]aminocarbonyl-4-methoxyquinoline.

47. The compound of Claim 42 wherein:

R^2 is hydrogen, alkyl, aryl, aralkyl or hydroxyalkyl; and

R^3 is hydrogen, hydroxy, or alkoxy.

48. The compound of Claim 47 selected from the group consisting of the following:

2-[(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(3-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(2-methylpropoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(methoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonylethyl]aminocarbonyl-4-methoxyquinoline;
2-[(2-methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-phenylethyl]aminocarbonyl-4-methoxyquinoline;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-methylpropyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(methoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-hydroxyethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-ethoxyquinoline;
2-[(3-benzyloxy)carbonyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(3-carboxy-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl](carboxymethyl)aminocarbonyl-4-methoxyquinoline;
2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;
2-[(2,4-di(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-carboxy-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-n-propoxyquinoline;

2-[(3-(methoxycarbonyl)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(3-(carboxy)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-hydroxyphenyl)methyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-carboxyphenyl)methyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-(methoxycarbonyl)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[(2-(carboxy)methyl-4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(4-(carboxymethoxy)phenyl)methyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(ethoxycarbonyl)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-(carboxymethoxy)phenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(2-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-hydroxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(ethoxycarbonyl)methoxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(carboxymethoxyphenyl)ethyl)aminocarbonyl-4-methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-carboxyphenyl)ethyl]aminocarbonyl-4-methoxyquinoline;

2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-4-hydroxyquinoline;

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonylquinoline;
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-hydroxyquinoline; and
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-methoxyquinoline.

49. The compound of Claim 1 wherein:

a is 1 or 2;

b is 1;

A is =N-;

R¹ is hydrogen or alkoxy carbonyl;

R² is carboxyalkyl or alkoxy carbonylalkyl;

R³ is hydrogen, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl, di(alkoxy carbonyl)alkoxy,

di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy,

hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyl oxy,

(cycloalkyl)(alkoxy carbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy,

(dialkylamino carbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino,

(hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino,

mono(alkoxy carbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl,

mono(di(alkoxy carbonyl)alkyl)aminocarbonyl,

mono((alkoxy carbonyl)(carboxy)alkyl)aminocarbonyl,

mono(dicarboxyalkyl)aminocarbonyl, dialkylaminocarbonylalkoxy,

monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, or

mono(alkoxy carbonylalkyl)aminocarbonylalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy,

aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl,

aminocarbonyl, alkyl carbonyl, nitro, amino, monoalkylamino, dialkylamino,

carboxyalkylamino, alkyl carbonyl amino, di(alkyl carbonyl)amino, hydroxyalkyl,

dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy, and

heterocyclalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl,

aralkyl, carboxy, alkoxy carbonyl, aralkoxy carbonyl, carboxyalkyl, and

alkoxy carbonylalkyl;

R⁶ is -N(R⁷)-C(O)-; and

R⁷ is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl.

50. The compound of Claim 49 wherein R³ is hydrogen, hydroxy, halo, alkoxy, hydroxyalkoxy, haloalkoxy, haloalkenyl, or alkylthio.

51. The compound of Claim 50 selected from the group consisting of the following:

2-[1-(piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-methoxyquinoline;,
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-hydroxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-8-methoxy-4-hydroxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-5-nitroquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(2,2,2-trifluoroethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(3,3,3-trifluoropropoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3,3,3-trifluoropropoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(3,4,4-trifluorobut-3-en-1-oxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3,4,4-trifluorobut-3-en-1-oxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-hydroxyethoxy)quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(methylthio)quinoline; and
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5,7-dichloro-4-(methylthio)quinoline.

52. The compound of Claim 49 wherein R³ is carboxyalkenyl, alkoxy carbonyl, di(alkoxycarbonyl)alkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, cyanoalkoxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, carboxy, dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, or mono(alkoxycarbonylalkyl)aminocarbonylalkoxy.

53. The compound of Claim 52 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-hydroxy-1-carboxypropoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(cyanomethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(dimethylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(dimethylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(ethoxycarbonylmethylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1-cyanoethoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(benzylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(benzylaminocarbonyl)methoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-((carboxy)methylamino)carbonylmethoxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-carboxy-3-(diethylamino)propoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]-aminocarbonyl-4-(methoxycarbonyl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methoxycarbonyl)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-carboxyquinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-(1,1-di(ethoxycarbonyl)methoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1,1-di(carboxy)methoxy)quinoline;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-carboxyethenyl)quinoline (34 mg);

- 201 -

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-cyclohexyl-1-carboxymethoxy)quinoline; and
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-cyclohexyl-1-(methoxycarbonyl)methoxy)quinoline.

54. The compound of Claim 49 wherein R^3 is
mono(alkoxycarbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl,
mono(di(alkoxycarbonyl)alkyl)aminocarbonyl,
mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, or mono(dicarboxyalkyl)aminocarbonyl.

55. The compound of Claim 54 selected from the group consisting of the following:
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]-aminocarbonyl-4-(methoxycarbonylmethyl)aminocarbonylquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]-aminocarbonyl-4-(carboxymethyl)aminocarbonylquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)aminocarbonylquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-[(1-carboxy-3-(1,1-dimethylethoxycarbonyl)propyl)aminocarbonyl]quinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-[(1-(methoxycarbonyl)-3-carboxypropyl)aminocarbonyl]quinoline; and
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-[(1,3-dicarboxypropyl)aminocarbonyl]quinoline.

56. The compound of Claim 49 wherein R^3 is
(dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino,
(dialkylaminoalkyl)(alkyl)amino, or carboxyalkylamino.

57. The compound of Claim 56 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-(carboxymethyl)aminoquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-((dimethylamino)carbonylmethyl)(methyl)aminoquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)(methyl)aminoquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-di(acetyl)aminoquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-5-acetamidoquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methyl)(2-hydroxyethyl)aminoquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(methyl)(2-(dimethylamino)ethyl)aminoquinoline; and
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(carboxymethyl)aminoquinoline.

58. The compound of Claim 1 wherein:

a is 1 or 2;

b is 1;

A is =CH-;

R¹ is alkoxy carbonyl;

R² is hydrogen, carboxyalkyl, or aralkoxycarbonylalkyl;

R³ is hydrogen;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and hydroxy;

R⁵ is hydrogen;

R⁶ is -N(R⁷)-C(O)-; and

R⁷ is hydrogen or alkyl.

59. The compound of Claim 58 selected from the group consisting of the following:

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(benzyloxycarbonyl)propyl]aminocarbonylnaphthalene;

2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonylnaphthalene;
and

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonylnaphthalene.

60. The compound of Claim 1 wherein:

a is 1;

b is 1;

A is =CH- or =N-;

R¹ is alkoxy carbonyl;

R² is hydrogen, aralkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, alkoxy carbonylalkyl, or tetrahydrofuranonyl;

R³ is hydrogen, alkoxy, or carboxyalkoxy;

R⁴ is hydrogen, hydroxy, carboxyalkoxy, or alkoxy carbonylalkoxy;

R⁵ is hydrogen;

R⁶ is -C(O)-N(R⁷)-; and

R⁷ is hydrogen, alkyl or carboxyalkyl.

61. The compound of Claim 60 selected from the group consisting of the following:

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]carbonyl]aminonaphthalene;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-

(ethoxycarbonyl)ethyl)carbonyl]aminonaphthalene;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxyethyl)carbonyl]aminonaphthalene;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-(methoxycarbonyl)phenyl)ethyl)carbonyl]-aminonaphthalene;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(3-carboxyphenyl)ethyl)carbonyl]aminonaphthalene;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-(methoxycarbonyl)phenyl)ethyl)carbonyl]aminonaphthalene;


2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-1-(tetrahydro-2-oxofuran-3-yl)methyl)carbonyl]aminonaphthalene;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-carboxy-4-hydroxybutyl)carbonyl]aminonaphthalene;

2-[(1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-2-(4-carboxyphenyl)ethyl)carbonyl]aminonaphthalene;

2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-5-hydroxynaphthalene;
 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-4-methoxynaphthalene;
 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-5-(
 carboxymethoxy)naphthalene;
 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-5-(3-
 (ethoxycarbonyl)propoxy)naphthalene;
 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-5-(3-
 carboxypropoxy)naphthalene;
 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]amino-4-
 (carboxymethoxy)naphthalene;
 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][carboxymethyl]-
 aminonaphthalene; and
 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl][carboxymethyl]amino-4-
 methoxynaphthalene.

62. A pharmaceutical composition useful in treating a mammal having a disease-state characterized by thrombotic activity, which composition comprises a pharmaceutically acceptable excipient and a compound of formula (I):



wherein:

a and b are independently 1 to 4;

A is =CH- or =N-;

R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, alkoxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxy carbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, alkoxycarbonylaminocarbonyl, alkylsulfonyl, arylsulfonyl, heterocyclyl, or heterocyclylcarbonyl;

R^2 is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxy carbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxy carbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, tetrahydrofuranonyl, or heterocyclalkyl;

R^3 is hydrogen, alkyl, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxycarbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyloxy, carboxyalkenyloxy, alkoxy carbonylalkenyloxy, (cycloalkyl)(alkoxycarbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylaminocarbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxycarbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl, mono(di(alkoxycarbonyl)alkyl)aminocarbonyl, mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl, mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylaminocarbonylalkoxy, monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy, mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy, alkoxy carbonylcycloalkoxy, aminocarbonylcycloalkoxy, heterocyclyl, tetrahydrofuranonyloxy, or heterocyclalkoxy;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkyl carbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkyl carbonylamino, di(alkyl carbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy, or heterocyclalkoxy;


each R^5 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxy carbonyl, aralkoxycarbonyl, carboxyalkyl, or alkoxy carbonylalkyl;

R^6 is $-N(R^7)-C(O)-$ or $-C(O)-N(R^7)-$;

R^7 is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

63. A method of treating a disease-state characterized by thrombotic activity, which method comprises administering to a mammal having a disease-state characterized by thrombotic activity a therapeutically effective amount of a compound of formula (I):



wherein:

a and b are independently 1 to 4;

A is =CH- or =N-;

R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, alkoxyalkyloxyalkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxy carbonylalkylcarbonyl, alkoxy carbonylalkyl, alkoxy carbonyl, aryl carbonyl, aryloxy carbonyl, aralkoxy carbonyl, cycloalkylcarbonyl, haloalkoxy carbonyl, aminocarbonyl, monoalkylaminocarbonyl, alkoxy carbonylaminocarbonyl, alkylsulfonyl, arylsulfonyl, heterocyclyl, or heterocyclylcarbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminooalkyl, carboxyalkylthioalkyl, alkoxy carbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxy carbonylalkyl, aralkoxy carbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxy carbonylalkyl, aminocarbonylalkyl, aralkoxy carbonylaminooalkyl, alkoxy carbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxy carbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, tetrahydrofuranonyl, or heterocyclylalkyl;

R³ is hydrogen, alkyl, hydroxy, halo, carboxyalkenyl, alkoxy, alkoxy carbonyl, alkoxy carbonylalkoxy, di(alkoxy carbonyl)alkoxy, carboxyalkoxy, di(carboxy)alkoxy, (carboxy)(hydroxy)alkoxy, (dialkylamino)(carboxy)alkoxy, hydroxyalkoxy, cyanoalkoxy, haloalkoxy, haloalkenyl, carboxyalkenyl, alkoxy carbonylalkenyl, (cycloalkyl)(alkoxy carbonyl)alkoxy, (cycloalkyl)(carboxy)alkoxy, alkylthio, carboxy, (dialkylamino carbonylalkyl)(alkyl)amino, (carboxyalkyl)(alkyl)amino, (hydroxyalkyl)(alkyl)amino, (dialkylaminoalkyl)(alkyl)amino, carboxyalkylamino, mono(alkoxy carbonylalkyl)aminocarbonyl, mono(carboxyalkyl)aminocarbonyl,

mono(di(alkoxycarbonyl)alkyl)aminocarbonyl,
mono((alkoxycarbonyl)(carboxy)alkyl)aminocarbonyl,
mono(dicarboxyalkyl)aminocarbonyl, aminocarbonylalkoxy, dialkylaminocarbonylalkoxy,
monoaralkylaminocarbonylalkoxy, mono(carboxyalkyl)aminocarbonylalkoxy,
mono(alkoxycarbonylalkyl)aminocarbonylalkoxy, carboxycycloalkoxy,
alkoxycarbonylcycloalkoxy, aminocarbonylcycloalkoxy, heterocyclyl,
tetrahydrofuranonyloxy, or heterocyclylalkoxy;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy,
aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, aloxycarbonyl,
aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino,
carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl,
dialkylaminoalkyl, carboxyalkoxy, aloxycarbonylalkoxy, dialkylaminoalkoxy, or
heterocyclylalkoxy;

each R⁵ is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl,
aralkyl, carboxy, aloxycarbonyl, aralkoxycarbonyl, carboxyalkyl, or aloxycarbonylalkyl;

R⁶ is -N(R⁷)-C(O)- or -C(O)-N(R⁷)-;

R⁷ is hydrogen, alkyl, carboxyalkyl, or aloxycarbonylalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture;
or a pharmaceutically acceptable salt thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 December 2002 (12.12.2002)

PCT

(10) International Publication Number
WO 2002/098856 A3

(51) International Patent Classification⁷: C07D 403/12, (74) Agents: ZELANO, Antony, J. Millen, White, Zelano & A61K 31/496, A61P 7/02 Branigan, P.C. et al.; Arlington Courthouse Plaza 1, 2200 Clarendon Boulevard, Suite 1400, Arlington, VA 22201 (US).

(21) International Application Number:
PCT/US2002/017821

(22) International Filing Date: 6 June 2002 (06.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/296,498 6 June 2001 (06.06.2001) US
10/163,742 5 June 2002 (05.06.2002) US

(71) Applicant (for all designated States except US): SCHER-
ING AKTIENGESELLSCHAFT [DE/DE]; Müllerstr.
170/178, Postfach 65 03 11, D-13342 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRYANT, Judi, A. [US/US]; 318 Forest Run, Mill Valley, CA 94941 (US).
BUCKMAN, Brad, O. [US/US]; 2042 Leimert Boulevard, Oakland, CA 94602 (US). ISLAM, Imadul [US/US]; 165 Caprice Circle, Hercules, CA 94547 (US). MOHAN, Raju [US/US]; 3125 Caminito Ricardo, Encinitas, CA 92024 (US). MORRISSEY, Michael, M. [US/US]; 129 Alta Vista Way, Danville, CA 94806 (US). WEI, Guo, Ping [CN/US]; 1105 Vista Point Circle, San Ramon, CA 94583 (US). XU, Wei [US/US]; 327 Glasgow Circle, Danville, CA 94526 (US). YUAN, Shendong [CN/US]; 708 Forest Run, Hercules, CA 94547 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(88) Date of publication of the international search report:
4 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2002/098856 A3

(54) Title: PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS



(57) Abstract: Compounds of the following formula (I): where a, b, R¹, R², R³, R⁴ and R⁶ are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 02/17821

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D403/12 A61K31/496 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 92 08709 A (PENTAPHARM AG) 29 May 1992 (1992-05-29) * see claim 1, definition of R1 = d,e, R2 = piperazinyl, R4 = naphthyl, quinolyl * the whole document ---	1-63
Y	WO 98 56771 A (SCHERING AG) 17 December 1998 (1998-12-17) * see p.7/8, defintion of R3 -R6 * the whole document ---	1-63
Y	EP 0 739 886 A (LG CHEMICAL LIMITED) 30 October 1996 (1996-10-30) * see claims * the whole document ---	1-63 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

8 January 2003

Date of mailing of the international search report

05/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International	Application No
PCT/US2002/17821	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PIERCE, A.C ET AL.: "Estimation of Binding Affinities for Selective Thrombin Inhibitors via Monte Carlo Simulations" J.MED.CHEM., vol. 44, no. 7, 2001, pages 1043-1050, XP002226501 WASHINGTON * see p.1045, fig. 2, cpds. 8, 12 and 20 * the whole document</p> <p>---</p>	1-63
Y	<p>KAMM, W. ET AL.: "Transport of Peptidomimetic Thrombin Inhibitors with a 3-amidino-Phenylalanine Structure : Permeability and Efflux Mechanism in Monolayers of a Human Intestinal Cell Line (Caco-2)" PHARM.RES., vol. 18, no. 8, 2001, pages 1110-1118, XP009003114 * see p.1111, Fig. 1, formula 10, 11 * the whole document</p> <p>---</p>	1-63
Y	<p>DULLWEBER, F. ET AL.: "Factorising Ligand Affinity : A Combined Thermodynamic and Crysstallographic Study of Trypsin and Thrombin Inhibition" J.MOL.BIOL., vol. 313, 2001, pages 593-614, XP002226502 * see p. 594, Fig. 1, last 2 cpds. * the whole document</p> <p>-----</p>	1-63

INTERNATIONAL SEARCH REPORT

Internat'l application No.
PCT/US 02/17821

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 63 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/ compositions.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US 02/17821

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9208709	A 29-05-1992	AU	8868991 A	11-06-1992
		CA	2073776 A1	16-05-1992
		WO	9208709 A1	29-05-1992
		EP	0511347 A1	04-11-1992
		JP	5503300 T	03-06-1993
		US	5518735 A	21-05-1996
WO 9856771	A 17-12-1998	US	6207665 B1	27-03-2001
		AU	735462 B2	12-07-2001
		AU	8625898 A	30-12-1998
		EE	9900565 A	15-06-2000
		WO	9856771 A2	17-12-1998
		EP	1254899 A2	06-11-2002
		EP	0988292 A2	29-03-2000
		HU	0003929 A2	28-05-2001
		JP	2002503239 T	29-01-2002
		NO	996068 A	11-02-2000
		PL	337758 A1	11-09-2000
		SK	171399 A3	12-09-2000
		TR	9903034 T2	21-06-2000
		US	2002177598 A1	28-11-2002
EP 0739886	A 30-10-1996	AU	696380 B2	10-09-1998
		CA	2188690 A1	23-04-1998
		WO	9749673 A1	31-12-1997
		NZ	299659 A	19-12-1997
		AU	7048196 A	07-05-1998
		EP	0739886 A2	30-10-1996
		JP	2844329 B2	06-01-1999
		JP	8301833 A	19-11-1996
		JP	11005780 A	12-01-1999
		US	5747535 A	05-05-1998
		KR	173034 B1	30-03-1999
		US	5977114 A	02-11-1999
		US	5985899 A	16-11-1999
		RU	2142939 C1	20-12-1999